Effects of maternal body weight on Wharton’s Jelly mesenchymal stromal cells (Pilot study) by Badraiq, Heba Ghazi O
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Effects of maternal body weight on Wharton’s Jelly mesenchymal stromal cells (Pilot
study)
Badraiq, Heba Ghazi O
Awarding institution:
King's College London
Download date: 15. Dec. 2017
  
Effects of Maternal Body Weight on 




Heba Ghazi Badraiq 
 
 
Faculty of Life Science and Medicine 
Division of Women’s Health 











I, Heba Ghazi Badraiq, declare that this PhD thesis contains no material that has been 
submitted previously, in whole or in part, for the award of any other academic degree. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
The work presented in this PhD thesis is my own except for the following: 
 
• Part of the statistical analysis was performed by the statistician Khadija Rantell. 
• RT-PCR was performed by Dr. Aleksandra Cvoro. 
• Western blotting was performed by Dr. Dusko Ilic.  
 






1- Isolation and expansion of mesenchymal stromal/stem cells from umbilical cord 
under chemically defined conditions. Badraiq H, Devito L, Ilic D. Methods Molecular 
Biology. 2015;1283:65-71. 
 
2- Wharton's jelly mesenchymal stromal/stem cells derived under chemically defined 
animal product-free low oxygen conditions are rich in MSCA-1(+) subpopulation. Devito 
L, Badraiq H, Galleu A, Taheem D, Codognotto S, Siow R, Khalaf Y, Briley A, 
Shennan A, Poston L, McGrath J, Gentleman E, Dazzi F, Ilic D. Regenerative 
Medecine. 2014;9(6):723-32. 
 
3- Induced pluripotent stem cell differentiation and three-dimensional tissue formation 
attenuate clonal epigenetic differences in trichohyalin. Petrova A, Capalbo A, Jacquet L, 
Hazelwood-Smith S, Dafou D, Hobbs C, Arno M, Farcomeni A, Devito L, Badraiq H, 
Simpson M, McGrath JA, Di WL, Cheng JB, Mauro TM, Ilic D. Stem Cell Development 
2016 September15;25(18):1366-75. 
 
4- Effects of maternal obesity on Wharton’s jelly mesenchymal stromal cells. Badraiq 
H, Cvoro A, Galleu A, Simon M, Miere C, Hobbs C, Schulz R, Siow R, Dazzi F, Ilic D. 





It has been a great honor to have had the opportunity to study a PhD at King’s College 
London, in particular the Division of Women’s Health. This PhD journey would not have 
been achieved without the support of a number of members and divisions. 
Firstly, I would like to express a deep gratitude to the Saudi Arabian Cultural Bureau in 
London for their continuous guidance and support throughout my scholarship, from the 
early beginning to the late end. Special thanks go to Dr. Ghazi Makki, Ibrahim Al-Trairi, 
Amel Trabelsi and Dr. Faisal Aba Al-Khail. 
Similarly, a deep gratitude to my supervisors: Dr. Dusko Ilic, who introduced me to the 
world of stem cells and epigenetics and offered me the opportunity to undertake this 
program and developed as a scientist; Dr. Richard Siow, who developed my lab skills 
from the beginning, advised and supported until the end of this journey. 
Secondly, I would like to express my deepest sense of thankfulness to volunteers who 
donated their umbilical cords and made this study possible. Also my deepest sense of 
thankfulness to doctors, midwives, nurses and research assistants of the Division of 
Women’s Health at St. Thomas Hospital. Special thanks go to Hannah Powles, Annette 
Briley, Prof. Andrew Shennan, Funso Adegoke and Prof. Lucilla Poston. 
Furthermore, I would like to acknowledge all members of Biomedical Research Center 
at Guy’s Hospital for their facilities. In Flow Cytometry facility, special thanks go to Dr. 
Susanne Heck, PJ Chana and Anna Rose. In Genomics facility, special thanks go to Dr. 
Alka Saxena and Rosamond Nuamah. Also, I thank all members of the Division of 
Cardiovascular Medicine, especially Dr. Sarah Chapple, and from the Department of 
Haemato-Oncology at King’s College London, Prof. Francesco Dazzi and Dr. Antonio 
Galleu. Additionally, I would like to thank members at King’s College, Dr. Eileen 
Gentleman and Dheraj Taheem from Department of Craniofacial Development and 
Stem Cell Biology. Also Dr. Reiner Schulz from Division of Genetics & Molecular 
Medicine. 
In particular I would like to thank Cristian Miere for his support and friendship through 
the journey. I would like to thank Stefano Codognotto, Dr. Heema Hewitson, Sreekala 
	5	
Sathyavruthan and Justo Gonzalez for their collegiality and also Ghazala Mirza and 
Viktoria Husz for their continues support through the journey.  
In particular I would like to thank my friend and PhD partner Laila Noli, who made my 
journey easier and worthwhile since the bachelor degree, and most of all made me feel 
like having a sister in a country that is not my own. Educational achievement in my life 
is nothing if I do not have friend with whom to share the highs and lows. 
A great deal of my gratitude goes to my dearest mother (Ameera Gazzaz) and father 
(Ghazi Badraiq) for their prayers, support, belief and encouragement. Also, my siblings 
nieces and nephew: Ghada, Nouf, Bader, Faris, Essam, Mohammed, Tala, Layan and 
Omar. Without continuous family support, I would not have been able to make it this far. 
A big thank you to my extended family: uncles, aunts and cousins especially, Bodor, 
Laila, Abeer, Howida, Hattan, Husam, Bassam, Nada and Alaa for their support and 
care. 
Finally, I appreciate all my dear friends: special thanks go to my childhood friend Aseel 
Khafaji; also, a big thank you to my close friends Abrar Madani, Nouf Nass, Ashjan 
Zainalabdeen and Nojoud Abokhamees for their extended support. 
Most of all I fully appreciate my dear fiancé Alhasan Madani for entirely care, love and 
constant encouragement and support, for cheering me on and making me smile and 
laugh through the whole journey. Is so appreciated. Thank you.    
 
Above all, I give glory to Allah for watching me through to completion. 
 
 
Heba Ghazi Badraiq 
                                                                                                        December 2016 
  
	6	
Table of Contents 
 
 
Abstract ............................................................................................................. 7 
Abbreviation ...................................................................................................... 9 
Introduction ..................................................................................................... 12 
Mesenchymal Stromal/Stem Cells ............................................................................ 13 
MSC clinical trials  ..................................................................................................... 23 
Umbilical Cord and Wharton’s Jelly ........................................................................... 35 
Epigenetic and developmental reprogramming  ........................................................ 49 
Obesity  ..................................................................................................................... 58 
The link between epigenetics and obesity ................................................................. 61 
Objectives  ................................................................................................................. 67 
Materials and Methods ................................................................................... 68 
Patient selection  ....................................................................................................... 69 
Isolation and culture of WJ-MSCs from UCs and assessment of initial outgrowth and 
proliferation rate  ....................................................................................................... 73 
Comparison of the properties of WJ-MSCs derived from obese and non-obese 
subjects  .................................................................................................................... 78 
Samples preparation and analysis for the DNA methylation study  .......................... 94 
Copy number variation analysis for segmentally duplicated genes  ........................ 107 
Samples preparation and analysis for gene expression array analysis  ................. 108 
Confirmation of a significant difference in PNPLA7 between obese and non-obese 
 ................................................................................................................................ 116 
Results ........................................................................................................... 120 
Isolation and evaluation of WJ-MSCs ..................................................................... 121 
Analysis of WJ-MSCs DNA Methylation .................................................................. 144 
Copy number variation analysis of segmentally duplicated genes  ......................... 178 
Gene expression array analysis between obese and non-obese donors  ............... 180 
Discussion ..................................................................................................... 198 
Effect of obesity on the properties of WJ-MSCs  ..................................................... 201 
Effect of obesity on DNA methylation  ..................................................................... 208 
Role of obesity in PNPLA7  ..................................................................................... 217 
Summary  ....................................................................................................... 219 
Future work  .................................................................................................. 220 






To investigate whether the maternal metabolic environment affects the DNA 
methylation of mesenchymal stromal/stem cells (MSCs) from umbilical cord (UC) 
Wharton’s Jelly (WJ), potentially rendering them unsuitable for clinical use in multiple 
recipients, a pilot study was conducted on fourteen UCs obtained post partum from 
healthy non-obese (BMI=19-25; n=7) and obese (BMI≥30; n=7) donors receiving 
elective Caesarean sections. 
 
The time of first WJ-MSCs outgrowth from UC explants was similar in samples from 
obese and non-obese donors. However, the cells from non-obese donors proliferated 
faster after 34 hours of culture than cells from obese donors. Differentiation into 
adipogenic, osteogenic and chondrogenic lineages was similar between obese and 
non-obese donor samples as demonstrated by tissue-specific staining and RT-PCR for 
lineage markers. However, WJ-MSCs from obese donors exhibited stronger 
immunosuppressive activity than those from non-obese donors. 
 
Genome-wide DNA methylation of triple-positive (CD73+CD90+CD105+) WJ-MSCs 
sorted from the first passage of a mixed population of cells was assessed. Samples 
from the obese and non-obese donors clustered separately, and 5,767 of the analysed 
CpG sites (1%) exhibited different methylation. Sixty-seven genes were observed with 
at least one CpG site with a methylation difference ≥0.2 in four or more obese donors. 
These 67 genes were further refined based on a list of polymorphic CpG sites and 
segmental duplications. In 18 of the 67 genes with a different CpG methylation pattern, 
the CpG sites were in non-polymorphic regions. However, two genes (DCAF6 and 
	8	
ZNF714) resided in segmentally duplicated regions. 
  
To determine whether methylation differences altered gene expression, the samples 
were analysed using a HumanHT-12 Expression BeadChip array and, of the 18 genes, 
only PNPLA7 was significantly affected at the mRNA level, which was confirmed 
independently by RT-PCR and Western blotting.  
Although the number of analysed donors was limited, the data suggest that an 
abnormal metabolic environment related to excessive body weight might alter the 
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1.1 Mesenchymal Stromal/Stem Cells (MSCs) 
Over the last few decades, researchers have taken a significant interest in 
understanding mesenchymal stem cells (MSCs). Their stem-like properties, including 
their ability to proliferate in vitro for many passages without displaying any senescence 
characteristics while remaining stable and undifferentiated, their differentiation potential 
under certain conditions, and their capability to commit to multiple lineages, have been 
a major focus of studies investigating therapies for tissue repair and regeneration (El 
Omar et al., 2014; Wang et al., 2008). More recently, researchers have identified 
additional properties of MSCs that have furthered the understanding of their 
involvement in tissue regeneration; their secretion of immunomodulatory and 
cytoprotective factors has been shown to beneficially contribute to the tissue 
regeneration process (Squillaro et al., 2015). 
In addition to such properties, other benefits of MSCs have received global attention, 
and many new investigators are extensively studying MSCs in the context of 
developing novel and effective cell-based therapeutic applications (Baksh et al., 2004). 
The growing number of research studies is increasing the pace of advances in pre-
clinical research; valuable findings have been reported from clinical trials of treatments 
for various diseases (Dominici et al., 2006; Squillaro et al., 2015). However, the 
outcomes from the ever-increasing number of publications are somewhat inconsistent; 
therefore, it is necessary for laboratories to adopt tighter standardization procedures to 
ensure that ambiguities are absent from publications (Dominici et al., 2006). Other 
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remarkable attributes of MSCs that make them notable candidates for cell-based 
therapeutics include their ease of collection, safe use, and minimal associated ethical 
concerns (Ullah et al., 2015).   
MSCs are also known as mesenchymal stromal cells (MSCs); they have the potential 
to differentiate into multiple lineages and, therefore, are multipotent (Ilic & Polak, 2011). 
Although MSCs are often referred to as stem cells, the only attribute of stem cells they 
possess is the capacity for self-renewal, meaning that they maintain their identity after 
many cell divisions. However, they are not capable of giving rise to any type of cell 
found in the human body, unlike pluripotent stem cells (Nombela-Arrieta et al., 2011). 
Thus, strictly speaking, MSCs do not fulfil the criteria of true stem cells. The term 
‘mesenchymal stem cell’ has caused many disagreements as a result of these defining 
criteria of stem cells (Dominici et al., 2006). The Greek word ‘stroma’ translates as 
‘bed’, which anatomically refers to supportive tissue comprising connective tissue, 
endothelium and blood vessels; stroma is indicative of a structure, an organ or a gland 
that is distinct from the functional elements of an organ (Spraycar, 1995). Stromal cells 
are part of the stromal fraction that provides a physical support structure, which is 
mainly composed of collagen and adherent cells, such as fibroblastic, vascular and 
immune cells (Troyer & Weiss, 2008). Furthermore, stroma and stromal cells release 
signals and cues, such as growth factors and chemokines, which drive the maturation 
and differentiation of haematopoietic cells (Baksh et al., 2004).  
 
1.1.1 History of MSCs  
In 1867, Cohnheim, a German biologist, was the first to discuss the presence of 
regenerative cells in the human body; he hypothesized that bone marrow (BM)-derived 
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fibroblasts were involved in wound healing (Cohnheim, 1867; Murray & Peault, 2015). 
Approximately a century later, Alexander Friedenstein discovered the presence of 
MSCs in BM. He also described a procedure to isolate them using plastic adherence in 
which extracted cells are plated at a low density and BM-MSCs rapidly adhere to the 
plate. By repeatedly washing the cells, BM-MSCs are easily separated from non-
adherent cells, such as haematopoietic cells. Under favourable culture conditions, 
distinct colonies emerge from the BM, and each colony can be derived from a single 
precursor cell known as the colony-forming unit fibroblast (CFU-F) (Bianco et al., 2001; 
Friedenstein et al., 1974; Friedenstein et al., 1976; Friedenstein et al., 1966; Murphy et 
al., 2013). In the 1980s, Friedenstein, Owen, and their colleagues utilized in vitro 
culture and transplantation in laboratory animals in either closed systems (diffusion 
chambers) or open systems (under the renal capsule or subcutaneously), to 
characterize the cells generating the physical stroma of BM (Bianco et al., 2001; 
Friedenstein et al., 1970; Friedenstein et al., 1966; Owen, 1988). Long-term BM 
cultures were found to yield BM-MSCs; in addition, the cultures also exhibited 
osteogenic differentiation characteristics, specifically the ability to form bone, fat, 
cartilage and muscle cells in vitro as well as the capacity to regenerate ectopic bone, 
stroma and haematopoietic tissue in vivo upon re-transplantation (Murphy et al., 2013; 
Murray & Peault, 2015). These properties are the hallmarks of this cell type and have 
been validated and undisputed from their first identification. Further characterization 
revealed that BM-MSCs were capable of differentiating into other cell populations of 
mesodermal origin, such as ligaments and tendons (Young et al., 1998), 
cardiomyocytes (Makino et al., 1999) and muscle (Wakitani et al., 1995). Additionally, 
during the 1980s, Arnold Caplan proposed the mesengenic process as an adult 
marrow pathway that contains multipotent progenitor cells, in which MSCs differentiate 
into several mesodermal cell types that can differentiate along many lineages to 
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generate the end-stage differentiated cells that fabricate and maintain mature 
mesenchymal tissue (Caplan & Correa, 2011).  
Later, in the 1990s, Caplan identified the first surface antigens expressed by MSCs, 
cluster of differentiation (CD)73 and CD105. He also showed an association between 
the differentiation characteristics of MSCs and the embryonic development of various 
mesenchymal tissues, leading him to coin the term ‘mesenchymal stem cell’ to 
describe MSCs (Caplan, 1991; Murphy et al., 2013; Murray & Peault, 2015).  
In the 21st century, many studies have shown that the differentiation potential of MSCs 
is not limited to tissues of mesodermal origin, and studies have been designed to 
determine whether MSCs can differentiate into progeny from other embryonic germ 
layers, i.e., to differentiate into ectodermal, mesodermal and endodermal lineage tissue 
types (Kobolak et al., 2015). One study, designed by Munoz-Elias et al. (2004), 
showed that MSCs differentiated in vitro into presumptive neurons, which are cells of 
ectodermal origin. Moreover, they demonstrated that adult MSCs transplanted into 
embryonic rat brain in vivo exhibited a plastic ability to respond specifically to different 
microenvironments by expressing gene products and cell morphologies in a regionally 
and temporally specific manner. Other studies reported that MSCs can break the germ 
layer commitment and can differentiate into a wide range of ectodermal and 
endodermal tissue type lineages, including skin cells (Nakagawa et al., 2005), lung 
cells (Ortiz et al., 2003; Sato et al., 2005), and hepatocytes and pancreatic islet cells 
(Schwartz et al., 2002; Tang et al., 2004). Although MSCs can develop into a broad 
range of cells, they are not considered true stem cells; however, they are functionally 
defined as non-haematopoietic, multipotent cells of ‘mesenchymal’ origin (Caplan, 
2007; Kobolak et al., 2015).  
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In 2008, Crisan et al. (2008) identified perivascular cells, principally pericytes, in 
multiple human organs. Caplan further established that all MSCs are derived from 
perivascular cells, and by cell sorting for pericytes (CD146, CD34, CD45 and CD56), 
he revealed that MSCs can be isolated from every vascularized tissue of the body 
(Caplan, 2008). He also hypothesized that MSCs are activated by the local micro-
environment and react by secreting two sets of bioactive molecules. First, as the front 
of the MSCs enter the injury field, molecules inhibit interrogating immune cells from 
entering (the first line of defence against the establishment of autoimmune reactions). 
Second, at the rear of locally activated MSCs, another complex set of factors is 
secreted and helped establish a regenerative microenvironment. The functions of 
MSCs led Caplan to redefine the MSC as a medicinal signalling cell that functions as a 
drug store at the site of tissue injury or inflammation (Caplan, 2015). He suggested that 
a range of variables must be optimized before MSC-based therapy can be considered 
for cellular medicine (Caplan & Hariri, 2015). 
 
1.1.2 Main criteria provided by the International Society for 
Cellular Therapy to define MSCs  
The rapidly expanding collection of information and published data on MSCs 
highlighted the need to unify the definition of the basic characteristics of MSCs. Within 
the literature, the acronym MSC has been used to represent many cell types, including 
BM stromal cells, mesenchymal stem cells, and multipotent mesenchymal stromal cells, 
and this has resulted in confusion (Troyer & Weiss, 2008).  
The International Society for Cellular Therapy (ISCT) distinguishes mesenchymal 
stromal cells from mesenchymal stem cells via in vivo characterization. For example, 
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after cell engraftment, the cell behaviour is monitored, and they are identified as 
mesenchymal stem cells if they self-renew and exhibit multipotent differentiation. 
Unfortunately, the surface markers that enable stem cells to be selected with certainty 
in BM isolates can be difficult to identify (Troyer & Weiss, 2008). Currently, neither a 
single definition nor a quantitative assay to help improve the identification of MSCs in 
mixed cell populations exists (Horwitz et al., 2005; Ullah et al., 2015). Moreover, these 
stem cells do not have well-defined growth conditions, such as low-glucose Dulbecco’s 
modified Eagle’s medium (DMEM) containing relatively high concentrations of foetal 
bovine serum (FBS) (10–20%); commercially available lots of FBS are variable, and 
this variability can affect the ability to maintain MSCs. Other complexities of 
differentiating MSCs arise from differences between individual donors, such as donor 
age; additional challenges include any changes in potency or phenotype occurring 
during in vitro expansion and limited MSC capability of expanding in vitro (Troyer & 
Weiss, 2008). 
In 2006, the ISCT declared minimal criteria for defining MSCs. The ISCT proposed the 
following identification criteria as a basis for additional characterization of these cells by 
investigators. First, MSCs must be plastic-adherent when maintained in standard 
culture conditions (i.e., α minimal essential medium plus 20% FBS). Second, ≥95% of 
the MSC population must express CD105, CD73, and CD90, and MSCs must not 
express (≤2% positive) the haematopoietic stem cell (HSC) markers CD45, CD34, 
CD14, CD11b, CD79α or CD19 or human leukocyte antigen D-related (HLA-DR) 
surface molecules. Third, MSCs must have the ability to differentiate into osteoblasts, 
adipocytes, and chondroblasts in vitro (Dominici et al., 2006; Kobolak et al., 2015). 
These listed characteristics are valid for nearly all MSCs, although minor variations 
exist in MSCs that are isolated from different tissue origins (Ullah et al., 2015). 
However, since these criteria were published, several reports have suggested that 
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MSCs reside in almost all organs and are located specifically within the connective 
tissue of organs. Furthermore, in addition to isolating these cells by taking advantage 
of their adhesive feature, they can now be isolated using cell surface markers that 
known to be specific to the MSC phenotype (Kobolak et al., 2015). Dominic and 
colleagues (2006) used immunological methods to elucidate MSC surface antigen 
expression. Their results formed the identification criteria for MSCs: the expressed cell 
surface markers should include CD105 (known as endoglin and originally recognized 
by the MAb (monoclonal antibody) SH2), CD73 (known as ecto-5’-nucleotidase and 
previously recognized by the MAb SH3 and SH4) and CD90 (also known as Thy-1). 
These researchers recognized that these criteria can be modified if novel surface 
markers are identified in the future. Moreover, because the basic criteria state that 
MSCs should not express haematopoietic antigens, they proposed that investigators 
should include a panel of antigens to exclude those cells most likely to be found in 
MSC cultures and then select those markers that work reliably in their laboratory for 
their characterization. Cells of haematopoietic origin, namely, macrophages and 
monocytes, are the most likely haematopoietic cells to be found in an MSC culture, and 
they express CD14 and CD11b prominently. CD45 is a pan-leukocyte marker, CD34 is 
a marker of primitive haematopoietic progenitors and endothelial cells, CD79α and 
CD19 are markers of B cells that may also adhere to MSCs in culture and remain vital 
through stromal interactions. HLA-DR molecules are only expressed on MSCs after the 
cells are stimulated by factors such as interferon gamma (IFN-γ). 
 
1.1.3 Tissue sources of MSCs 
Although the name for these stem cells (mesenchymal or multipotent stem cells) is still 
debated, there is a consensus describing them as MSCs (Kalaszczynska & Ferdyn, 
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2015). MSCs have been identified and successfully isolated from almost all tissue 
sources, both foetal and adult. The efficient isolation of MSC populations has mainly 
been reported from BM (Campagnoli et al., 2001; Pittenger et al., 1999). MSC 
populations have also been isolated from other tissues, including adipose (Wagner et 
al., 2005; Zhang et al., 2006; Zuk et al., 2001), lung (Fan et al., 2005; Hennrick et al., 
2007), heart (Chong et al., 2011), and liver tissues (Campagnoli et al., 2001); 
Wharton’s Jelly (WJ) (Erices et al., 2000; Hou et al., 2009; Wang et al., 2004); 
synovium (De Bari et al., 2001); the placenta (Fukuchi et al., 2004); amniotic fluid (In 't 
Anker et al., 2003; Tsai et al., 2004); foetal blood (Noort et al., 2002); limb buds (Jiao et 
al., 2012); endometrium (Cho et al., 2004; Schuring et al., 2011); menstrual blood 
(Allickson et al., 2011); peripheral blood (Ab Kadir et al., 2012; Kassis et al., 2006); 
dental pulp (Gronthos et al., 2000); salivary glands (Rotter et al., 2008); corneal stroma 
(Branch et al., 2012); skin and foreskin (Bartsch et al., 2005; Riekstina et al., 2008); 
skeletal muscle (Williams et al., 1999); and perivascular areas (Kuznetsov et al., 2001). 
Researchers have obtained MSCs from multiple tissues, and the main tissue sources 
exhibit properties that are either beneficial or disadvantageous in terms of multipotent 
properties (Table 1). 
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Advantages Disadvantages References 
BM - Most studied and utilized   
 
- Difficult to procure 
- Lack of suitable donors 
- Proliferation rate related to 
donor age  
- Invasive 
 
(Nemeth & Mezey, 2015) 
Adipose tissue 
 




- Requires digestive enzymes 
 
(Chavez-Munoz et al., 
2013) 




- Easy accessibility (clinical 
waste) 
- Non-invasive 
- Easy to isolate 
 
- Explant or digestive enzymes 
needed 
- Heterogeneous population 
(Kern et al., 2006) 
(Pytlík, 2011) 
(Troyer & Weiss, 2008) 
Placenta 




- Requires digestive enzymes 
- Heterogeneous population 
- Difficult to isolate 
 
(Barlow et al., 2008) 
(Brooke et al., 2009) 
 
 
1.1.4 Adult versus foetal MSCs 
The successful therapeutic application of stem cells depends on the success of stem 
cell extraction and expansion, as well as their immunosuppressive properties. Some 
investigators have harvested human MSCs from foetal BM as well as adult BM, and 
they observed many behavioural differences between the foetal and adult MSCs. In 
vitro, foetal MSCs show greater expansion capacity, with no loss of phenotypic 
characteristics and faster doubling time than that of adult MSCs; these observed 
differences have been suggested to be due to the chromosomes in foetal MSCs having 
longer telomeres than the chromosomes of adult MSCs (Campagnoli et al., 2001; 
Guillot et al., 2007; Troyer & Weiss, 2008). The observed capabilities of foetal MSCs 
may result from their youth and lack of maturity; foetal MSCs have a different 
physiology that is likely due to their naive status (Gotherstrom et al., 2005; Weiss & 
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Troyer, 2006). Adult MSCs exhibit immunosuppressive properties that do not seem to 
exist in foetal MSCs (Gotherstrom et al., 2003; Troyer & Weiss, 2008). Moreover, they 
express class II human leukocyte antigen (HLA), which is absent in foetal MSCs 
(Gotherstrom et al., 2005; Troyer & Weiss, 2008). Likewise, foetal MSCs appear to 
synthesize human leukocyte antigen G (HLA-G), which is absent in adult MSCs. HLA-
G is a ligand for inhibitory receptors on natural killer (NK) cells and lymphocytes; it has 
been suggested to act as an immunosuppressor during pregnancy. Despite some 
differences in the expression profiles of these cell types, neither foetal nor adult MSCs 
appear to be innately immunogenic as they are not recognized by lymphocytes 
(Gotherstrom et al., 2005). Furthermore, comparisons of the cytokine profiles of both 
MSC types have shown some differences. Similar observations have been reported 
regarding umbilical cord (UC) blood and adult peripheral blood (Troyer & Weiss, 2008). 
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1.2 MSC clinical trials 
1.2.1 MSC biological properties to support clinical trials 
The first-ever clinical trial using culture-expanded MSCs from BM was conducted by Dr. 
Hilary Lazarus in 1995; 15 patients who presented with haematologic cancer became 
the recipients of the therapy (Lazarus, 1995). Since then, several clinical trials have 
been conducted with over 2,000 patients to determine the feasibility and efficacy of 
using either autologous or allogeneic MSCs to treat various congenital and acquired 
diseases, including graft-versus-host disease (GVHD) (Squillaro et al., 2015).  
The effectiveness of MSCs for treating acute GVHD has been shown by Le Blanc and 
colleagues (2004) via the first transplantation of haploidentical MSCs in a 9-year-old 
child receiving treatment for therapy-resistant grade IV acute GVHD of the gut and liver. 
After 1 year, a remarkable clinical response without any complications was observed. 
Another example of an MSC-based application for the treatment of acute leukaemia 
was reported by Lee and colleagues (2002), who described a 20-year-old patient with 
myelogenous leukaemia; this patient received an allogenic HSC and MSC 
transplantation from the haploidentical father. The cells engrafted rapidly, and the 
patient did not exhibit signs of acute GVHD. After 31 months, a haematological 
response was observed to have occurred, and the patient showed a complete 
remission of the leukaemia. Recently, Zhao et al. (2015) was able to treat 47 patients 
with refractory acute GVHD; 28 patients out of 47 received the MSC treatment, and the 
rest were infused with saline. The overall response rate to the treatment was 75% in 
the MSC group and 42.1% in the non-MSC group. The authors concluded that the 
incidence and severity of chronic GVHD might be reduced via MSC-based treatment in 
acute GVHD patients.  
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MSCs have been shown to be promising candidates for the treatment of many types of 
immunological and non-immunological disorders. Several models implementing the 
beneficial properties of MSCs have arisen (Squillaro et al., 2015; Wei et al., 2013); 
specifically, such properties include their ability to i) differentiate, ii) secrete factors 
important for cell survival and proliferation, iii) modulate immune response, and iv) 
migrate to injury sites. These four aspects are combined and overlapped, and their 
exact roles in the therapeutic effects of MSCs have not yet been clearly defined (Wang 
et al., 2012).  
 
1.2.1.1 Differentiation potential 
The multipotent characteristics of MSCs enable them to differentiate into cells of 
mesenchymal lineages, such as osteoblasts, chondroblasts, adipocytes, myocytes, 
and tenocytes, both in vitro and in vivo. MSCs obtained from a range of adult and birth-
related tissues exhibit various differentiation characteristics (Table 2). MSCs have also 
been reported to transdifferentiate into non-mesodermal cell types similar to neuronal 
cells, hepatocytes, and pancreatic islet-like cell clusters that express insulin and 
glucagon (Chao et al., 2008; Chen et al., 2004). Furthermore, Kopen and colleagues 
(1999) were the first to show that MSCs injected into the central nervous system of 
newborn mice could adopt the morphological and phenotypic characteristics of 
astrocytes and neurons. These reports suggested that MSCs possess tremendous 
plasticity and can rapidly alter their phenotype via transdifferentiation, producing cells 
bearing the features and characteristics of different lineages (Squillaro et al., 2015).   
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Type equation here. 
 
Table 2. Properties of differentiation for MSCs from different sources. 
 
MSC source 
Multi-lineage differentiation ability 




BM-MSCs Good ability for all three lineages 
Charbord et al. (2011) described novel factors implicated in 
osteogenesis and adipogenesis. 
 
Johnstone et al. (1998) developed a culture system that 
facilitates the chondrogenic differentiation of postnatal 
marrow mesenchymal progenitor cells. 
Synovial MSCs Very good ability for all three lineages 
Yoshimura et al. (2007) found that synovium-derived cells 
have the highest proliferation rate and chondrogenic 
potential after passage in rats, and similar results were 
observed in humans. 
Adipose MSCs Good ability for all three lineages 
Heo et al. (2016) demonstrated that MSCs derived from BM 
and adipose tissue shared not only in vitro tri-lineage 
differentiation potential but also gene expression profiles. 
Tendon MSCs Very good ability for osteogenic and chondrogenic lineages 
Rui et al. (2010) showed that tendon MSCs exhibited higher 
osteogenic differentiation than BM-MSCs. 
Circulating MSCs Fair ability for osteogenic and adipogenic lineages 
Zvaifler et al. (2000) showed that circulating blood contains 
a small population of CD34 mononuclear cells that 
proliferate and differentiate into several lineages such as 
osteoblasts and adipocytes. 
Placenta MSCs Varied ability for all three lineages 
Jeon et al. (2016) placental MSCs have a lower potential to 
undergo adipogenesis but have a higher potential to 
undergo osteogenesis than other MSCs. 
Heart stromal 
MSCs Good ability for all three lineages 
Srikanth et al. (2013) showed that rat foetal cardiac MSCs, 
in addition to suitability for cardiovascular regenerative 
therapy, have the potential to differentiate into cells of all 
three germ layers. 
Amniotic fluid 
MSCs Fair ability for all three lineages 
Pievani et al. (2014) found that amniotic fluid MSCs 
completely fail to differentiate into cartilage and show that 
their multipotent capacity is limited to osteogenic 
differentiation. 
Chorionic villi 
MSCs Fair ability for all three lineages 
Barlow et al. (2008) found human placental MSCs derived 
from placental tissue (including chorion, amnion and 
desidua basalis) showed the potential for osteogenic and 
chondrogenic differentiation but were less able to 
differentiate into adipocyte lineages. 
 
The transdifferentiation and differentiation properties of these cells have sparked 
innovative ideas for potential clinical applications. Their ability to differentiate into 
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epithelial-type cells holds much promise for tissue engineering and cellular therapy 
(Squillaro et al., 2015). For example, Li and colleagues (2010) used the infusion of 
human adipose-derived MSCs and their transdifferentiation into renal tubular 
epithelium to recover tissue by repairing damaged cells and maintaining their structural 
integrity. Others have reported some related challenges; for example, MSCs have 
been observed to become trapped within the capillaries of lung tissues (Galderisi & 
Giordano, 2014; Lee et al., 2009; Sohni & Verfaillie, 2013). Other studies have 
investigated animal models of lung injury that is inflicted by bleomycin exposure; these 
studies demonstrated that the MSCs engrafted into these lungs either differentiated 
into type I pneumocytes and type II epithelial cells or they seemed to bear features of 
all myofibroblasts (Kotton et al., 2001; Ortiz et al., 2003; Rojas et al., 2005). 
A significant point to consider is that the evidence of the benefits of MSCs to treat 
disease have been reported using in vitro-based studies; therefore, the assessment 
and interpretation of these results are limited. With this under consideration, recent 
studies have adopted in vivo approaches for studying many MSC features; aside from 
MSC differentiation potential, these studies have strived to understand other 
mechanisms of MSC action that contribute therapeutic effects (Squillaro et al., 2015). 
In addition, more data have emerged, suggesting that the replacement of damaged 
cells by MSCs through specific differentiation may be just a small part of the process 
underlying the therapeutic effects of MSCs (Wang et al., 2012).  
 
1.2.1.2 Bioactive molecule secretion  
Many studies have identified key findings that explain the successful use of MSCs for 
transplantation. These studies suggest that MSCs interact with their environment by 
secreting many types of active biological factors, such as cytokines, chemokines and 
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growth factors (Galderisi & Giordano, 2014). In turn, these molecules profoundly affect 
the dynamics of the local cellular microenvironment. Studies have shown that these 
biological factors may not only prevent cells in the vicinity from undergoing apoptosis 
but also stimulate their proliferation, thereby recovering sites of tissue injury. Other 
researchers have observed in their experiments that regardless of the number of MSCs 
implanted in injured tissues, the resulting cell numbers were too low to consider them 
to have significantly contributed to tissue recovery or wound healing (Wang et al., 
2011). However, other evidence has demonstrated the contrary, whereby once MSCs 
were infused into injured tissue, they exerted paracrine effects and interacted with local 
stimuli, such as inflammatory cytokines, the ligands of Toll-like receptors, and hypoxia. 
In this way, MSCs were observed to stimulate the cells to exhibit many growth factors 
that carry out several functions in tissue regeneration (Caplan & Dennis, 2006; 
Crisostomo et al., 2008). Current knowledge highlights the need not only for 
comprehensively testing MSCs to ascertain their strategies for modulating their 
secretion of molecules with greater certainty but also for developing techniques to 
identify the important factors released by MSCs. Proteins secreted by MSCs include 
interleukin-6 (IL-6), IL-8, and monocyte chemoattractant protein-1 (MCP-1), which are 
known for their signalling role in the immune system, as well as transforming growth 
factor-β (TGF-β), which is known to suppress T-lymphocyte proliferation (Di Nicola et 
al., 2002). Other important molecules that are secreted and known for their role in 
remodelling the extracellular matrix (ECM) include metallopeptidase inhibitor-2 (TIMP-
2), fibronectin, periostin, collagen, decorin and metalloproteinase inhibitors. Growth 
factors and their regulators are also released, such as granulocyte-macrophage 
colony-stimulating factor (GM-CSF), bone morphogenetic protein 2 (BMP2), basic 
fibroblast growth factor (bFGF), insulin-like growth factor-binding protein 3 (IGFBP3), 
IGFBP4 and IGFBP7 (Galderisi & Giordano, 2014). The bioactive molecule vascular 
endothelial growth factor (VEGF) is known to enhance the proliferation of endothelial 
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cells and smooth muscle cells (Kinnaird et al., 2004). IL-10, IL-1 receptor antagonist 
and prostaglandin-E2 are known to play anti-inflammatory roles (Foraker et al., 2011; 
Gupta et al., 2007; Nemeth et al., 2009; Ortiz et al., 2007). The secretory molecule 
cathelicidin antimicrobial peptide (LL-37) is known to function as an antimicrobial 
peptide, and it also reduces inflammation (Krasnodembskaya et al., 2010). MSCs are 
thought to secrete angiopoietin-1 to restore epithelial protein permeability (Fang et al., 
2010). Matrix metallopeptidase-3 (MMP3) and MMP9 are known to mediate 
neovascularization (Kim et al., 2007). In addition, keratinocyte growth factor is known 
to play a role in alveolar fluid transport (Lee et al., 2009; Wang et al., 2012).  
Other studies have reported that the administration of MSC-conditioned medium may 
support the theory of paracrine effects; components of this conditioned medium may 
act as chemoattractants for recruiting other cells such as macrophages and endothelial 
cells to the site of tissue injury, thereby promoting the healing process (Chen et al., 
2008). A good example of this paracrine feature of MSCs has been shown by 
Takashashi and colleagues (2006). MSC-conditioned medium infused into hearts 
undergoing acute necrosis improved cardiac function by inhibiting the apoptosis of 
cardiomyocytes and controlled ischaemic injury by increasing capillary density; these 
effects stemmed directly from the preserved contractile capacity of the myocardium 
and the stimulated therapeutic angiogenesis of the infarcted heart. Van Poll and 
colleagues (2008) have reported evidence that MSC-conditioned medium provides 
trophic support to injured liver tissue by inhibiting hepatocellular death and inducing 
regeneration, thus enabling new methods for treating fulminant hepatic failure. 
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1.2.1.3 Immunomodulatory MSC effects 
Liechty et al. (2000) was the first to recognize the immunomodulatory effects of MSCs 
upon in utero transplantation in sheep. Since then, numerous researchers have 
demonstrated, in both human and animal models, the ability of MSCs to treat various 
immune-related disorders (Wei et al., 2013). Unfortunately, the mechanism of MSC 
immunomodulatory function remains to be elucidated. The most commonly accepted 
theory for this mechanism of action is based on cell-to-cell interactions and the ability 
of MSCs to release many immunosuppressive molecules (Squillaro et al., 2015; Wang 
et al., 2012).  
Many studies have demonstrated the ability of MSCs to interact with a variety of 
immune cells as well as their ability to suppress responses by T cells, B cells, dendritic 
cells, macrophages and NK cells (Han et al., 2012; Uccelli et al., 2008). Moreover, 
MSCs have been shown to induce and regulate the capability of regulatory T cells, 
which are thought to expand and persist in the presence of MSCs (Ghannam et al., 
2010; Gonzalez et al., 2009; Tasso et al., 2012). When MSCs are injected in vivo, they 
are thought to function as catalysts for the expansion of antigen-specific regulatory T 
cells, indicating their potential to regulate important immunomodulatory functions 
(Tasso et al., 2012). This makes them suitable for the treatment of autoimmune 
diseases and GVHD. For example, Popp and colleagues (2008) showed that donor-
derived MSCs induced long-term allograft acceptance in a rat model of heart 
transplantation. Based on these findings, MSCs have been proposed to play a 
beneficial role in promoting tissue repair. In addition, the systematic use of MSCs has 
been suggested for treating subjects with damaged tissues or organs causing 
inflammation or inflammatory activities that are associated with diseases such as 
kidney failure, heart injury and rheumatoid arthritis (Squillaro et al., 2015).  
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Recently, new findings have emerged that shed light on the immunomodulatory 
properties of MSCs. These findings propose that MSCs interact with their local 
environments by negatively regulating the immune response when major inflammation 
occurs and by stimulating the release of proinflammatory factors when levels of 
inflammatory cytokines are low (Bernardo & Fibbe, 2013; Galderisi & Giordano, 2014).  
 
1.2.1.4 Homing efficiency     
Another remarkable feature of MSCs is their ability to respond when injury occurs. 
Through a perfect combination of signalling molecules emitted from a site of injury and 
corresponding surface receptors, MSCs are able to locate and migrate to damaged 
tissue and subsequently engraft in the sites of inflammation. Many researchers have 
studied this homing ability of leukocytes to migrate to sites of inflamed tissue (Moser & 
Loetscher, 2001) in an effort to elucidate the roles of surface receptors and involved 
molecules that are known to be drivers of the homing mechanism. However, a clear 
explanation for how these MSCs are recruited to sites of injury has not yet been found. 
Other studies using MSCs have shown their capacity to home to sites of inflammation 
in damaged tissues, regardless of tissue type (Forte et al., 2008; Horwitz et al., 2002; 
Mahmood et al., 2003); however, MSCs migrating towards inflammation in the lungs 
have been reported to become lodged in the lung microvasculature (Squillaro et al., 
2015).  
Cell migration is thought to be regulated by and dependent on multiple signals ranging 
from growth factors to chemokines secreted by injured cells and/or responding immune 
cells (Spaeth et al., 2008). Studies examining MSC homing have shown that the 
mechanism involves many trafficking-related molecules, such as chemokines, 
adhesion molecules and matrix metalloproteinases (Wei et al., 2013), as well as 
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important signalling factors, such as stromal-derived factor 1 (SDF1), chemokine C-X-
C motif receptor 4 (CXCR4) and hepatocyte growth factor and its receptor, the 
transmembrane tyrosine kinase (HGF-c-MET axes) (Neuss et al., 2004; Shi et al., 
2007; Son et al., 2006). These studies have shown that the migration process relies on 
the receptor CXCR4 and its binding partner, SDF1 chemokine C-X-C motif ligand 12 
(CXCL12) (Sohni & Verfaillie, 2013). Wynn and colleagues (2004) have shown that 
CXCR4 is found in subpopulations of MSCs, which facilitates CXCL12-dependent 
homing and migration. Furthermore, BM-MSCs have been shown to express other 
molecules that are thought to be involved in the migration process, namely, chemokine 
C-C motif receptor 1 (CCR1), CCR4, chemokine C-X-C motif receptor 5 (CXCR5), 
CXCR6, CCR7, CCR9 and CCR10 (Sohni & Verfaillie, 2013). MSCs migrate by a 
coordinated process known as transendothelial migration, which involves adhering to 
vascular endothelial cells and then crossing the endothelial barrier (Schmidt et al., 
2006). The mechanism of adhesion between MSCs and the microvascular endothelium 
indicates coordinated rolling on and adhesion to endothelial cells mediated by the late 
antigen-4/vascular cell adhesion molecule-1 (VLA-4/VCAM-1) (Ruster et al., 2006; 
Wang et al., 2011). Furthermore, matrix metalloproteinases, such as matrix 
metallopeptidase-2 (MMP2) and membrane type 1 metalloprotease (MT1-MMP), have 
been shown to be important to the invasiveness of MSCs (Ding et al., 2009; Ries et al., 
2007). Homing-related molecules can be up-regulated by inflammatory cytokines, such 
as tumour necrosis factor (TNF) and IL-1 (Ren et al., 2010). This suggests that 
different inflammation states may promote specific and distinctive MSC engraftment 
and therapeutic actions (Wei et al., 2013).  
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1.2.2 MSC clinical trials to date  
Squillaro et al. (2015) report that the number of current and previously undertaken 
MSC-based clinical trials has doubled in the last few years. The majority of the trials 
are in phase I, which includes safety studies (n=109), phase I/II (n=185), or phase II, in 
which proof-of-concept for efficacy in human patients needs to be demonstrated (n=98). 
A few trials have reached phase II/III (n=17) or phase III (n=26), in which a newer 
treatment is compared with a standard or well-known treatment. Remarkably, phase I/II 
and phase II/III are mixtures of each other. The data show that when MSC-based trials 
are classified by disease type, the highest proportion of trials are studying bone and 
cartilage disease, followed by neurological disease, cardiovascular disease, GVHD, 
liver disease, diabetes, and haematological disease. The smallest proportion of clinical 
trials includes those studying treatments for Crohn’s disease and lupus 
erythaematosus (Squillaro et al., 2015). 
Indeed, as of December 2016, the number of either completed or on-going MSC-based 
clinical trials registered in the official database of the United States National Institute of 
Health (U.S. National Institute of Health, 2016) under the search term ‘mesenchymal 
stem cells’ stood at 676; together, these trials covered a very wide range of therapeutic 
applications. These trials have and will provide information and evidence pertaining to 
the outcomes of MSC infusion and administration, and these results should support 
preliminary observations that the efficacy of MSC-based therapy can extend to 
diseases beyond the few that are currently targeted by therapeutic applications 
(Squillaro et al., 2015). Presently, the main challenges facing the use of MSCs in 
clinical practice are issues such as donor heterogeneity, the lack of standardized 
procedures regulating ex vivo expansion that is known to affect MSC properties, 
immunogenicity and cryopreservation (Galderisi & Giordano, 2014; Galipeau, 2013).   
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1.2.3 MSC donor criteria  
The guidelines recommended for the screening and testing for MSC donations 
are similar to those in place for other cell-based or tissue-based products. The 
purpose of these guidelines is both to determine who can be a donor and to 
protect the health and safety of recipients. According to the National Health 
Service (NHS) UC Bank, the use of health questionnaires is recommended to 
determine the status of a donor, such as whether a donor tested positive for 
hepatitis C antibody or hepatitis B surface antigen or whether female donors 
have had malaria within the last three years or a full course of anti-malaria 
treatment within the past six months. The viral testing of female donors who are 
at higher risk for or who have Human Immunodeficiency Virus (HIV) is also 
recommended (National Marrow Donor Program, 2016; NHS Blood and 
Transplant, 2016). Furthermore, donor age is an important factor to consider. It 
has been observed that BM from children contains a higher concentration of 
CFU-F precursors than does BM from adults (Baxter et al., 2004). Moreover, an 
MSC donor should have no abnormalities or risks for abnormalities potentially 
involving MSCs, which may currently be difficult to assess. The guidelines also 
recommend that an extra blood sample be taken from each donor for testing in 
an effort to exclude any medical reasons that may prevent them from being a 
donor (Sharma et al., 2014).  
Wu and colleagues (2013) hypothesized that obesity has an inhibitory effect on 
the multipotent potential of MSCs. Their findings indicate that obesity affects 
MSCs by resulting in altered in vitro adipogenic and osteogenic potential; 
	34	
furthermore, they suggest that increased body mass seems to promote bone 
formation and that the characteristics of stem cells resident in many tissues be 
significantly affected by obesity, such that their capacity for therapeutic 
applications becomes undermined. By the current definition of epigenetics, the 
issue of qualifying MSCs as universal donors should be reconsidered carefully, 
even more so when they are to be used for multiple recipients.  
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1.3 Umbilical Cord and Wharton’s Jelly  
1.3.1 UC formation and structure 
The human UC is a flexible tube-like structure that is formed during pregnancy. It 
connects the developing embryo to the placenta and not only supplies the developing 
embryo with oxygen and nutrients from the mother but also removes waste products 
from the embryo (Sadler, 1990). The UC is formed by 22 days post coitum (dpc), when 
the body stalk and the extra-embryonic omphalomesenteric duct (an intermediate 
structure formed from the primary yolk sac and a precursor of the secondary yolk sac, 
or secondary yolk) become completely surrounded by the amnion; during this stage, 
extensions of the allantois also occupy the UC (Baergen, 2011). During the period from 
28-40 dpc, the amniotic cavity starts to surround the connecting stalk and the embryo, 
pressing the stalk into a thin tube-like structure; the cavity then becomes surrounded 
by the amniotic epithelium. During this time, the allantois and yolk sac regress 
(Baergen, 2011; Subramanian et al., 2015) (Figure 1). This newly formed UC continues 
to lengthen; it is essentially composed of the umbilical vessels surrounded by a 
connective tissue called WJ (Baergen, 2011). The main feature of the UC is its 
elasticity, which enables it to protect the umbilical vessels from compression, torsion, 
and bending and to avoid compromising the bi-directional blood flow between the 
mother and embryo (Kim et al., 2013). A striking feature of the UC is its helical-like 
arrangement; most of the cords that have been examined in mothers exhibit counter-
clockwise turns (Malpas & Symonds, 1966), and the veins and arteries within the cord 
are also arranged in a helical format. Both the helical coils and the mean length of the 
UC are used to calculate the umbilical coiling index (UCI), and these measurements 
are used to determine whether a foetus is at risk (Can & Karahuseyinoglu, 2007; Peng 
et al., 2006; Trevisanuto et al., 2007). At term, the UC is approximately 60-cm to 65-cm 
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long on average, approximately 1.5-cm in diameter, and approximately 40-g in weight 
(Can & Karahuseyinoglu, 2007; Di Naro et al., 2001; Raio et al., 1999).  
 
 
Figure 1. Simplified schematic of the developing UC at approximately day 20 post coitum. The connecting 
stalk progresses ventrally as a result of the cephalocaudal flexion of the embryo and fuses with the yolk 
sac stalk to form the UC. Reproduced from (Pansky, 1982).  
 
The UC consists of two umbilical arteries and one umbilical vein, which are all 
embedded within the WJ (Figure 2). The UC is enveloped by a single or multiple 
layer(s) of squamous-cubic epithelial cells, which are thought to be derived from the 
amniotic epithelium. As this tissue grows to cover the surface layer of the UC, it also 
becomes contiguous with the placenta and developing embryo (Can & 
Karahuseyinoglu, 2007; Copland et al., 2002; Mizoguchi et al., 2004). The tissues of 
the human UC are compartmentalized into distinct regions, and the regions consist of 
unique tissue structures in terms of ECM component composition, including connective 
tissue fibres and proteins. The cellular characteristics of these regions show 
differences in both the number and nature of cells. The results of functional and 
immunohistochemical studies have led to the hypothesis that these regions may 
	37	
originate from different pre-existing formations (Akerman et al., 2002; Karahuseyinoglu 
et al., 2007; Nanaev et al., 1997; Sarugaser et al., 2005; Takechi et al., 1993). For 
example, myofibroblast cells of the WJ may have been derived from either the adjacent 
vascular smooth muscle cells or pre-existing fibroblasts (Can & Karahuseyinoglu, 
2007). Can & Karahuseyinoglu (2007) reviewed and described six distinct zones in the 
UC. In order from the outermost to the innermost region, they are as follows: a) The 
amnion epithelium and UC epithelium comprise type IV and type VII collagen and are 
located in the epithelial basement membrane in term cord. b) The subamniotic stroma 
comprises collagen types I, III, and VI. c) Clefts form a spongy network of interlacing 
collagen fibres in a continuous, soft skeleton enclosing a wide system of 
interconnected cavities and canaliculi-like structures. This structure is thought to have 
a mechanical function that prevents any inconsistences of ground substance during 
any compression events that may arise. The remaining three zones include the 
following: d) WJ, e) the perivascular stroma, and f) vessels (Figure 2). Collagen can not 
be easily solubilized by organic or chemical substances; it builds strong ionic bonds 
with glycosaminoglycans and proteoglycans, and the structure of collagen is what 
allows it to fulfil its functions by providing the stroma with extraordinary strength (Can & 
Karahuseyinoglu, 2007; Sobolewski et al., 1997).  
Stem cells have been shown to be derived from distinct regions of the UC. The 
nomenclature used in the literature for the listed compartments has been 
unstandardized (Bongso & Fong, 2013; Jeschke et al., 2011). Within these 
compartments, stem cell populations with various stem cell-like properties have been 
described (Conconi et al., 2011). Various derivation protocols for isolating stem cells 
have been described by researchers in the literature. These protocols are not 
standardized, and at times, the variations in stem cell populations from different 
compartments have not been considered (Bongso & Fong, 2013). Recent studies have 
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demonstrated that MSCs isolated from the WJ, in particular, are preferred over those 
isolated from other UC compartments due to the simple and easily standardized 
isolation procedure, smaller non-stem cell populations; additional advantages include 
the large numbers of MSCs that can be generated with minimal manipulation, as well 
as the rich stemness characteristics and ability of these MSCs to proliferate with a 
broad differentiation potential (Subramanian et al., 2015).   
 
 
Figure 2. A cross-sectional diagram illustrating the compartments of the human UC, including the amnion, 
the subamnion, WJ, the perivascular region, the adventitia, the endothelium, and the UC blood and 
vessels.  
 
1.3.1.1 UC-MSC versus embryonic stem cell surface markers 
UC-MSCs are classified as perinatal stem cells. The term ‘perinatal’ refers to the period 
from immediately before (prenatal) to the period immediately after (postnatal) birth. 
These stem cells are considered to be valuable for their broad use in developing 
regenerative medicine strategies and for their impressive ability to modulate the 
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immune response (Aggarwal & Pittenger, 2005; Friedman et al., 2007; Le Blanc & 
Ringden, 2005).  
UC-MSCs share common surface markers with other MSCs, such as BM-MSCs. They 
adhere to and grow on surfaces such as plastic. Various techniques, namely, 
polymerase chain reaction (PCR), real-time polymerase chain reaction (RT-PCR), 
immunocytochemistry and microarray analysis, have been employed to identify UC-
MSCs, which are identified by the presence of the surface markers CD105, CD90, and 
CD73. However, these markers are also present amongst MSCs from different sources 
(Can & Karahuseyinoglu, 2007; Dominici et al., 2006). Additional identification of MSCs 
is based on their in vivo characterization; for instance, upon engraftment, MSCs self-
renew and undergo multipotent differentiation (Troyer & Weiss, 2008). Studies have 
shown that they express certain embryonic stem cell (ESC) markers, e.g., HLA-1, 
albeit in low levels. Some reports in the literature have shown cultured UC cells to have 
inconsistent gene expression profiles. Sarugaser et al. (2005) demonstrated that HLA-
1 expression in UC-MSCs was stable for up to five passages and that no HLA-1 
expression could be detected in cells recovered after cryopreservation. In contrast, 
Weiss and colleagues (2006) did not find any changes in expression throughout a 
number of passages. One potential explanation for the variations in gene expression is 
differences in epigenetic factors, which may have been caused by varying culture 
conditions.  
Many studies have reported that three specific transcription factors expressed in 
human ESCs are thought to play a central role in the events regulating pluripotency 
and self-renewal. These transcription factors include POU5F1 (OCT4), SRY-box 2 
(SOX2) and NANOG homeobox (NANOG) (Carlin et al., 2006; Chambers et al., 2003; 
Mitsui et al., 2003). It has been shown that down-regulation of NANOG induces the 
differentiation of human ESCs into extra-embryonic lineages (Hyslop et al., 2005; Liu et 
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al., 2009). In addition, the expression of these three markers has been reported in 
cultured WJ-MSCs (Carlin et al., 2006). Human UC-MSCs inherit some of the 
stemness properties of both ESCs and adult MSCs. Developmentally, the UC exists 
between the embryo and adult, and that is likely the reason behind UC-MSCs inheriting 
some ESC markers (Bongso & Fong, 2013; Pappa & Anagnou, 2009). 
Liu and colleagues (2009) discussed increased MSC growth rate and enhanced colony 
formation due to an ectopic expression of NANOG, suggesting that an overexpression 
of NANOG maintained MSC stemness. In addition, this expression might function in 
mature MSCs in the same fashion as it does in ESCs, showing the capacity of NANOG 
to act as a key player in sustaining the pluripotency of stem cells. Furthermore, MSCs 
overexpressing NANOG have much higher capabilities for expansion and osteogenesis 
(Go et al., 2008). Oct4 has been shown to be temporally expressed in the endoderm 
and neuroectoderm of developing embryos (Palmieri et al., 1994; Reim & Brand, 2002). 
Furthermore, down-regulation of Oct4 in ESCs causes trophectoderm differentiation, 
while overexpression of the same marker causes differentiation into extra-embryonic 
mesoderm and endoderm (Niwa et al., 2000), demonstrating that Oct4 is an important 
dose-dependent determinant of ESC pluripotency status. Liu’s group (2009) 
demonstrated that overexpression of OCT4 in MSCs not only promoted proliferation 
rate but also enhanced colony formation, suggesting that overexpression of OCT4 
plays a critical role in maintaining the stemness of MSCs. 
Researchers have shown that the main three transcription factors (i.e., Nanog, Oct4 
and Sox2) are expressed at high levels in ESCs and are markers of primitive stem cells. 
The down-regulation of all three transcription factors is correlated with the loss of 
pluripotency and the capacity for self-renewal (Chambers et al., 2003; Mitsui et al., 
2003). It has been reported that stem cells isolated from postnatal sources, such as 
BM (Kucia et al., 2005), vascular and perivascular space (Kim et al., 2004; Romanov et 
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al., 2003; Sarugaser et al., 2005), placental tissue (Fukuchi et al., 2004; Yen et al., 
2005) and UC blood (Bodger, 1987; Erices et al., 2000; Yang et al., 2004), have more 
restricted differentiation potential, and these cells are not thought to be pluripotent. 
OCT4, SOX2 and NANOG are expressed in these cells but not at high levels (Carlin et 
al., 2006). The results reported by Carlin and colleagues (2006) from research using 
porcine UC cells have been consistent with the interpretation that porcine UC cells 
represent a stem cell population that expresses OCT4, NANOG and SOX2 and that 
these factors are central regulators of gene transcription in primitive stem cells. All of 
these transcription factors have been reported to be occupying the promoters of over 
2,000 human genes and co-occupying over 350 gene promoters (Boyer et al., 2005). 
Some reports in the literature have concluded that these three transcription factors 
control pluripotency and self-renewal both individually and together in human ESCs. 
In contrast, other studies by Fong and others (2007, 2011) using different 
characterization techniques have found low expression levels of the key pluripotency 
markers, such as NANOG, OCT4 and SOX2, in human WJ-MSCs. These results 
confirm the stemness of WJ-MSCs. These researchers hypothesized that this could be 
the reason why human WJ-MSCs do not produce teratomas when they are 
transplanted in an undifferentiated status. One explanation for the different expression 
levels of OCT4 that have been reported could be that in humans, there are two 
isoforms of POU5F1 (i.e., OCT4A and OCT4B), and POU5F1 becomes difficult to 
detect because only OCT4A is included in the maintenance of pluripotency, whereas 
OCT4B is expressed ubiquitously (La Rocca et al., 2009; Lee et al., 2006; Takeda et 
al., 1992). Additionally, differences in cell isolation procedures and culture conditions 
may explain divergent results in the literature. These pluripotency markers are up-
regulated in undifferentiated human ESCs and have been shown to maintain 
pluripotency in self-renewing human ESC populations (Zhao & Daley, 2008). The 
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reduced relative expression of these pluripotent markers in UC-MSCs would suggest 
that they are not as pluripotent as ESCs; nonetheless, the data suggest that UC-MSCs 
are notably multipotent (Taghizadeh et al., 2011). Based on the findings that WJ-MSCs 
express common mesenchymal CD markers similar to those of other MSCs, they are 
typically considered to originate from mesenchymal or connective tissue 
(Karahuseyinoglu et al., 2007). Furthermore, WJ-MSCs have been shown to express 
matrix receptors and not receptors of haematopoietic lineage, suggesting more 
similarities to MSCs (Fong et al., 2007). 
 
1.3.2 WJ description  
Within the UC, between the amniotic epithelium and the umbilical vessels, lies WJ 
(Figure 2), which was initially described by Thomas Wharton in 1956 as a substance 
that is composed of a primitive mucus and connective tissue (Taghizadeh et al., 2011; 
Wharton, 1656). In the 1990s, instead of discarding UCs, scientists re-examined the 
WJ stromal cells and ECM composition of the UCs. Two main drivers were behind 
these examinations. One driver was the search to detect potential structural alterations 
present in cases of pre-eclampsia, as ECM components of the WJ had been found to 
be altered and were associated with the ‘premature ageing’ observed in pre-eclampsia 
patients (Bankowski et al., 2004; Bankowski et al., 1996). The second driver was the 
cellular identification of UC stromal cells, which essentially resemble mesenchymal 
fibroblasts found elsewhere during in utero development (Can & Karahuseyinoglu, 
2007).  
WJ is known to be rich in proteoglycans, particularly hyaluronic acid, which is an 
important substance that retains water and maintains the elasticity of the UC. Another 
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major component of the ECM of WJ is the ground substance, which is mainly 
composed of glycosaminoglycans (GAGs). The total abundance of GAGs in WJ is 
twice as high as that contained in the arteries, the amount of sulphated GAGs (i.e., 
keratin, heparin, dermatan, chondroitin-4, and chondroitin-6 sulphate) is very low, and 
traces of heparin are present (Sobolewski et al., 1997). Structurally, WJ does not 
contain any capillaries or lymphatics. The main function of WJ is to prevent any 
obstruction of the umbilical vessels, such as that caused by compression and torsion, 
and to prevent bending of the umbilical vessels so that not only is an uninterrupted 
supply of oxygen and nutrients, namely, glucose and amino acids, provided to the 
developing foetus but also the removal of carbon dioxide and other waste products 
from the placenta and the foetus is maintained (Can & Karahuseyinoglu, 2007; 
Taghizadeh et al., 2011; Troyer & Weiss, 2008; Wang et al., 2008). 
WJ is known to contain primitive MSCs, and it has been shown that during the early 
stages of embryogenesis, before embryonic day 10.5, the MSCs migrate through the 
aorta-gonad-mesonephros (AGM) region of the developing cord. These MSCs are 
thought to be trapped in the connective tissue matrix during their migration. Through 
the early stages of embryogenesis, haematopoiesis occurs within the yolk sac and then 
in the AGM region. Colonies of early HSCs and MSCs migrate to the placenta via the 
developing UC between embryonic day 4 and embryonic day 12. A second migration of 
the HSCs and MSCs from the placenta occurs through the developing UC to the liver 
of the developing foetus, after which the cells finally engraft into the foetal BM, where 
they reside for the entire lifespan of the human. The colonies contain precursors of 
HSCs and primitive MSCs. The MSCs are thought to become embedded in the WJ 
quite early in embryogenesis, perhaps during the migration events, and to remain there 
for the entire gestation period (Wang et al., 2008).  
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The formation of these perinatal stem cells during the early embryonic stages enables 
them to exhibit characteristics resembling those of ESCs as well as bear features of 
the somatic MSCs found in the BM (Taghizadeh et al., 2011). This resemblance has 
been defined by the ISCT (Dominici et al., 2006). Taghizadeh and colleagues (2011) 
define WJ stem cells as native stem cells that are found within the UC-ECM, and they 
define UC-MSCs as in vitro cell populations derived from WJ-MSCs. 
Cells derived from WJ have a higher CFU-F frequency. Consequently, more MSCs 
may be found in the initial isolation from WJ than in those from BM or UC blood 
(Karahuseyinoglu et al., 2007; Sarugaser et al., 2005; Troyer & Weiss, 2008). 
Moreover, WJ-MSCs have greater expansion capability and grow faster in vitro, and 
they are thought to synthesize cytokines, such as GM-CSF and granulocyte colony-
stimulating factor (G-CSF), that have not been shown to be synthesized by BM-MSCs 
(Lu et al., 2006). Additionally, cells from WJ can go through greater numbers of 
passages before reaching senescence, and even though they have faster doubling 
times than those of BM-MSCs, they differentiate into adipocytes more slowly than do 
the MSCs derived from BM (Karahuseyinoglu et al., 2007); this feature is thought to 
reflect the primitive nature of these MSCs (Troyer & Weiss, 2008). Along these lines, it 
is generally accepted that MSCs harvested from WJ, which is a young tissue, will be 
much more proliferative, immunosuppressive and even therapeutically active stem 
cells than the stem cells isolated from adult tissue sources, such as BM (Kim et al., 
2013). A remarkable feature of the cells isolated from WJ is that they maintain their 
growth potential even when they are harvested from UCs that have been stored for 48 
hours (Carlin et al., 2006). Additionally, these WJ-MSCs are able to maintain a normal 
karyotype, which is another confirmed marker used for stem cell characterization 
during primary, early and late passages (Fong et al., 2007). Conversely, genomic 
mutations causing chromosomal instability are commonly observed in ESC lines 
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expanded in vitro (La Rocca et al., 2009; Mantel et al., 2007; Rao, 2006; Rebuzzini et 
al., 2008). 
1.3.2.1 WJ-MSCs fulfil MSC criteria 
In 1991, McElreavey and colleagues reported WJ as an alternative source of stem cells, 
as they were successfully able to isolate and culture these cells (McElreavey et al., 
1991). A few years later, Wang et al. (2004) provided evidence that these WJ-derived 
stem cells could indeed be classified as MSCs. Since their first isolation, many 
advances have been made in not only optimizing their isolation but also enabling them 
to undergo differentiation (Kadner et al., 2002; Kadner et al., 2004; Mitchell et al., 2003; 
Romanov et al., 2003; Takechi et al., 1993). Together with the discoveries that have 
been made and the milestones that have been reached, the use of WJ-derived stem 
cells should significantly impact the development of therapeutic, cell biology-based 
strategies for clinical applications (Kim et al., 2013).    
Wang and colleagues (2004) described MSC features to resemble those of fibroblasts 
when they are cultured in vitro; they also reported that upon stimulation, MSCs are 
successfully able to differentiate into cells from multiple lineages, such as osteoblasts, 
adipocytes and chondrocytes. Furthermore, their work provided additional phenotypic 
information; reportedly, MSCs expressed high levels of CD29, CD44, CD51, CD73 and 
CD105, which are also expressed by BM-MSCs. In addition, the MSCs did not express 
the haematopoietic markers CD34 and CD45. Many other reports have provided 
further details on the phenotypic features and characteristics of MSCs, including 
specific membrane molecules on MSCs that can be used for cell identification, such as 
CD90, CD146, CD166 and ganglioside 2 (Carlin et al., 2006; Dominici et al., 2006; 
Fong et al., 2011; Wang et al., 2004; Xu et al., 2009). According to the ISCT, a cell 
must exhibit all three characteristics of MSCs, i.e., the morphology, immunophenotype 
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and differentiation potential of MSCs, to meet the criteria for identification (Dominici et 
al., 2006). Currently, no specific marker for UC-MSCs has been identified; therefore, 
researchers are required to ensure that cells derived from UC tissues also meet the 
identification criteria for MSCs (Batsali et al., 2013). 
 
1.3.2.2 WJ-MSC isolation methods 
Several isolation methods for the stem cell sources within the UC exist in the literature, 
and the experimental approaches that can be used vary considerably. Moreover, the 
cells isolated from the UC tend to be heterogeneous and contribute to the bias, 
particularly when researchers carry out protocol comparisons (Batsali et al., 2013). 
However, all the methods reported demonstrate that the procedure is complex, and all 
the methods have been designed to ensure maximal cell recovery in as little time as 
possible. At the present, there are two main methods used for isolating WJ-MSCs; 
‘enzymatic digestion’ and/or ‘tissue explant’ methods can be used, but none of the 
methods have been standardized (El Omar et al., 2014; Han et al., 2013; Klontzas et 
al., 2015). Selected methods are briefly described here to illustrate the extent of the 
variations that exist among the practices. 
One method involves scraping off the WJ, while keeping the blood vessels intact, to 
isolate stem cells from the scrapings. An alternative method includes removing the 
blood vessels first and then scraping off the WJ. The method described by Han and 
colleagues (2013) involves immersing a UC sample in a solution containing 0.2% 
collagenase enzyme at 37°C and incubating it for 16-20 hours to allow completion of 
the digestion reaction. Other groups have used collagenase enzyme alone or in 
combination with trypsin and/or hyaluronidase, which separates the stem cells from the 
WJ and perivascular mesenchyme; with this method, dissecting the UC into smaller 
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pieces with or without removing the blood vessels is optional (Fong et al., 2010; 
Karahuseyinoglu et al., 2007; Lu et al., 2006; Sarugaser et al., 2005; Tong et al., 2011; 
Tsagias et al., 2011; Wang et al., 2004). 
Other groups have avoided using enzymatic approaches because they have found that 
the enzymes damage cells, alter cell functions and reduce cell populations. These 
groups have developed explant methods by taking advantage of MSC properties, i.e., 
their ability to migrate and adhere to a plastic surface, from which cultures can 
subsequently be established (La Rocca et al., 2009; Majore et al., 2011; Mitchell et al., 
2003). A simple and rapid method to isolate UC-MSCs was developed by De Bruyn 
and colleagues (2011), whereby an UC is cut into longitudinal segments that are plated 
with the WJ facing down on the plastic surface; this method avoids both dissection and 
the use of enzymes. An explant method described by Ding and colleagues (2015) 
involves removing the UC vessels and manually mincing the remaining fragments until 
they are approximately 1-2 mm3 in size. These fragments are then incubated for 7 days 
to allow stem cell outgrowth. One issue with this method is that the fragments become 
suspended in the medium, and variable numbers of MSCs are recovered. However, 
the enzymatic method generally yields consistent numbers of isolated MSCs. 
A recent study demonstrated that expression patterns of the MSC markers CD73, 
CD90, and CD105 varied depending on whether an enzyme or an explant method was 
used for their isolation. The differences that have been identified highlight the 
importance of further work to establish precisely how the different methods used for 
isolation impact the cells (Salehinejad et al., 2012). Hua et al. (2013) compared the two 
main methods for isolating WJ-MSCs and examined many variables, including primary 
culture duration, recovered cell number, and cell morphology, as well as 
immunophenotypic features and differentiation potential. They concluded that the 
optimal method for isolating MSCs is the protocol using 10-mm tissue explants. 
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One standardized and comprehensive procedure for the isolation, characterization and 
ex vivo expansion of MSCs is required so that investigation outcomes are more reliable, 
particularly regarding the exact source and homogeneity of the stem cell populations 
within the UC. Unfortunately, no consensus on a standard method has yet been 
reached among researchers. Therefore, it is nearly impossible to come to an 
agreement on the characteristics and biological properties of MSCs, which is an 
essential requirement for designing any translational clinical studies concerning the use 
of these cells.  
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1.4 Epigenetic and developmental reprogramming  
In principle, the cells of a multicellular organism all carry an identical genotype, despite 
exhibiting broad morphological and functional diversity within the organism. Therefore, 
the identity and developmental potential of an individual cell is not only influenced by its 
genetic component but also by changes that do not involve changes in the 
deoxyribonucleic acid (DNA) sequence. Differential gene expression, an area of 
research known as ‘epigenetics’, is the process by which these changes are achieved. 
Mechanisms resulting in differential gene expression involve methylation, acetylation, 
ubiquitination, and other chemical interactions that either modify DNA itself or its 
packaging proteins, histones, or change micro-ribonucleic acid (miRNA) expression 
(Baccarelli & Bollati, 2009). The word ‘epi’ is derived from the Greek meaning ‘over’, 
‘above’ or ‘in addition to’; in this sense, epigenetic modifications can be regarded as 
another layer of information in addition to the genetic code. In 1942, Conrad Hal 
Waddington first defined epigenetics as ‘the study of the interactions between genes 
and their products which bring phenotype into being’ (Waddington, 2012). Epigenetics 
is now understood as ‘the study of mitotically and/or meiotically heritable changes in 
gene expression that are not caused by changes in the DNA sequence but by 
biochemical modifications’ (Bird, 2002). Epigenetics broadly connects genotype and 
phenotype by altering the final outcome of the genome in a stable manner without 
changing the underlying DNA sequences (Wu & Morris, 2001). Modifications to DNA 
and histone proteins can occur via covalent and non-covalent mechanisms that 
influence the overall chromatin structure. Epigenetic modifications are stable and 
heritable and thus can be transferred from one cell generation to the next (mitotic 
inheritance) as well as inter-generationally (meiotic inheritance). The heritability of 
epigenetic traits in plants from one generation to the next has been well documented 
(Cubas et al., 1999). However, less evidence has been collected on the heritability of 
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epigenetic modifications between generations in mammals, although some studies 
have demonstrated environmentally induced epigenetic transgenerational inheritance 
of adult-onset disease phenotypes in F3 generations (Guerrero-Bosagna & Skinner, 
2012). For example, certain variations in nutrition are known to result in obesity in the 
F3 generation as a result of epigenetic transgenerational inheritance (Waterland et al., 
2008). Thus, epigenetics is central to understanding both developmental plasticity and 
how the intrauterine environment affects short-term and long-term phenomena, 
including obesity.  
 
1.4.1 Epigenetic mechanisms 
The mechanisms by which epigenetic regulation exerts effects alter the physical 
accessibility of gene promoters and regulatory regions, thereby influencing expression. 
These mechanisms include DNA methylation, histone modification, chromatin-
remodelling complexes, and RNA interference (RNAi) (Grewal & Elgin, 2007; Hake & 
Allis, 2006; Jenuwein & Allis, 2001; Reik et al., 2001; Vaissiere et al., 2008). DNA 
methyltransferases (DNMTs) and enzymes that either modify histones or remodel 
chromatin operate in conjunction with miRNA mechanisms to form a specific chromatin 
structure that results in specific genetic transcription (Figure 3). Epigenetic 
mechanisms are vital for development during normal embryogenesis and for the 
differentiation of individual cell lineages in adult organisms (Reik, 2007). Furthermore, 
epigenetic control directs cell fate during early development following fertilization, as 
dividing blastocysts increasingly develop trophectoderm and inner cell mass gene 
expression patterns. 
Although almost every cell in the human body contains the same DNA sequences, 
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epigenetic marks promote gene expression in cells that are relevant for each tissue 
type. For example, a neuronal cell expresses genes necessary for the development of 
dendrites and axons. In a liver cell, epigenetic tags on those same genes result in 
tighter binding of the DNA, thereby silencing expression because the resulting gene-
epigenetic tag structure is inaccessible to transcription machinery. Although they are 
stable, epigenetic mechanisms that enable the inheritance of gene expression states 
from one generation of cells to the next are not definitive; instead, they are flexible. 
Normal ageing can lead to changes arising in a stochastic manner; changes can also 
occur in response to environmental stimuli (Baccarelli & Bollati, 2009; Fraga et al., 
2005; Probst et al., 2009). Thus, epigenetic changes facilitate genomic adaption to 
environmental factors and enable development towards a specific phenotype. This 
capacity to alter phenotype as a result of environmentally sensitive dynamic processes 
ensures that offspring will be more suited to the environment after birth, thereby 





Figure 3. The three distinct mechanisms of epigenetic regulation are DNA methylation, histone 
modification, and RNAi. All described epigenetic mechanisms have a two-way, interdependent control 
relationship between them, creating multifaceted regulatory machinery. This figure was modified from 
(Barnes et al., 2005; Morales Prieto & Markert, 2011; Ulrey et al., 2005; Yeung et al., 2005). 
 
DNA methylation, because methylation is the subject of study for this doctoral thesis, 
it is discussed in greater detail in section 1.4.2. Other epigenetic modifications are 
described below.  
Histone modification is another major epigenetic mechanism that alters gene 
expression. Histone proteins are packaging proteins that organize and compact DNA 
into structural units called nucleosomes. Each nucleosome consists of a histone 
octamer composed of the four core histones, H2A, H2B, H3 and H4 (Bentley et al., 
1984). The core histone proteins can undergo various modifications, including 
phosphorylation, methylation, ubiquitination, sumoylation, and acetylation, among 
others. (Kouzarides, 2007; Ruthenburg et al., 2007). A set of histone modifications, or 
a ‘histone code’, can mark the chromatin as active or inactive and thus has the 
potential to influence DNA transcription (Strahl & Allis, 2000). The most common 
histone modifications are histone acetylation and histone methylation. Acetylation 
occurs at the lysine residues of the N-terminus via histone acetyl transferases (HATs); 
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these residues can also be subjected to deacetylation via histone deacetylases 
(HDACs). Acetylation at the lysine residue removes the normal positive charge; this 
change reduces the affinity between the histone and DNA and allows the chromatin 
structure to open up, making the DNA more accessible for transcription (Ruthenburg et 
al., 2007). Histone methylations are facilitated by histone methyl transferases (HMTs) 
and can either increase or decrease gene expression. 
RNAi is a biological mechanism that is only found in eukaryotic cells. The effects of 
RNAi are exerted either via miRNA or through small interfering RNA (siRNA). RNAi 
contributes to the control over the activity and degree of gene expression. miRNAs are 
distinct from siRNAs in their biogenesis, rather than function, and differentiating 
between the various classes of small ribonucleic acid (RNAs) is becoming increasingly 
difficult. miRNAs are a class of small, non-coding RNAs consisting of approximately 23 
nucleotides; the main function of miRNAs is to down-regulate gene expression via 
mechanisms such as translational regression, messenger RNA (mRNA) cleavage and 
deadenylation (Bartel, 2004). They are single-stranded products of an organism’s own 
genome that are endogenously and purposefully expressed. In contrast, siRNAs are 
double-stranded and exogenous in origin, and they enter cells via vectors such as 
viruses or transposons. In addition, miRNAs are processed from stem-loop precursors 
with incomplete double-stranded character, whereas double-stranded siRNAs are 
excised from long, fully complementary strands (Tomari & Zamore, 2005). 
 
1.4.2 DNA methylation 
1.4.2.1 DNA methylation basics 
the first recognized epigenetic modification, is mostly linked to transcriptional silencing 
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(60-90% of genes) (Nakao, 2001). In mammalian cells, DNA methylation involves the 
addition of a methyl group (-CH3) to the 5th carbon atom of the cytosine in cytosin-
phosphate-guanin site (CpG) (Chen & Li, 2004), which is a reaction catalysed by 
DNMTs. DNMT3A and DNMT3B mainly execute de novo methylation of unmethylated 
CpG islands, and DNMT1 acts as a maintenance methyltransferase by ensuring the 
mitotic inheritance of the methylated patterns (Bestor, 2000). CpG islands 
predominantly occur in the promoter regions, the regulatory domains in the genome, as 
well as in the intergenic regions to some extent. DNA methylation can interfere with the 
transcriptional machinery; hence, it plays a crucial role in gene regulation and 
development (Bestor, 2000). In fact, studies have shown using mouse models that 
DNMT-knockout results in embryonic death (Fatemi et al., 2005; Li et al., 1992).  
In mammals, methylation mainly occurs at the 5’ position of the pyrimidine ring of the 
cytosine in the CpG dinucleotide sequence (Bird, 2002), which results in two 
methylated cytosine residues existing diagonally opposite to each other on different 
DNA strands (Suzuki & Bird, 2008). In mammalian genomes, 5-methylcytosine 
accounts for ~1% of all bases, although this varies slightly according to tissue type. 
Most CpG dinucleotides (75%) are methylated (Tost, 2010). The methylation of 
cytosines in alternative formations, such as CpNpG or CpA sequences, is common in 
plants and in some fungi. Furthermore, non-CpG methylation has been identified in 
mammalian ESCs (Gupta et al., 2010; Lister et al., 2009; Ramsahoye et al., 2000), 
although its function is currently unknown. 
CpGs reside along a gene in particular patterns, allowing for multiple forms of 
epigenetic control. For example, some CpGs lie in clusters known as CpG islands, and 
these are found in over 50% of genes in the vertebrate genome (Illingworth & Bird, 
2009). CpG islands are important for determining whether a gene is expressed in a 
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specific cell type. According to Gardiner-Garden and Frommer (1987) or Takai and 
Jones (2002), depending on the parameters involved, a CpG island can occur when 
the G+C content is more than 50% (55%) and when the ratio of observed versus 
expected occurrence of CpGs is greater than 0.6 (0.65); in addition, CpG islands have 
a minimum size of 200 (500) base pairs (bp). Some CpGs occur less frequently and 
tend to appear at sites where transcription factors bind, which are sites that are likely to 
be especially important in developmental plasticity. CpGs generally occur at a lower 
frequency in the genome than those of other dinucleotides, which is a phenomenon 
that may be caused by the conversion of methylated CpGs to TpGs via spontaneous or 
enzymatic deamination (Jones, 2012). Compared with those of other transitional 
mutations, estimates of CpG mutation rates range from 10 to 50 times greater. This 
discrepancy is likely to have had an evolutionary impact via the depletion of this 
dinucleotide over time (Tost, 2010). 
De novo DNA methylation and its maintenance require the activity of a family of DNMT 
enzymes. For example, DNA methylation during early embryogenesis is executed by 
DNMT3A and DNMT3B; hence, these enzymes are central to cell fate during 
mammalian embryonic development. Another member of the DNMT3 family, DNMT3L, 
has no DNMT activity. Rather, it serves a general stimulatory function for DNMT3A and 
DNMT3B. It is also a prerequisite for maternal genomic imprinting. Parental imprinting 
is a specific type of epigenetic control, whereby a gene is methylated and thus silenced 
if derived from one parent but not the other. Imprinted genes seem to be especially 
significant for placental function as well as certain aspects of brain function, and the 
loss of imprinting is associated with some diseases (Reik & Walter, 2001).  
Historically, it was believed that DNA methylation is maintained exclusively by DNMT1, 
which adds methyl groups (-CH3) to non-methylated daughter strands, thereby 
restoring hemimethylated DNA generated during DNA replication to a fully methylated 
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state. Consequently, the possibility of the inheritance of DNA methylation and its 
corresponding effects on gene expression from cell to cell arises. Because correctly 
maintaining DNA methylation is essential for embryonic development, imprinting, and 
X-inactivation, accurately understanding these processes is central to research on 
developmental epigenetics. Several recent studies have supplemented the collective 
understanding of the subject and have demonstrated that, in fact, all three DNMTs (i.e., 
DNMT1, DNMT3A and DNMT3B) are involved and cooperate in both de novo 
methylation and methylation maintenance (Handy et al., 2011; Hermann et al., 2004; 
Jones, 2012; Okano et al., 1999; Portela & Esteller, 2010). 
 
1.4.2.2 Key processes regulated by DNA methylation 
Epigenetics research is challenging because of the wide range of different epigenetic 
modifications contributing towards epigenetic marks as well as the multiple 
environmental factors that can influence the epigenome. For the most part, 
environmental cues that influence long-term phenotypic variations are initiated during 
intrauterine and perinatal periods (Martinez-Frias, 2010). During the mammalian life 
cycle, two significant global epigenetics reprogramming events occur, which remove 
any epigenetic errors that have accumulated during a parent’s lifetime; these events 
ensure the correct introduction of embryonic gene expression and establish new 
gender-specific imprints in the developing germ cells (Lange & Schneider, 2010; Reik, 
2007). The first reprogramming event occurs in the primordial germ cells. Studies in 
mice have shown that global DNA methylation and histone modifications occur in 
primordial germ cells, where cell reprogramming is initiated in the developing embryo 
at approximately mid-gestation. Although most of the DNA methylation events return to 
somatic levels during late foetal stages or at birth, genomic imprints have already been 
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made at this stage in a sex-dependent manner (Hajkova et al., 2008; Hajkova et al., 
2002; Sasaki & Matsui, 2008). The second reprogramming event occurs immediately 
following fertilization, and it continues until the blastocyst stage. Research has shown 
that complex histone modifications and DNA methylation events occur throughout the 
pre-implantation phase (Burton & Torres-Padilla, 2010). 
These two genome-wide reprogramming events are the time points in the life cycle 
where the most widespread epigenetic changes occur. Some of these epigenetic 
marks are maintained throughout the lifetime of an individual. Hence, a suboptimal 
intrauterine environment can induce epigenetic changes that can persist into adult-
hood, even in the absence of the original stimulus, and this persistence carries the 
potential to pass changes on to the next generation. Unlike epigenetic changes in adult 
cells or tissues, changes in gametes or early embryos can effectively influence the 
whole body (Martin et al., 2011). Hence, according to the early origins hypothesis 
proposed by Barker and Hales, suboptimal intrauterine conditions during crucial 
periods of foetal growth could cause permanent changes via foetal programming in 
metabolism, hormone production and structures that can affect vulnerability to major 
diseases in adult life (Hales et al., 1991). Indeed, cellular differentiation, tissue 
deposition, organ size and high-level neuro-endocrine control systems are all affected 
by developmental control factors, such as nutrition. Thus, scientists exploring the 
mechanisms of inheritance and evaluating an individual’s risk of developing diseases 
such as obesity are interested in studying the programming events that occur before 




Currently, obesity is one of the most important medical and global health problems, 
and it is defined by the World Health Organization (WHO) as a condition of excessive 
body fat accumulation to an extent that can cause detrimental health defects (World 
Health Organization, 2000). Obesity affects all genders and ages but is highly 
prevalent in women. Once considered a problem for affluent countries, this condition is 
now on the rise in countries of all economic backgrounds (World Health Organization, 
2011). An economic boom in the Arabian Gulf region invariably also led to an 
increased incidence of nutritional health conditions and associated diseases. In Saudi 
Arabia, the prevalence of obesity in individuals from 15-64 years old was 66.2% in men 
and 71.4% in women. In the younger population, consisting of individuals from 18-30 
years old, the prevalence of obesity was almost double for women than it was for men, 
at 18% and 10%, respectively (Ng et al., 2011). A WHO survey conducted in 2010 
among high-income populations showed that 33% was obese (men 28.6% and women 
39.1%) (World Health Organization, 2011) and that the body mass index (BMI) had 
steadily been increasing in both genders over the previous several years (Figure 4). In 
the Arabian Gulf states, differences in obesity prevalence between genders can be due 
to multiple factors, such as marriage and childbirth. Additional explanations could 
include cultural norms for women, such as high-fat diets, ‘plumpness’ being considered 
beautiful and indoor lifestyles with limited access to vigorous activities being preferred 
(Ng et al., 2011). According to WHO records, in 2014, the prevalence of obesity 
amongst 18+ adults from both sexes was 28.1%, particularly in the United Kingdom 




Figure 4. A steady increase in BMI was observed during the period from 1980-2008 in both sexes among 
high-income populations in Saudi Arabia (World Health Organization, 2011). 
 
Obesity is one of the greatest global health challenges, particularly because it 
increases the risks of other chronic diseases, such as type 2 diabetes, hypertension, 
cardiovascular diseases, musculoskeletal disorders and some types of cancer. 
Therefore, with worldwide obesity more than doubling since 1980, this poses a 
significant threat to quality of life in general and places strain on healthcare budgets 
(World Health Organization, 2015). Hence, there is a strong need for a deeper 
understanding of the complex pathophysiology and factors contributing to this disease 
to facilitate the use of more effective intervention, prevention and treatment options and 
to reduce the worldwide burden of this disease. Obesity is a multifactorial disease with 
key elements that have been identified, including genetic factors and environmental 
factors that have been found to contribute to the cause and progression of the disorder 
(Day & Loos, 2011). Although candidate gene studies and genome-wide association 
studies (GWAS) have revealed several genetic loci associated with this disorder, the 
portion of obesity variation explained by these genetic variants is quite small 
(Hebebrand et al., 2010; Sandholt et al., 2012). The emerging field of epigenetics 
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paves a new path for understanding causes of complex diseases, such as obesity. 
Adiposity can be measured using a diverse array of methods; some are as basic as 
only using a tape measure, and other methods involve the use of complex equations 
and expensive equipment. The most basic and commonly used method for measuring 
body fat is the BMI, which is a ratio of weight to height that is calculated as weight in kg 
divided by height in m2 (kg/m2) (Hu, 2008). BMI is an indirect measure of adipose 
tissue, as it does not distinguish between body fat and lean body mass. Furthermore, 
BMI does not take into account factors such as the greater muscle loss that occurs with 
age in women than in men or the higher fat content that tends to be observed in 
women than in men who have the same BMI; these factors often lead to 
misclassifications. However, several studies have shown that BMI has a strong 
correlation with body fat levels and obesity-related comorbidities, as measured by most 
accurate methods (Mei et al., 2002; Sun et al., 2010). 
Due to simplicity, the use of anthropometric measurements, such as BMI, is considered 
to be one of the favoured methods for assessing obesity in both clinical settings and 
population studies. Because BMI is only a screening tool and not a diagnostic tool, 
determining whether excess weight imposes a health risk in individuals with a high BMI 
can be accomplished by a healthcare professional for verification via more accurate 
methods (World Health Organization, 2000). Although BMI is always calculated the 
same way, its interpretation depends on the gender, ethnicity and age of each 
individual (Prentice & Jebb, 2001). The WHO classifies a BMI ≤18.5 as underweight, a 
BMI from 18.6-24.99 kg/m2 as normal, a BMI from 25-29.99 kg/m2 as overweight and a 
BMI ≥ 30 kg/m2 as obese (World Health Organization, 2000). 
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1.6 The link between epigenetics and obesity 
The foetal programming hypothesis suggests that limited intrauterine nutrition can 
cause the foetus to programme its metabolism to anticipate a similar environment in 
adult life; hence, the foetus prepares for an adult life of limited nutrition, as well.  
The uterine environment is under strict placental control, and by directly regulating 
foetal nutrient supply and growth, it plays an important role in foetal programming. The 
placenta constitutes the active interface between the maternal and foetal blood 
supplies. The placenta mediates the supply of nutrients to the foetus, secretes 
hormonal mediators of maternal and foetal physiology and acts as a modulator of 
developmental plasticity (Jansson & Powell, 2007).  
Developmental plasticity refers to the set of changes that occur during development in 
response to variations in environmental cues, especially via the uterine environment or 
during infancy. Developmental plasticity is a normal biological and physiological 
function, and it allows for the foetus to develop appropriately according to 
environmental conditions. Having the capacity to alter phenotype according to the 
environment increases the probability of survival through to adulthood and reproduction. 
However, developmental plasticity requires an accurate prediction of the environment 
into which the offspring will be born and risks developmental mismatch. This means 
that an abundant nutritional diet postnatally can result in a metabolic imbalance or 
mismatch leading to a metabolic syndrome. However, studies using animal models 
have shown that both over-nutrition and under-nutrition during the gestational period 
can lead to similar metabolic disorders in adult life. Thus, the fact that opposite diet 
stresses lead to similar outcomes suggests the involvement of a common mechanism 
in both pathways (Li et al., 2010).  
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Obesity is a metabolic disorder, and much attention has been focused on foetal 
programming as a facilitator of predisposition to this disorder in later life. Obesity has 
become a global concern and is one of the greatest public health challenges in the 
world. It is a multifactorial disorder comprising both genetic and environmental factors, 
and it can cause predisposition to many chronic diseases, including type 2 diabetes, 
hypertension, coronary heart disease and some types of cancer (Day & Loos, 2011). 
Numerous epidemiological studies have shown that over-nutrition, under-nutrition, 
stress or exposure to certain chemicals during gestation or lactation can lead to obesity 
(Bruce & Cagampang, 2011; Morris, 2009). Studies indicate that maternal obesity can 
lead to increased foetal insulin production and fat deposition (Gluckman et al., 2008). 
Additionally, a considerable amount of data suggests that obese mothers confer a 
greater risk to their children of developing metabolic disorders, even during childhood 
(McIntyre et al., 2012). Interestingly, it has also been shown that under-nutrition or 
famine during gestation and early infancy is associated with obesity in the adult 
offspring (Ravelli et al., 1976). Although details of the exact mechanisms involved have 
remained limited, several animal studies have gained insight into some mechanisms 
involved; most importantly, these studies have established a link between the early-life 
programming and altered body composition and metabolism of adult offspring.  
A study by Burdge et al. (2007) demonstrated that feeding a protein-restricted diet to 
rats during pregnancy in the F0 generation increased the expression of peroxisome 
proliferator-activated receptor alpha (Pparα) and glucocorticoid receptor 1 (GR1). The 
study also found increased expression of the corresponding hepatic target genes, acyl-
CoA oxidase (AOX) and phosphoenolpyruvate carboxykinase (PEPCK), in the F1 and 
F2 offspring. This increase in expression coincided with reduced methylation of the 
Pparα and GR1 promoters in the liver, which was induced in the F1 offspring by the 
maternal protein-restricted diet and was, interestingly, passed on to the F2 generation. 
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This study demonstrated the transmission of a modified metabolic phenotype caused 
by changes in the prenatal environment to both the first-generation and second-
generation offspring as a heritable epigenetic mark. Pparα is a ligand-activated 
transcriptional activator that regulates the expression of genes crucial for lipid and 
lipoprotein metabolism. Another investigation by Drake et al. (2005) used a model of 
rats exposed to dexamethasone, which is a poor substrate for 11β-hydroxysteroid 
dehydrogenase type 2 (11β-HSD 2) that leads to exposure of the foetus to high levels 
of glucocorticoids. The exposed rats showed reduced birth weight associated with high 
hepatic PEPCK activity, which was constant in the first-generation male offspring. The 
study also demonstrated that even in the absence of the initial stimulus, the reduced 
birth weight and high PEPCK activity were also transmitted to the second-generation 
male offspring. 
Studies involving humans have also suggested a causal link between epigenetics and 
obesity. A human study of two cohorts involving screening the methylation status of 68 
candidate genes from UC-derived DNA revealed that elevated methylation at Retinoid 
X receptor-α (RXRA) strongly correlated with increased adiposity in late childhood and 
was subsequently associated with maternal carbohydrate consumption (Godfrey et al., 
2011). The methylation of endothelial nitric oxide synthase (eNOS) was associated 
with increased adiposity in one cohort. The hyper-methylation of CpG islands in both 
eNOS and RXRA and the hypo-methylation of superoxide dismutase 1 (SOD1) were 
strongly correlated with fat distribution. These findings not only confirmed that the early 
pregnancy environment can affect offspring adiposity but also indicated that epigenetic 
measurements in neonates such as these are more accurate indicators of later obesity 
than the conventional measures, such as body weight and BMI. Another independent 
study by Relton et al. (2012), involving the use of peripheral blood for DNA methylation 
profiling in two cohorts, revealed associations between altered gene expression and 
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childhood body composition and size. Several genes involved in the cell cycle and 
proliferation, including cyclin-dependent kinase inhibitor 1C (CDKN1C) and nidogen-2 
(NID-2), showed differential methylation and expression levels. 
Research has also indicated that when maternal fat intake is increased during 
pregnancy and lactation, the proportion of polyunsaturated fatty acids (PUFAs) in the 
liver of the adult offspring is changed. This observation was accompanied by a varied 
epigenetic regulation of fatty acid desaturase 2 (FADS2), which encodes Δ6 
desaturase, an enzyme involved in the rate-limiting step of PUFA synthesis (Hoile et al., 
2013). The high-fat diet induced an increased methylation of specific CpG sites in the 
promoter region of FADS2, which was associated with a reduced expression of this 
gene in the offspring (Hoile et al., 2013; Kelsall et al., 2012). Apart from being vital 
components of the cell membrane, PUFAs are further metabolized into more highly 
unsaturated fatty acids that are utilized in the synthesis of lipid second messengers 
(Burdge & Calder, 2006). 
In addition to maternal diet and other environmental factors that are likely to exert 
heritable, epigenetic effects in the offspring, paternal factors can also exert an 
influence. The testes are formed during early development, and the germ cells from 
which sperm ultimately differentiate are sequestered during foetal development; thus, it 
is likely that epigenetic changes can also occur in paternal sperm from conception of 
the father through to the production of sperm in adult life. Because spermatogenesis 
occurs over 2-3 months, environmental factors affecting the father during this time and 
immediately prior to conception can result in changes to the sperm that can also affect 
the offspring. For example, evidence suggests that epigenetic inheritance of paternal 
origin can result in offspring having a greater risk for obesity (Drake & Liu, 2010). 
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1.6.1 Global methylation and Obesity 
Global methylation is an overall measure of cytosine methylation in the genome. 
However, for ease of measurement, the methylation status of repetitive elements, such 
as Alu and long interspersed nucleotide elements (LINE1), which make up 
approximately 50% of the genome, is frequently used as a substitute to represent the 
overall genome methylation; these metrics have been found to correlate well with the 
overall genomic cytosine methylation (Weisenberger et al., 2005). The importance of 
epigenetic alterations in human pathology was first identified in cancer (Laird & 
Jaenisch, 1996). Global hypo-methylation or reduced global methylation has been 
associated with cancer causation and progression, and because epigenetic 
modifications are typically reversible, thereby allowing a malignant cell to revert to a 
more normal state, epigenetic marks have become valuable targets for chemotherapy 
(Huang et al., 2011). In contrast, less is known about the impact of global methylation 
on other human diseases, such as obesity. Although numerous studies have been 
conducted to investigate the association between global methylation and obesity, the 
results have been inconsistent; some studies have demonstrated that both global 
hyper-methylation and global hypo-methylation are associated with increased BMI, 
which is the most commonly employed method of measuring obesity. In a study based 
on 323 women, hypo-methylation of Alu elements was associated with increased BMI 
(Jintaridth et al., 2013). Similarly, another study conducted in women found that 
reduced methylation of LINE1 elements was associated with increased risk for both 
obesity and insulin resistance. However, one limitation of this study is that the 
association was observed in women with lower levels of the dietary methyl donor folate 
(Piyathilake et al., 2013). In contrast, in a study consisting of both men and women of 
Samoan origin, LINE1 methylation in peripheral blood showed a significant positive 
association with BMI (Cash et al., 2011). Similarly, in a study conducted in Singapore 
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also including both men and women, a positive association was found between global 
methylation in peripheral blood leukocytes and BMI (Kim et al., 2010). Another study 
demonstrated that global methylation levels in the placenta were higher in obese 
women than those in non-obese women (Nomura et al., 2014). Because there is no 
consistent pattern of association between global methylation and obesity shown by the 
studies that have performed to date, it is difficult to determine what global methylation 
changes might occur in obesity. Multiple factors, including gender, ethnicity and 
lifestyle choices, such as tobacco use and diet, have been found to influence the 
methylation levels of the whole genome (Zhang et al., 2011). Therefore, even though 
some studies have taken these factors into account, all the confounding factors are 
often not known, which may account for the inconsistent results between studies. The 
relationship between obesity and DNA methylation might be better understood by 
investigating the global methylation status of native cells, particularly from early 
passages, and this is the area of interest.   
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1.7 Objectives  
Historically, UCs have been considered clinical waste and were generally discarded 
after birth. Recently, UCs have been recognized as a rich source of MSCs that can be 
used for therapeutic applications, although it has been suggested that an abnormal 
metabolic environment during pregnancy might induce epigenetic changes that globally 
alter gene expression in UC tissues, rendering them unsuitable for cellular therapy. 
Metabolic diseases, such as obesity, might affect the stem cell niche or the properties 
of MSCs, but no experimental evidence has demonstrated this effect in WJ-MSCs. 
The overall goal of this study was to determine the effects of an abnormal metabolic 
environment on WJ-MSCs using UCs from healthy obese donors. The objectives of the 
study were to  
1. Determine the optimal WJ-MSC isolation method (enzymatic versus explant). 
2. Determine the cell behaviours, such as initial outgrowth and cell proliferation, of 
WJ-MSCs in tissue culture. 
3. Determine the expression of MSC surface markers. 
4. Determine the effect of obesity on the differentiation potential of WJ-MSCs into 
three mesodermal lineages: adipocytes, chondrocytes and osteoblasts. 
5. Determine the effect of obesity on the immunomodulatory properties of WJ-
MSCs. 
6. Determine differences in the global DNA methylation profile of WJ-MSCs from 
obese and non-obese donors. 
7. Determine differences in the gene expression profile of WJ-MSCs from obese 








Materials and Methods 
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2. Materials and Methods 
 
2.1 Patient selection  
Human UC samples were collected at the time of delivery from mothers who had 
provided consent (REC reference 12/NE/0371). The UC samples were collected from 
full-term infants who were delivered by elective Caesarean section at Guy’s and St. 
Thomas’ NHS Foundation Trust.  
WJ samples were chosen based on their suitability for the investigation, which is 
looking at the impact of obesity and its contribution to an abnormal maternal metabolic 
environment during pregnancy. This study further investigates whether the interaction 
with such an abnormal metabolic environment during pregnancy changes the DNA 
methylation profile of MSCs. Any significant outcomes could be clinically relevant and 
could potentially render MSCs from such donor types unsuitable for clinical use in 
multiple recipients. During their first-trimester prenatal check-up at the clinic, healthy 
mothers were classified as obese if they had a BMI >30 kg/m2, and healthy mothers 
with a BMI from 19-25 kg/m2 were classified as non-obese. The total number of UCs 
recovered from the mothers after childbirth was 14 (n=7, non-obese; n=7, obese). All 
deliveries were without complications; the babies and mothers were healthy, with no 
apparent abnormalities. The placentas and UCs were assessed by midwives for any 
abnormalities, and all tissues were confirmed to have a normal appearance. The 
majority of the participating women did not smoke or drink during pregnancy. Only one 
woman in the healthy obese group (subject O2) was a smoker and reported smoking 
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one to four cigarettes per day during her pregnancy.  
All women who were classified as non-obese had Caucasian ethnicity and were aged 
between 35 and 43 years. The obese group comprised three women who were of 
Caucasian origin (aged 34, 35 and 39), two Black-African women (aged 34 and 38) 
and two Black-Caribbean women (aged 28 and 35); a summary of the patient 
information is shown in Table 3.  
 
Table 3. Non-obese and obese donor age, BMI and ethnicity (N=non-obese, O=obese). 
Non-obese Obese 
Donor Age BMI Ethnicity Donor Age BMI Ethnicity 
N1 43 24 Caucasian O1 39 36 Caucasian 
N2 35 21 Caucasian O2 35 30 Caucasian 
N3 36 22 Caucasian O3 34 39 Caucasian 
N4 35 21 Caucasian O4 34 30 Black-African  
N5 38 25 Caucasian O5 38 45 Black-African 
N6 39 23 Caucasian O6 28 41 Black-Caribbean  
N7 39 23 Caucasian O7 35 35 Black-Caribbean 
 
 
2.1.1 Sample size justification 
Because no a priori information was available from any publications to assist with 
sample size estimates, a sample size of twelve per group was considered appropriate 
for this pilot investigation and justified to be sufficiently large to provide feasibility for 
the estimate of variance and precision. Others can use the sample size information 
from this study to formally calculate a sample size for future studies (Julious, 2005). 
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The anticipated recruitment rate was two subjects per month in each group from a 
single site (Guy’s and St. Thomas’ NHS Foundation Trust).  
The target recruitment for this study was not met for several reasons. Despite efforts 
made to obtain consent by involving midwives and providing patient leaflets explaining 
the aims of the study, most women were very reluctant to consent to participate in the 
study; women who belonged to the healthy obese group were particularly reluctant. 
Some women simply declined to participate without giving a reason. There were also 
challenges in identifying healthy obese participants because most obese women had 
other co-morbidities that kept them from meeting the study eligibility criteria. Moreover, 
there was a high demand for the participants to participate in other research projects. I 
was therefore permitted limited time to recruit participants, resulting in one-day-per-
week access to participants at the hospital. The most common reasons for not 
consenting to participate in the study were as follows:  
• Subject already participating in other study 
• Religious beliefs 
• Misconceptions regarding genetic testing 
• Plan to bank UCs for future use 
The participant consent process did not offer any monetary incentives, such as gift 
vouchers or a prize draw, for the subjects, nor any financial recompense for their time. 
The lack of rewards for potential participants for our study was an oversight on our part 
and may have contributed to a low recruitment rate compared with other studies that 
had offered such compensation for their participants.  
The study timeline allowed six months for the recruitment of participants to allow 
sufficient time for meeting other milestones, such data collection, processing, analysis 
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and results dissemination. The study timeline also included four weeks to process each 
cord after collection.  
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2.2 Isolation and culture of WJ-MSCs from UCs 
(enzymatic versus explant) and assessment of 
initial outgrowth and proliferation rate 
WJ-MSCs can be isolated and expanded from UCs using two different approaches: an 
enzymatic digestion method (Fong et al., 2007) or an explant method (La Rocca et al., 
2009). In this study, I applied both isolation methods to each cord and proceeded with 
the isolation method that resulted the most successful outcome. After identifying the 
optimal isolation method, the first outgrowth and proliferation rates were assessed, and 
differences and similarities were compared for obese and non-obese donors.  
 
2.2.1 Enzymatic protocol versus explant protocol for WJ-MSC 
isolation 
The first five cords (N1, N2, O1, O2, and O3) that were collected were used to 
determine the optimum isolation method for WJ-MSCs from UCs. Both explant and 
enzymatic digestion procedures were used in parallel for isolation and culturing of WJ-
MSCs from each UC. Once the optimal isolation and expansion method was 
determined, it would be used for the remaining UCs that are expected to be processed 
during the course of this thesis.  
After the UC samples were retrieved, they were kept in phosphate-buffered saline 
(PBS) supplemented with 10-µg/ml gentamycin and 0.25-µg/ml amphotericin B (Life 
Technologies, UK). The samples were then processed within 2-4 hours from the time 
they were collected as described below. Each UC was cut into equal halves; one half 
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of the cord was processed using the enzymatic digestion method, and the other half 
was processed using the explant method.   
The isolation of WJ-MSCs from UCs using the enzymatic digestion method followed 
the procedure reported by Fong et al. (2007) and her group. The UC was washed to 
remove any blood and then cut into 2-cm segments. Each segment was cut into very 
fine pieces under aseptic conditions using a pair of scissors. The resulting pieces from 
the five cords (N1, N2, O1, O2, and O3) were placed in separate 100-mm Petri dishes 
(Corning, UK) containing enzymatic solution and incubated for different durations (60 
minutes, 90 minutes, 120 minutes, 150 minutes and 180 minutes) on a gentle rocking 
platform (Eppendorf, UK) at 37°C. The enzymatic solution was composed of 2-mg/ml 
collagenase type I, 2-mg/ml collagenase type IV and 100-IU/ml hyaluronidase (all from 
Sigma-Aldrich, UK) in DMEM containing 4.5-g/L glucose and L-glutamine (Life 
Technologies, UK).  
The next stage of the enzymatic method included the use of DMEM containing the UC, 
which was transferred to a 15-ml Falcon tube (Fisher Scientific, UK) and re-suspended 
using a 10-ml sterile pipette (Dutscher Scientific, UK). The tube was centrifuged 
(Thermo Scientific) at 1,200 rpm for 5 minutes, after which the supernatant was 
discarded, and the cell pellet was repeatedly washed by re-suspending it in fresh 
DMEM. After the washes, the pellet was re-suspended in fresh DMEM supplemented 
with 10% FBS (HyClone, New Zealand), 10-µg/ml gentamycin and 0.25-µg/ml 
amphotericin B in a T25 flask (25-cm2) (Falcon, UK) and maintained in an incubator 
(Thermo Scientific) at 5% O2, 5% CO2 and 37°C. Cell growth was assessed visually for 
three weeks and controlled by changing the medium three times a week.  
The other half of the UC segment was processed using the explant method. Under 
sterile conditions and using aseptic techniques, each UC segment was initially washed 
with PBS to remove the blood. The samples were dissected into 3-cm-long segments 
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and then further dissected into fragments approximately 1-cm2 in size, which were 
inspected to confirm that they were free of blood vessels. Then, 10 small fragments 
were seeded on a 100-mm Petri dish with the WJ side of each fragmented UC facing 
down on the plastic and they were left exposed to air for 10 minutes to facilitate the 
attachment. The explanted fragments were grown in 15-ml of DMEM containing 4.5-g/L 
glucose and L-glutamine supplemented with 10% FBS and gentamycin/amphotericin B 
solution. The Petri dish was then placed in an incubator with 5% O2 and 5% CO2 at 
37°C (Badraiq et al., 2015). The culture medium was replaced with fresh medium two 
to three times a week, and cell growth was assessed visually and controlled for three 
weeks.  
 
2.2.2 Assessment of initial out growth and proliferation rate of 
the UC received from obese and non-obese donors using 
the explant method 
The explant method was selected as the preferred isolation method for this study. The 
initial growth of fibroblast-like cells was visually assessed in samples from both non-
obese and obese donors using light microscopy (Olympus).  
The cells had reached confluence (80-90%) in the explanted cords after 3 weeks; 
colonies of cells were visible, and the cord segments were floating in the medium. The 
culture medium containing the floating cord pieces was decanted, and then, the 
adherent cells were ready for harvesting. The adherent cells were rinsed once with 
PBS containing ethylenediamine tetraacetic acid (PBS-EDTA) (Lonza, UK) and were 
subsequently detached by exposing them to 5-ml of a solution containing the adherent 
cell dissociation product TrypLE (Life Technologies, UK) for approximately 5 minutes in 
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an incubator set at 37°C with 5% CO2 to allow the solution to become activated and to 
cause the adherent cells to detach from the plastic surface. Light microscopy was used 
to confirm that the cells had detached from the surface. Once the cells were observed 
to be floating, an equal volume of wash solution only containing DMEM was 
immediately added to inactivate the TrypLE. The cells were then collected in a tube 
and were centrifuged for 5 minutes at 12,000 rpm. The supernatant was eluted, and 
the pelleted cells were gently re-suspended in fresh medium and mixed thoroughly to 
eliminate aggregates and to produce a uniform suspension. The total population 
recovered was determined by cell counting; 10-µl of the cell suspension from each tube 
was collected and loaded below a coverslip that sits firmly on the chamber of a 
haemocytometer instrument (Hausser). The slide was then examined under a 
microscope, and the number of cells present in the four corner squares of the grid was 
counted using a cell counter. The total cell counts were calculated using the following 
formula: 
 
                        Total cells/ml = !"#$% !"##$ !"#$%&' × !"#$%"&' !"#$%& × !",!!! !"##$/!"!"#$%& !" !"#$%&! 	
 
At this point, the cells were assigned a population doubling stage figure of 0 (PD0). The 
PD time was calculated using the formula PD=[log(A/B)]/0.301, where A is the number 
of harvested cells, and B is the number of cells seeded onto the plate. The cells from 
PD0 were re-plated in a T75 flask (75-cm2) (Falcon, UK) for further expansion in an 
incubator with 5% O2 and 5% CO2 at 37°C. When the cells reached confluence (80-
90%), they had reached stage PD1 and were harvested and re-suspended for 
cryopreservation in a medium that consisted of FBS supplemented with 10% dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich, UK) for cryopreservation. The cells were aliquoted 
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into cryotubes (Thermo Scientific, UK) and placed in a freezing container (Sigma-
Aldrich, UK) at -80°C for 24 hours; the cells were then transferred into liquid nitrogen 
for longer term storage until future use (Badraiq et al., 2015). The proliferation rate (PD 
time), which represents the ability of cells to double their population, was evaluated 
between PD1 and PD2 for the two groups. 
The statistical analysis methods used to describe and compare the growth and 
proliferation rates between obese and non-obese groups are described in the statistical 
analyses section (2.3.4). 
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2.3 Comparison of the properties of WJ-MSCs 
derived from obese and non-obese subjects 
Once WJ-MSCs had been recovered from cords collected from obese and non-obese 
subjects with the explant method, properties such as immunophenotypic properties, 
differentiation properties and immunomodulatory properties were evaluated and 
comparatively analysed for similarities and differences between the two groups.    
 
2.3.1 Immunophenotypic comparative analysis of WJ-MSCs 
isolated from obese and non-obese subjects 
Cell surface epitope profiles were analysed using flow cytometry to compare WJ-MSCs 
isolated from obese and non-obese donors. Cells from PD2 of fourteen different WJ-
MSC cultures were harvested, as described previously (section 2.2.2). The supernatant 
was aspirated before re-suspending the cell pellet in cold PBS containing 10% FBS. 
Cell suspension aliquots (100-µl, approximately 1×106 cells) were prepared. Antibodies 
listed in Table 4 (Miltenyi Biotec and BD Biosciences, UK) were added to the cell 
suspensions at a final concentration of 1:50. The cells were gently vortexed 
(Whirlimixer, UK) and then incubated for 10 minutes at 4°C in the dark. In addition, 
separate WJ-MSC aliquots not stained with antibodies were prepared to serve as a 
negative control; these samples were used to determine the WJ-MSC population gate. 
Four compensation bead tubes (Miltenyi Biotec, UK) were prepared in parallel; one 
tube contained blank beads as a negative control, and the other three individual tubes 
each contained anti-human Igκ beads conjugated with fluorescein isothiocyanate 
(FITC), phycoerythrin (PE) and allophycocyanin (APC) as positive controls. All four 
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bead tubes were incubated for 10 minutes in the dark at room temperature. After the 
incubation step, the stained cells, unstained cells and the beads were washed once 
with 1,000-µl of cold PBS/10% FBS. The PBS was decanted, and the cells and beads 
were then re-suspended in 500-µl of PBS/10% FBS per tube and were analysed on a 
FACSCanto™ II using DIVA software (BD Biosciences, Biomedical Research Centre 
(BRC) Flow Cytometry Core, King’s College London). To confirm that specific CD45 
and CD34 markers were being detected, a Kasumi cell line (acute myeloid leukaemia 
cells) was used as a positive control for flow cytometry, and clinical-grade BM-MSCs 
were also used as a positive control to confirm the antibodies identified by MSC flow 
cytometry (Devito et al., 2014). 
The flow cytometry analysis was based on the MSC profile that was determined by the 
forward scatter (FSC), known to correlate with cell size and shape. The side scatter 
(SSC) correlates with cell granularity. Because the FSC and SSC differ for each cell 
type, the combination helps improve the identification of the different cell types. 
Following staining and cytometry, the differences between the non-obese and obese 
groups were compared for each marker. The statistical analysis methods used to 
describe and compare the proportions of positive markers between obese and non-







Table 4. Antibodies used for cell surface epitope profiles and isotypes 
for flow cytometry. 
MSC Markers Isotype 
CD90-FITC Mouse IgG1 
CD73-PE Mouse IgG1 
CD105-APC Mouse IgG1 
CD44-FITC Mouse IgG1 
CD29-APC Mouse IgG1κ 
CD56-APC Mouse IgG1 
CD45-FITC Mouse IgG2a 
CD34-PE Mouse IgG2a 
CD271-FITC Mouse IgG1 
Anti-MSCA-1 Mouse IgG1 
 
 
2.3.2 The differentiation properties of WJ-MSCs from obese 
and non-obese donors  
 
The ISCT describes the minimal criteria that are required to positively identify MSCs; 
one of the elements includes the ability of these cells to differentiate into adipocytes, 
osteoblasts and chondrocytes (Dominici et al., 2006). Therefore, the cells recovered 
from the donors were evaluated to determine whether they met the criteria set for 
MSCs by the ISCT. MSCs from all donors differentiated into adipocytes, chondrocytes 
and osteoblasts under differentiation conditions; furthermore, their commitment 
towards differentiation between obese and non-obese groups was also compared. 
Firstly, cells were differentiated, and they were then tested for the presence of targeted 
gene expression using RT-PCR and stained to confirm their differentiation state. For 
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both gene expression and staining experiments, undifferentiated cells from all fourteen 
cell lines were included in the assays as a control.  
 
2.3.2.1 Adipogenesis differentiation 
The StemPro® adipogenesis differentiation kit (Gibco, UK) was designed for the 
adipogenic differentiation of MSCs. In these experiments, it was used to induce the 
adipogenesis of cells from obese and non-obese donors and to compare the ability of 
the cells from both groups for their level of commitment towards adipogenicity.  
Once WJ-MSCs cultures had reached 70-80% confluence using standard medium, the 
cells were washed gently with PBS-EDTA and detached using TrypLE solution, as 
described previously in section 2.2.2. The collected cells were re-plated onto a 4-well 
plate (Thermo Fisher, UK) for the staining procedure and on a 6-well plate (Thermo 
Fisher, UK) for the gene expression assay. The cells were incubated in DMEM 
supplemented with 10% FCS with 5% O2 and 5% CO2 at 37°C. After 2 days, the 
medium was replaced with complete StemPro adipogenesis differentiation medium. 
The adipogenic medium was changed every 3-4 days. The active components and 
their concentrations in the kit that were used to promote adipogenic differentiation were 
proprietary information of the manufacturer and hence, were unknown.  
After incubation for 14 days under differentiation conditions, the cells cultured for the 
staining procedure were washed with PBS and fixed with 4% formaldehyde solution 
(Sigma-Aldrich, UK) for 30 minutes at room temperature. After fixation, the cells were 
washed twice with PBS and incubated for 30 minutes in a 1:100 dilution of LipidTOXTM 
green neutral lipid stain (Invitrogen, UK). LipidTOX™ green neutral lipid stain detects 
cellular lipids. After incubation, the cells were washed twice with PBS and then 
mounted in Vectashield Mounting Medium supplemented with 1.5-µg/ml 4’,6-diamidino-
2-phenylindole (DAPI) (Vector Labs, UK). The cells were then visualized using an 
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epifluorescence microscope (Nikon ECLIPSE 50i) for qualitative analysis, and three 
black and white images were chosen for each line. The signals in the images were 
quantified using ImageJ64 software by calculating the percentage of cellular lipids per 
cell to obtain the total surface area of LipidTOX™ positive droplets per number of 
nuclei in one field. For each of the lines, I screened on average about 900 cells per 
each of the three fields. 
For the gene expression assay, cells were also collected from 6-well plates after 14 
days of culturing under differentiation conditions. RNA was extracted using an RNeasy 
mini kit (Qiagen, UK) according to the manufacturer’s instructions; all necessary 
reagents were provided in the kit. Briefly, 600-µl of RLT buffer was added to the well for 
direct cell lysis. The cells were collected into 1.5-ml micro-centrifuge tubes (Ambion, 
UK), and the mixtures were vortexed for 1 minute, resulting in a homogenous solution; 
this step confirmed adequate cell lysis. The cell lysates were washed with 600-µl of 
70% ethanol (Sigma-Aldrich, UK) and mixed thoroughly by pipetting. The lysates were 
carefully transferred to the RNeasy spin columns that had been placed in 2-ml 
collection tubes and were centrifuged in a bench-top micro-centrifuge (Eppendorf) at 
10,000 rpm for 15 seconds. The collection tubes containing the flow-through were 
discarded, and the spin columns containing the RNA bound to the silicon filter were 
retained. Then, 700-µl of RW1 buffer was added on top of the RNA bound filter, and 
the columns were centrifuged at 10,000 rpm for 15 seconds; then, the columns were 
transferred to new 2-ml collection tubes. The RNA-bound filters were washed with 500-
µl of RPE buffer and were centrifuged at 10,000 rpm for 15 seconds. A further washing 
step was performed by adding another 500-µl of RPE buffer and re-centrifuging the 
column at 10,000 rpm for 2 minutes, making sure the flow-through was discarded after 
each spin. The collection tubes were replaced with new tubes to prevent carryover 
from RPE buffer, and the columns were dried further by an additional centrifugation 
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step at the maximum speed of 14,000 rpm for 1 minute. Finally, the RNeasy spin 
columns were placed in sterile 1.5-ml micro-centrifuge tubes, and 40-µl of RNeasy-free 
water was added directly to the spin column membrane to elute the RNA; then, the 
columns were centrifuged at 10,000 rpm for 1 minute. The spin columns were 
discarded at this stage because the eluted RNA had been recovered in the micro-
centrifuge tubes. The concentration of the extracted RNA samples was determined 
using a Qubit fluorometer (Invitrogen; the device was provided by BRC Genomics 
Core, King’s College London), and the RNA samples were stored at -80°C until use. 
For the Qubit RNA quantification assay, the Qubit® RNA BR assay kit (Life 
Technologies, UK) was used. A working solution was prepared by diluting Qubit RNA 
BR reagent in Qubit RNA BR buffer to 1:200; both solutions were from the reagent kit. 
The final volume in either the standard or sample tube was 200-µl for the assay. Two 
standard tubes were individually prepared by mixing 190-µl of the working solution with 
10-µl of standard-1 solution in tube 1 and 10-µl of standard-2 solution in tube 2. Next, 
sample tubes were prepared by combining 199-µl of working solution with 1-µl of 
sample. The tubes containing the diluted RNA samples were then vortexed for 2-3 
seconds and incubated at room temperature for 2 minutes. The standard curve for the 
assay was generated by taking a reading first from standard-1 and then from standard-
2; thereafter, RNA in the tubes was quantified using the Qubit fluorometer.  
Next, 1000-ng of RNA was used for cDNA synthesis (Bio-Rad, UK). For optimal cDNA 
synthesis, each 20-µl reaction should have 1000-ng of RNA, 4-µl of 5× iScript reaction 
mix, and 1-µl of iScript reverse transcriptase prepared to a total 20-µl volume with 
nuclease-free water (Table 5). The reaction mix was incubated in a thermocycler (G-
Strom) using the following conditions: 5 minutes at 25°C, 30 minutes at 42°C, 5 
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minutes at 85°C and held at 4°C. The resulting synthesized cDNA from each RNA 
sample was kept at -20°C until further use. 
 



























































































































































































The RT-PCR assay using the synthesized cDNA was performed on the Roche 
LightCycler 480 RT-PCR instrument (Roche), 2X SYBR green master mix (Roche, UK) 
was included in the reaction. Primer pairs for adipogenesis target gene, fatty acid 
binding protein-4 (FABP4) (Table 8). A 10-µl reaction was prepared for each sample by 
adding 90-ng/µl of cDNA, 10-µM of each forward and reverse primers for the gene of 
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interest, 2X SYBR green master mix and nuclease-free water to reach to a final volume 
of 10-µl. After that, the reaction mix was placed in a thermocycler for a pre-incubation 
step for 5 minutes to denature the components. The amplification step consisted of 45 
cycles at 95°C for 10 seconds, 10 seconds at 60°C and 10 seconds at 72°C, followed 
by a dissociation curve run consisting of a 3-step procedure at 95°C for 5 seconds, 
65°C for 60 seconds, and a gradual increase in temperature at a rate of 0.11/second 
up to 97°C. Next, the tubes were cooled at 40°C for 30 seconds. Undifferentiated WJ-
MSCs were also included as a control in parallel with the assay. The data were 
collected and analysed using the comparative threshold cycle method with TATA-box 
binding protein (TBP) and glucuronidase beta (GUSB) as reference genes (Table 8).  
The statistical analysis methods used to describe and compare adipogenicity between 
obese and normal groups are described in the statistical analysis section (2.3.4). 
 
2.3.2.2 Chondrogenesis differentiation 
The StemPro® chondrogenesis differentiation kit (Gibco, UK) was used for the 
chondrogenic differentiation of MSCs. In this experiment, the kit was used to induce 
chondrogenesis of cells from obese and non-obese donors and to compare the ability 
of the cells from both groups to commit towards chondrogenicity.  
Briefly, once the WJ-MSCs reached confluence, the cells were washed and detached. 
Again, the collected cells were re-plated onto a 4-well plate and a 6-well plate for 
different purposes. For staining purposes, a micro-mass culture was generated by 
seeding 3-µl droplets of cell suspension in the centre of the well of a 4-well plate. After 
cultivating the micro-mass culture for 2 hours in 5% O2 and 5% CO2 at 37˚C, warmed 
complete StemPro chondrogenesis medium was added to the culture. For gene 
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expression purposes, the cells were re-plated as usual in 6-well plates and incubated 
in DMEM/10% FCS. After 48 hours, the medium was replaced with complete StemPro 
chondrogenesis differentiation medium. For both cultures, the chondrogenic medium 
was changed every 2-3 days. The names and concentrations of the active components 
in the kit that promote chondrogenic differentiation were proprietary information of the 
manufacturer and were not available.  
After incubation for 14 days under differentiation conditions, the cells designated for 
staining were washed and fixed. After fixation, the cells were washed and incubated for 
30 minutes with Alcian blue solution pH 1.0 (Abcam, UK). Blue staining indicates 
proteoglycan synthesis by chondrocytes. The cells were washed with PBS after the 
staining step and then left for drying. The cells were then visualized, and images were 
captured using a fluorescence microscope (Zeiss Axioskop) for qualitative analysis.  
The sample preparation for gene expression followed the same method as explained in 
section (2.3.2.1). After 14 days under differentiation conditions, the cells were collected 
from 6-well plates, RNA was extracted, and the eluate that was recovered was 
quantified. Then, cDNA synthesis was performed for the RT-PCR assay (Table 6). 
Primer pairs for the chondrogenesis target gene, collagen type XI alpha 1 chain 
(COL11A1), are reported in Table 8. RNA was extracted, and cDNA was synthesized 
from differentiated cells; cDNA resulting from undifferentiated cells was included as a 
control for the RT-PCR.  
The statistical analysis methods used to describe and compare chondrogenicity 




Table 6. The required mixture composition of RNA samples from chondroocytes for the cDNA synthesis 





























































































































































































2.3.2.3 Osteogenesis differentiation 
The StemPro® Osteogenesis differentiation kit (Gibco, UK) was selected for the 
osteogenic differentiation of MSCs. The kit was designed to induce osteogenesis of 
cells from obese and non-obese donors and to compare the ability of the cells from 
both groups and their level of commitment towards osteogenicity.   
Once WJ-MSCs reached confluence, the cells were washed and detached. The 
collected cells were re-plated onto a 4-well plate and a 6-well plate, then incubated in 
DMEM/10% FCS. After 2 days, the medium was replaced with complete StemPro 
osteogenesis differentiation medium. Fresh osteogenic medium was replaced in the 
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plates every 3-4 days. The active components and their concentrations in the kit that 
were used to promote osteogenic differentiation were proprietary information of the 
manufacturer, and hence, were unknown. 
After incubation for 21 days under differentiation conditions, the cultured cells 
underwent fixation for staining purposes. After fixation, the cells were washed with PBS 
and then incubated for 30 minutes with Alizarin Red staining solution	 (Sigma, UK). 
Calcium deposits were an indication of successful differentiation of MSCs into 
osteoblasts. After incubation, the cells were washed to remove excess stain and then 
dried to remove excess water. The cells were qualitatively analysed and visualized 
under a fluorescence microscope, and cell images were captured. 
For the gene expression procedure, the cells were collected 21 days after being 
subjected to differentiation conditions. RNA was extracted from the cells, quantified 
and then used to synthesize cDNA (Table 7), as explained previously (in section 
2.3.2.1). RT-PCR was performed using primer pairs for the osteogenesis gene runt 
related transcription factor 2 (RUNX2) (Table 8). RNA was extracted, and cDNA was 
synthesized from undifferentiated cells; the resultant cDNA was included as a control 
for the procedure.  
The statistical analysis methods used to describe and compare osteogenicity between 
































































































































































































Table 8. Primer sequences for differentiation (Life Technologies, UK). 
FABP4-F 5’-AGCACCATAACCTTAGATGGG-3’ 
Adipogenesis FABP4-R 5’-CGTGGAAGTGACGCCTTTCA-3’ 
COL11A1-F 5’-CCAGCGTCTGTTGGTTCAGT-3’ 
Chondrogenesis COL11A1-R 5’-CAGCTTCCCCTTTCTCTCCT-3’ 
RUNX2-F 5’-TTACTTACACCCCGCCAGTC-3’ 
Osteogenesis RUNX2-R 5’-TATGGAGTGCTGCTGGTCTG-3’ 
TBP-F CAGCGTGACTGTGAGTTGCT 
Reference gene TBP-R TGGTTCATGGGGAAAAACAT 
GUSB-F AAACGATTGCAGGGTTTCAC 




2.3.3 The immunomodulatory properties of WJ-MSCs from 
obese and non-obese subjects 
The immunomodulatory activities of WJ-MSCs isolated from obese group were 
assessed and compared with the immunomodulatory activities of WJ-MSCs isolated 
from the control group.  
T75 flasks were coated with CellStart (Invitrogen, UK) to enhance cell attachment 
before being used for expanding the WJ-MSCs from the fourteen donors. The cells 
were cultured using MezenGro®, a xeno-free medium (StemRD, USA), for two weeks 
or until the cells reached 80-90% confluence. Rho-associated kinase p160ROCK 
(ROCK inhibitor) (Santa Cruz Biotechnology, UK) was used during the sub-culturing to 
enhance the survival rate of the WJ-MSCs. When the cells reached confluence, they 
were harvested with TrypLE, washed with DMEM only and counted using a 
haemocytometer. A total of 1×106 diluted cells was recommended for the proliferation 
assay for every 1-ml of Roswell Park Memorial Institute (RPMI) medium supplemented 
with 10% FBS and 10,000-U/ml penicillin and 10,000-µg/ml streptomycin (Life 
Technologies, UK). Human peripheral blood mononuclear cells (PBMCs) were isolated 
from leukocyte cones, which were purchased from The National Blood Service 
(Colindale). The leukocyte cones were diluted 1:1 with PBS and layered on Histopaque 
(Sigma-Aldrich, UK) for density gradient separation.  
The proliferation assay was conducted using a 96-well plate (Costar, UK) with a total 
volume of 200-µl of RPMI/10% FBS, penicillin and streptomycin per well. The WJ-
MSCs were serially diluted, plated and incubated overnight. The PBMCs were then 
stained using violet dye from a CellTrace cell proliferation kit (Life Technologies, UK) 
using a working concentration of 1-µM cell suspension. Next, the cells were incubated 
at 37°C for 10 minutes and washed twice; the first wash used FBS, and the second 
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wash used RPMI. Subsequently, a total of 5x105 stained PBMCs were added to each 
well of WJ-MSCs to obtain co-cultures with MSC:PBMC ratios increasing from 1:5 to 
1:80. The PBMCs were then stimulated with 5-µg/ml phytohaemagglutinin (PHA) 
(Sigma-Aldrich, UK). BM was run in parallel as a reference and guide for the 
immunosuppression of the WJ-MSCs. Cultures of stimulated PBMCs without MSCs 
were used as a positive control, whereas non-stimulated PBMCs were used as a 
negative control. The cells were incubated in 5% CO2 at 37°C for 72 hours. After 3 
days, the cells were collected and washed once with PBS; thereafter, proliferation was 
measured using flow cytometry. 
PBMC proliferation was assessed according to the pattern and distribution of the peak 
of the cells that were labelled with violet dye. Non-stimulated PBMCs were used as a 
guide for gating the proliferation. With increasing dilutions, the pattern of the peak from 
stained cells also increases. The relative proliferation at each MSC:PBMC ratio was 
then calculated as a percentage of the proliferation obtained in the positive control, 
according to the following formula: A/Bx100, where A is the proliferation at one specific 
MSC:PBMC ratio, and B is the proliferation of the positive control. The percentage of 
inhibition was then calculated by subtracting the percentage of proliferation from 100 
(maximum inhibition). The statistical analysis methods used to describe and compare 
the immune response between obese and non-obese groups are described in the 
statistical analysis section (2.3.4). 
 
2.3.4 Statistical analysis  
Continuous data were summarized using mean, standard, median and range. 
Categorical data were summarized using count and percentages. 
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I used the Mann-Whitney U test (Sedgwick, 2012) to compare the sample distributions 
between two independent groups (obese and non-obese donors) with respect to 
numerical outcome. This test is the non-parametric equivalent to the two-sample t-test 
for comparing the mean between two independent groups with respect to a numerical 
outcome. I used the Wilcoxon rank test (Sedgwick, 2014) to compare the difference in 
outcomes relating to the same donor. This is the non-parametric equivalent to the 
paired t-test. 
Non-parametric tests do not make any assumption regarding data distribution and are 
valid when the data follow a normal distribution. Non-parametric methods use the rank 
of the data rather than the actual values. These methods are particularly useful when 
sample size is small (less than 12 subjects per group) because it is not possible to 
ascertain the data distribution, and the distribution test will lack sufficient power to 
provide meaningful results. Unlike the case when the sample size is large, even if the 
data do not follow the normal distribution, the results from the parametric test would still 
be valid. 
 
The Mann-Whitney U and Wilcoxon rank tests only provide p-values to confirm or 
reject the null hypotheses. However, to quantify the uncertainty around the estimates of 
the difference between the two groups or within subjects, the 95% confidence intervals 
are required. The 95% confidence interval represents the range of values within which 
the true population parameters, e.g., the mean, would lie. Generally, the computation 
of the confidence interval is based on normal approximation (asymptomatic inference). 
Asymptomatic theory is very convenient when available; however, in small samples, 
the results may be inaccurate. Therefore, I used Bootstrap as a re-sampling method 
(Bland & Altman, 2015) to obtain valid confidence intervals in this situation, as it 
improves the precision of asymptotic approximations in small samples. This method 
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estimates standard errors for the difference and confidence interval without making any 
assumption regarding the probability distribution of the data. The 95% confidence 
intervals were derived using 1000 replications. 
 
I used the Poisson regression model (Gardner et al., 1995) to model the association 
between obesity status and growth days. This model is based on count data, i.e., the 
number of growth days. 
I used the Kaplan-Meier method (Bland & Altman, 1998) to compare the median time 
to doubling by obesity status. This is a standard method for the analysis of time to 
event data. I first considered the ‘event’ as the doubling of the cell counts within a time 
less than or equal the overall median doubling time; in this case, it was 34 hours. I also 
looked at the difference in the Kaplan-Meier curves for an `event' that occurred within 
the first 24 hours. The medians of the time to doubling of the cells were compared 
between the groups using the log-rank test (Sedgwick & Joekes, 2013). 
I used either the Chi-square or Fisher's exact test (Altman, 1990) to compare the 
distribution of categorical variables, for example immunophenotypic markers, between 
two independent groups (obese and non-obese donors). The Chi-square test 
compares the observed frequency in each response category to the frequency I would 
expect if the null hypothesis of no association were true. When the expected 
frequencies are small (less than 5), Fisher's exact test can be used instead. 
All statistical analyses were performed in Stata V11.2. No adjustment was made to the 
p-values as a result of multiple testing. All hypothesis testing is considered exploratory. 
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2.4 Sample preparation and analysis for the DNA 
methylation study 
DNA was extracted from triple-positive (CD73, CD90 and CD105) WJ-MSCs from 
obese and non-obese donors, quantified and subjected to bisulfite conversion. 
Successful bisulfite conversion was confirmed using PCR with methylation-specific 
primers. Then, bisulfite-converted DNA was processed using Human Methylation 450K 
BeadChip (Illumina, UK) to determine whether obesity had any effects and changes on 
their methylation profiles; the methylation profiles of MSCs from the obese donors were 
compared with the profiles of MSCs obtained from the control group.  
 
2.1.1 WJ-MSC sorting and extraction analysis from obese and 
non-obese lines  
According to the ISCT, CD73, CD90 and CD105 are the most commonly used markers 
for MSC detection (Dominici et al., 2006). Cells that were positive for all three markers 
were selected using the fluorescence-activated cell-sorting technique (FACS) to 
confirm a pure MSC population. The samples were prepared using the same method 
that was used for flow cytometry (Section 2.3.1). In brief, WJ-MSCs were suspended in 
cold PBS/10% FBS. The cells were incubated with antibodies in the dark for 10 
minutes at 4°C and were then washed and re-suspended in 2-ml of PBS/10% FBS per 
tube. Negative and positive controls were tested in parallel for FITC, PE and APC. A 
BD FACSAria™ II/III Cell Sorter (BD Biosciences, BRC Flow Cytometry Core service 
provider, King’s College London) was used by a BRC Core staff member to identify the 
population of interest. The sorting was also based on the MSC profile that was 
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determined using both FSC and SSC. After the cell sorting was complete, the cell 
suspension was centrifuged at 12,000 rpm for 5 minutes, the supernatant was 
aspirated, and the pellet was re-suspended in PBS to a final volume of 200-µl.  
Genomic (g) DNA was extracted from the cells using a QIAamp DNA mini kit (Qiagen, 
UK) according to the manufacturer’s instructions; all necessary reagents were provided 
in the kit. In brief, 20-µl of Qiagen proteinase K was added to each cell suspension. 
Then, 200-µl of AL buffer was added, and the mixtures were vortexed for 15 seconds, 
resulting in a homogenous solution, which confirmed adequate cell lysis. Subsequently, 
the samples were incubated at 56°C for 10 minutes for optimal DNA yield after lysis; 
the tubes were then briefly centrifuged in a bench-top micro-centrifuge to collect any 
drops of DNA from inside the lid. The cell lysates were washed with 200-µl of 100% 
ethanol and were mixed thoroughly by being vortexed for 15 seconds. The lysates 
were carefully transferred to the QIAamp mini spin columns and centrifuged at 8,000 
rpm for 1 minute. The collection tubes containing the flow-through were discarded, and 
the spin columns containing the DNA bound to the silicon filter were placed in new 2-ml 
collection tubes. The spin columns were washed with 500-µl of AW1 buffer and were 
centrifuged at 8,000 rpm for 1 minute; then, the columns were placed in new 2-ml 
collection tubes. The QIAamp mini spin columns with bound DNA were washed further 
with 500-µl of AW2 buffer and were then centrifuged at the maximum speed for 3 
minutes. To prevent carryover from AW2 buffer, the collection tubes were replaced with 
new tubes, and the columns were dried further by an additional centrifugation step at 
the maximum speed for 1 minute. Finally, the QIAamp columns were placed in sterile 
1.5-ml micro-centrifuge tubes, and 200-µl of AE elution buffer was added. To promote 
optimal gDNA yield, the columns were incubated at room temperature for 5 minutes 
and then centrifuged at 8,000 rpm for 1 minute. The spin columns were discarded at 
this stage because the eluted DNA had been recovered in the micro-centrifuge tubes. 
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The concentration of the extracted gDNA samples was determined using a Qubit 
fluorometer. For Qubit DNA quantification assay, the Qubit® dsDNA BR assay kit (Life 
Technologies, UK) was used, and the same procedure was followed as described in 
section (2.3.2.1). The DNA samples were stored at -20°C until use.   
 
2.1.2 Bisulfite conversion of DNA from all donors 
The EZ DNA MethylationTM kit (Zymo Research, UK) was developed to enable a simple 
and accurate gDNA bisulfite conversion procedure. This procedure is based on an 
interaction between sodium bisulfite and cytosine, where unmethylated cytosine is 
converted to uracil, and methylated cytosine remains protected and unchanged.  
After the gDNA was extracted, it was ready for bisulfite conversion. The manufacturer’s 
instructions recommend that the amount of input DNA used for optimal bisulfite 
conversion should range from 200-ng to 500-ng. In this experiment, between 400-ng 
and 500-ng of gDNA from each of the fourteen samples was used for the reaction; 
three technical replicates were included in the bisulfite conversion reaction. 
The procedure was performed as recommended by the EZ DNA MethylationTM kit 
manufacturers. Exactly 5-µl of M-dilution buffer was added to each gDNA sample that 
ranged between 400-ng and 500-ng. Distilled water was used to adjust the final volume 
to 50-µl, and the solution was thoroughly mixed by either pipetting the solution or 
flicking the tube (Table 9). Then, the mixture was incubated for 15 minutes at 37°C. 
During the incubation, fresh CT conversion reagent was prepared; 750-µl of water and 
210-µl of M-dilution buffer were added to one reagent tube and vortexed for 10 minutes 
at room temperature. One hundred microlitres of the prepared reagent was added to 
the tubes containing gDNA and mixed thoroughly by pipetting. The tubes were then 
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incubated in a G-Storm thermocycler using the following conditions: 95°C for 30 
seconds and 50°C for 60 minutes, both for 16 cycles, followed by a hold at 4°C. 
After a 16-hour incubation, the samples were placed on ice for 10 minutes. Zymo-
spin™ IC columns were placed in collection tubes, and 400-µl of M-binding buffer was 
then added. The samples were loaded into the corresponding columns, the caps were 
closed securely, and the solutions were mixed several times by gently inverting the 
tubes, which were then centrifuged for 30 seconds at full speed. The flow-through was 
discarded. One hundred microlitres of M-wash buffer was then added to the tubes 
containing samples, which were then centrifuged for 30 seconds at full speed using a 
bench-top micro-centrifuge. Two hundred microlitres of M-desulphonation buffer was 
added to each sample, and then the samples were incubated at room temperature for 
15-20 minutes, followed by centrifugation at maximum speed for 30 seconds. The 
tubes were washed twice with 200-µl of M-wash buffer and were centrifuged for 30 
seconds at maximum speed. Finally, the column was placed into a new 1.5-ml micro-
centrifuge tube, and 12-µl of M-elution buffer was added directly to each column matrix. 
The DNA was eluted from the tubes containing matrix by centrifugation at maximum 
speed for 30 seconds. The eluted bisulfite-converted gDNA samples were stored at -
20°C for later use. 
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Table 9. The required mixture composition (water, gDNA volume and M-dilution buffer) of samples for 
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2.1.3 Verification of complete bisulfite conversion 
Two sets of primers, i.e., methylated and un-methylated, were designed to amplify the 
methylated and un-methylated copies of the differentially methylated regions of MEG3 
in the bisulfite-converted DNA (Sigma-Aldrich Oligo, UK). These primers were used to 
independently determine the successful completion of the gDNA bisulfite conversion; 
primers sequences and sizes descriptions are shown in Table 10 (Murphy et al., 2003). 
In this experiment, three technical replicates of bisulfite-converted and non-converted 
gDNA samples obtained from the same donor were tested for conversion efficiency. 
	99	
Each PCR reaction was performed in a total volume of 25-µl, comprising 1× PCR buffer, 
0.2-mM dNTPs, 0.5-µM of each primer, 2-U of Taq polymerase, and 1-µl of converted 
or non-converted gDNA, and H2O was added to obtain a final volume of 25-µl (all 
reaction components were obtained from Zymo Research, UK). The conditions used 
for the PCR reaction are shown in Table 11. 
The amplified products were loaded in plastic tubes and placed in an Agilent 2200 
TapeStation electrophoresis system (Agilent Technologies). This system is available 
for researchers to use by the service providers BRC Genomics Core at King’s College 
London. The run was set up as follows. The DNA ladder was prepared and loaded 
alongside the samples to size the fragments after electrophoresis. The D1000 reagents 
kit (Agilent Technologies, UK) was used for the electrophoresis, 3-µl of D1000 buffer 
was added to 1-µl of D1000 ladder in a 0.2-ml tube. One microlitre of the amplified 
sample was added to individual 0.2-ml tubes, and then 3-µl of D1000 buffer was added 
to the tube. The tubes were vortexed (IKA MS 3 basic, UK) at 2,000 rpm for 1 minute. 
After the tubes were vortexed, they were centrifuged for 1 minute to ensure that the 
mixture reached the bottom of the tubes. At this stage, the sample tubes and the 
D1000 ready to use screen tape (Agilent Technologies, UK) were loaded onto the 
TapeStation instrument, and the automated processing had started. Samples migrated 
through the channels of the screen tape. Once the process had completed, the 
resulting bands along with their sizes were visible in images. The sizes of each PCR 
product indicate either a successful or an unsuccessful bisulfite conversion. 
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Table 10. Primer sequences and product sizes in bp. 
Methylated-F GTT AGT AAT CGG GTT TGT CGG C 
160-bp Methylated-R AAT CAT AAC TCC GAA CAC CCG CG 
Un-methylated-F GAG GAT GGT TAG TTA TTG GGG T 
120-bp Un-methylated-R CCA CCA TAA CCA ACA CCC TAT AAT CAC A 
 
Table 11. PCR cycling conditions. 
Temperature Time Cycle number 












30 seconds/step 35 cycles 
72°C 5 minutes 1 cycle 
 
 
2.1.4 DNA methylation study using Infinium Human 
Methylation 450K BeadChips   
The Infinium Human Methylation 450K BeadChip consists of 485,764 cytosine 
positions from regions across the human genome; 99.3% of the sites are CpG 
dinucleotides, whereas 0.7% of the sites, corresponding to 3,343 positions, are more 
related to CNG targets. Regarding the distribution of CpG sites among chromosomal 
locations, the CpG sites can be found in all 23 human chromosomes. In particular, the 
Y chromosome contains the fewest positions (0.08%), while chromosome 1 contains 
the most CpG positions (9.6%). Regarding the relation between CpG sites and content 
and the surrounding context, 36.3% of CpGs are located in open seas, 30.9% are in 
islands, 23% are in shores, and 9.7% are in shelves. The functional genomic 
distribution of the CpG sites consists of 41% in proximal promoters, 30.9% in gene 
bodies, 24.6% in intergenic regions, and 3.16% in 3'-untranslated regions (3’UTRs) 
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(Sandoval et al., 2011). 
Generally, the beads on the chip are designed to represent 99% of the Reference 
Sequence genes, with an average of 17 CpG sites per gene region distributed across 
the promoter, 5'-untranslated region (5'UTR), exon 1 (1st exon), gene body, and 3'UTR 
from the whole genome. Ninety-six percent of CpG islands are also represented, 
including island shores and the regions flanking them. Each beadchip accommodates 
twelve samples for interrogation; therefore, a total of four beadchips were used to test 
45 samples. The experimental design for testing the methylation status of the samples 
involved processing all fourteen samples in triplicate on the array. Additionally, three 
blank samples (without template DNA) were processed on the array. Four microlitres of 
bisulfite-converted gDNA, which had been obtained from processing each DNA sample 
and was stored under -20°C conditions, was provided to the service providers of the 
BRC Genomics Core facility at King’s College London. The service provision covered 
the process steps described by the Infinium HD methylation assay protocol guide 
(Document # 15019519 v01). Additionally, built-in controls were used to evaluate the 
quality performance of each step in the assay for all samples. The results were 
provided in a raw data output for data analysis. 
 
2.1.4.1 Infinium Human Methylation 450K BeadChip principle 
To prepare the bisulfite-converted DNA for amplification, the samples were first 
denatured and neutralized (Figure 5.A). Through an overnight incubation step, the 
denatured DNA was isothermally amplified; the whole-genome amplification reaction 
generated a sufficient amount of each DNA sample by increasing the sample by 
several thousand fold (Figure 5.B). Using a controlled enzymatic process, the amplified 
DNA products were fragmented; an end-point fragmentation process was used to 
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prevent over-fragmentation of the DNA (Figure 5.C). The fragmented DNA was 
precipitated with isopropanol and collected via centrifugation at 4°C (Figure 5.D). The 
precipitated DNA samples were re-suspended in hybridization buffer (Figure 5.E). At 
this stage, the re-suspended DNA samples were denatured at 95°C for 20 minutes and 
allowed to cool at room temperature for 30 minutes before being individually loaded 
onto each beadchip stripe for hybridization. The beadchips were incubated in the 
Illumina hybridization oven (48°C) overnight to allow for hybridization of the samples 
onto the Infinium Human Methylation 450K BeadChips, and the DNA samples 
annealed to locus-specific 50-mers during hybridization (Figure 5.F). After a series of 
washing steps were performed to eliminate non-specifically hybridized and un-
hybridized DNA (Figure 5.G), the beadchips were ready for the subsequent staining 
and extension steps (Figure 5.H). The DNA fragments that had annealed specifically 
on the beads during the hybridization step were used as templates for the single-base 
extension reaction of the oligos on the beadchips. After the extension reaction, a series 
of staining steps allowed the incorporation of fluorescent dye labels onto the 
beadchips; label detection enabled the determination of the methylation status of the 
queried CpG sites. An Illumina iScan system was used to scan the beadchips (Figure 
5.I). The scanner recorded high-resolution images of the light emitted from the 
fluorophores after using a laser to excite the fluorophores of the single-base extension 










Figure 5. Principle of processing Infinium Human Methylation 450K BeadChips. A. Denaturing and 
neutralizing bisulfite-converted DNA. B. Incubating DNA for amplification. C. Fragmenting DNA. D. 
Precipitating DNA. E. Re-suspending DNA. F. Hybridizing to beadchip. G. Washing beadchip. H. 
Extending and staining beadchip. I. Imaging beadchip. Adapted from the Infinium HD assay methylation 
protocol guide (Document # 15019519 v01). 
 
 
2.1.4.2 Quality control principles of the Infinium Human Methylation 
450K BeadChip 
The controls test the key aspects of the protocol to ensure that the data generated are 
high quality; outcomes from sample-independent and sample-dependent controls were 
generated for all 42 gDNA samples. 
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The controls test for reaction efficiency at the critical steps of the protocol, including 
dinitrophenyl (DNP) and biotin staining, extension of the nucleotide bases on beads 
(probes), target removal, hybridization, CpG site detection, non-polymorphic controls, 
bisulfite conversion I and II, specificity controls 1 and 2 and negative controls.  
Purpose of sample-independent controls: 
The DNP and biotin staining control, determined the sensitivity and efficiency of the 
staining reaction. The intensities were captured for evaluation through the red and 
green channels during scanning. 
The extension control, used a hairpin probe to measure the extension efficiency of 
single base nucleotides (i.e., A, T, C and G). The ideally matched probes (A and T) 
were expected to produce a high-intensity signal that is shown in the red channel, 
whereas the mismatched probes (C and G) were expected to result in a low signal 
visible in the green channel. 
The target removal control, measured the efficiency of the stripping of the DNA after 
the hybridization step on the beads had occurred and after the DNA had acted as a 
template for the single base extension reaction to occur. Its efficiency was monitored in 
the green channel of the scanner; it should result in a low signal. 
The hybridization control, was designed to give an overall evaluation of the Infinium 
assay performance by using synthetic targets to probes on the array to enable perfect 
matches at three concentration levels, low (0.2-pM), medium (1-pM) and high (5-pM). 
This control was measured in the green channel. The intensity from these targets 
should be low, medium and high, respectively. 
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Purpose of sample-dependent controls: 
The CpG site detection control, was implemented by detecting CpG sites with p-
values between 0.01 and 0.05. 
The non-polymorphic controls, enabled the evaluation of overall assay performance 
from amplification to detection by querying bases (A, T, C and G) in non-polymorphic 
regions of the genome across samples. C and G were monitored in the green channel, 
while A and T were monitored in the red channel. 
The bisulfite conversion I and II controls, were sample-dependent controls used to 
confirm successful and complete sample conversion. For bisulfite conversion I, 
converted C probes matched the converted sequence and extended; in the case of 
incomplete conversion, the U probes extended instead. For bisulfite conversion II, the 
A base was incorporated, and the probe was observed with high intensity in the red 
channel; in the case of unconverted gDNA, the G base was incorporated, and the 
probe yielded a high-intensity signal in the green channel. 
Specificity controls 1 and 2, were both designed to observe the allele-specific 
extension of probes I and II. Three of each G/T mismatch controls were present on the 
array to evaluate perfect matches and mismatches and to identify any unspecific 
detection of methylation signal over un-methylated background. 
The negative controls, were designed to monitor the assay background. The probes 
on the array were permutated bisulfite-converted sequences that did not contain CpGs 
and, therefore, were not able to hybridize to DNA. There were approximately 600 of 
these probes on the array, and they were expected to show background-level 
intensities.   
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2.1.4.3 Statistical analysis of the data 
Array data analysis was performed using GenoSplice (www.genosplice.com, France). 
The data were normalized for adjustment of type-II bias using the Beta-MIxture 
Quantile dilation (BMIQ) method (Teschendorff et al., 2013) from the Chip Analysis 
Methylation Pipeline (ChAMP) R package (Morris et al., 2014). The 450K array 
contains 65 single nucleotide polymorphism (SNP) probes that do not interrogate 
methylation, and these were filtered out. In addition, probes having a detection p-value 
above 0.01 were filtered out; thus, a total of 1,921 probes were removed from the 
analysis. The remaining 483,591 probes were included for the analysis. The CpGassoc 
R package (Barfield et al., 2012) and MethLAB software (Kilaru et al., 2012) were used 
for the differential methylation analysis together with information provided in the Human 
Methylation 450 v1.2 Manifest File for CpG annotations. T-statistics were calculated 
using logit-transformed beta values to help stabilize the variance (Du et al., 2010). The 
T-statistic measures the size of the difference relative to the variation in the sample 
data. The logit transform, log (beta/(1-beta)), is equivalent to the log ratio of the 
methylated signal to the unmethylated signal. Multiple tests were performed using the 
q-values, which are adjusted p-values that take the false discovery rate (FDR) into 
account. The q-value was obtained using an optimized FDR method (Storey, 2002). 
A comparative analysis using the averaged data obtained from the three replicates of 
all the obese donors versus the averaged data obtained from the three replicates of the 
non-obese donors were performed. Thereafter, the genes with at least one CpG site 
showing a methylation difference ≥0.20 in four or more obese donors were filtered 
based on the list of polymorphic CpG sites (Chen et al., 2013) and segmental 
duplication (Kent et al., 2002). The methylation data outcomes have been deposited in 
the Gene Expression Omnibus under the accession number GSE74167.  
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2.5  Copy number variation analysis for segmentally 
duplicated genes 
 
To confirm that the two segmentally duplicated genes, zinc finger protein 714 
(ZNF714) and DDB1- and CUL4-associated factor 6 (DCAF6), were present in multiple 
locations in all donors from both groups, Copy Number Variation (CNV) analysis was 
made possible by TaqMan Copy Number Assays. 
The same gDNA that was extracted from fourteen donors (obese and non-obese) in 
section (2.4.1) was used for this experiment. A 20-ng aliquot of gDNA was constituted 
in a volume of 4-µl. Probes for ZNF714 and DCAF6 were designed and synthesized by 
the manufacturer to be used for the copy number assay. RNase P was selected as a 
reference gene assay. Each 20-µl reaction contained 4-µl of gDNA, 10-µl of TaqMan 
genotyping master mix, 1-µl of TaqMan copy number assay (either ZNF714 or DCAF6 
in two different reactions), 1-µl of TaqMan copy number reference assay RNase P, and 
4-µl of nuclease-free water (all reagents from Thermo Fisher Scientific, UK). Then, the 
reaction mix was incubated in a thermocycler for 10 minutes at 95°C for 1 cycle 
followed by 15 seconds at 95°C and 60 seconds at 60°C for 40 cycles. Additionally, a 
no-template control was included to show the background fluorescence and to allow for 
the detection of contamination. Copy number was calculated by Applied Biosystems 
Copy CallerTM Software v2.0. 
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2.6 Sample preparation and analysis for gene 
expression array analysis  
Microarray gene expression analysis was performed on all fourteen donors to compare 
the global gene expression profiles of the obese and non-obese donors and to identify 
any significant changes that could affect gene expression levels. Then, the gene 
expression level was analysed in the 16 genes that have been highlighted in the 
experiments performed to this point. These 16 genes have significant differences in 
DNA methylation of one or more CpG sites not located in polymorphic regions. Briefly, 
WJ-MSCs from both groups were cell-sorted (CD73, CD90 and CD105), RNA was 
extracted and quantified, and the integrity of the recovered RNA was evaluated. The 
RNA was then used for whole-genome gene expression direct hybridization assay. 
 
2.6.1 WJ-MSC sorting, RNA extraction, quantification and 
qualification analysis 
WJ-MSCs that were triple positive for the markers CD73, CD90 and CD105 were 
selected using FACS. The samples from fourteen donors were prepared and sorted 
using the same methods that were used for preparation and sorting in section (2.4.1). 
RNA was extracted from the cells, the concentration of the extracted RNA samples 
was determined using a Qubit fluorometer, and the RNA samples were stored at -80°C 
until use. For RNA extraction and quantification assays, I followed the same 
procedures that were detailed in section 2.3.2.1. 
To ensure that highly accurate data were obtained, only good-quality RNA was used 
for the gene expression array protocol. The quality was determined by obtaining an 
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RNA integrity number (RIN) score for each sample; the RIN score was determined 
using the Agilent 2100 Bioanalyzer (Agilent Technologies, instrument was provided by 
BRC Genomics Core, King’s College London). The RNA quality of the samples was 
tested with the Agilent RNA 6000 Nano kit (Agilent Technologies, UK).  
The main steps of the protocol are briefly described. The RNA ladder was prepared by 
heat denaturation for 2 minutes at 70°C and then immediately cooled on ice. The gel 
was prepared next by allowing it to equilibrate at room temperature for at least 30 
minutes; a 550-µl aliquot of gel matrix was placed into a spin filter, and the spin filter 
was placed into a micro-centrifuge to spin for 10 minutes at 4,000 rpm. Next, a 65-µl 
aliquot of the filtered gel was transferred to a 0.5-ml tube. Following this step, the gel-
dye mix was prepared by adding 1-µl of dye concentrate to the 65-µl aliquot of filtered 
gel tube, and the mix was vortexed thoroughly and visually inspected to ensure proper 
mixing of gel and dye. The gel-dye mix vial was centrifuged at 14,000 rpm for 10 
minutes at room temperature.  
Then, a 9-µl aliquot of the gel-dye mix was collected from the filtered gel-dye mix vial 
and pipetted in the RNA Nano chip at the bottom of the well-marked G on the chip. The 
chip with gel-dye mix was placed in a chip priming station; the purpose of the priming is 
to ensure that the gel spreads evenly across the wells in the chip. Next, the timer was 
set to 30 seconds, and the plunger was set and checked that it was at 1-ml on the chip 
priming station. The latch of the station was closed until a click was heard, ensuring 
that the priming station was closed correctly. The plunger of the syringe was secured 
down under the clip and held there for exactly 30 seconds; the plunger was released 
by triggering the clip release mechanism. The plunger was checked to ensure that it 
moved back up at least to the 0.3-ml position on the syringe. After waiting for 5 
seconds, the plunger was gently pulled up manually to the 1-ml position. The latch of 
the chip priming station was opened, and the chip was placed on the bench-top. Then, 
9-µl of the gel-dye mix was pipetted in each of the wells marked gel-dye mix. Next, a 5-
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µl aliquot of RNA 6000 Nano marker was pipetted straight into the well marked with the 
ladder symbol and into each of the 12 wells for the samples. The RNA ladder was kept 
on ice during use; 1-µl of ladder was pipetted into the well marked with the ladder 
symbol, and 1-µl from each sample, which was also kept on ice, was pipetted into each 
of the sample wells. The chip was immediately placed horizontally in the adapter of the 
IKA vortex mixer (Agilent Technologies) and was vortexed for exactly 60 seconds at 





2.6.2 Gene expression array for obese and non-obese 
The new HumanHT-12 v4.0 Expression BeadChip (Illumina, UK) provides a 
comprehensive solution for viewing gene activity in samples and is designed to support 
flexible usage across a wide-spectrum of experiments, including large-scale studies 
that include human whole-genome gene expression profiling for applications, such as 
differential expression analysis, disease classification, expression-based quantitative 
trait loci studies, and pathway analysis.  
The content on the array was carefully selected by Illumina to ensure it was of high 
quality and that it provided genome-wide transcriptional coverage of well-characterized 
genes, gene candidates, and splice variants. The array targets more than 47,000 
probes, ensuring that >99.98% of the bead types are present on any given HumanHT-
12 array. Therefore, five probes may be represented with only 0, 1, or 2 copies on each 
HumanHT-12 array. Probes were derived from National Center for Biotechnology 
Information Reference Sequence (NCBI RefSeq) Release 38, as well as other sources, 
such as the legacy UniGene content. 
RNA from the samples was stored under -80°C conditions, ready to be processed on 
the global gene expression array with the aim to compare the data outcomes from 
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obese and non-obese groups. Each HumanHT-12 v4 Expression beadchip enables 
twelve samples to be processed, and each kit provides two beadchips. The 
experimental design for testing the gene expression of the samples required 
processing all fourteen samples in triplicate from obese and non-obese donors. 
Therefore, two kits were used, as they were sufficient for processing all fourteen 
samples in triplicate. Some statistical considerations for the analysis were based on the 
data outcomes from the DNA methylation microarray experiment.   
After confirming that the RNA quality was high, 5-µl aliquots containing 500-ng of each 
sample were provided to the service providers of the BRC Genomics Core facility at 
King’s College London. BRC Genomics provided the standard off-the-shelf Epicentre 
TargetAmp Nano-g Biotin RNA labelling kit (Epicentre, UK) and the RNeasy MinElute 
clean-up kit (Qiagen, UK) that are recommended by Illumina for labelling the RNA 
sample prior to committing it to hybridization on the expression beadchip. 
The instructions described by the Whole-Genome gene expression direct hybridization 
assay guide (Part # 11322355 Rev. A) were applied for the process of the arrays. The 
assay contained built-in controls that evaluated the quality performance of the main 
steps in the assay for all samples. The raw data output generated after scanning the 
beadchip was analysed by GenoSplice. 
 
2.6.2.1 Nano labelling for the Illumina expression beadchip process and 
the whole-genome gene expression direct hybridization assay 
principle 
 
First-strand cDNA Synthesis: the Poly(A) RNA contained in a total RNA sample was 
reverse transcribed into cDNA. The reaction was primed from an oligo(dT)-primer 
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containing a phage T7 RNA Polymerase promoter sequence at its 5′end. First-strand 
cDNA synthesis was catalysed by SuperScript III Reverse Transcriptase and 
performed at an elevated temperature to reduce RNA secondary structure. Second-
strand cDNA Synthesis: the cDNA produced from earlier step was converted to double-
stranded cDNA containing a T7 transcription promoter in an orientation that generated 
anti-sense RNA (aRNA; also called cRNA) during the subsequent in vitro transcription 
reaction. In vitro transcription of Biotin-aRNA: high yields of Biotin-aRNA (Biotin-cRNA) 
were produced in a rapid in vitro transcription reaction that utilized the double-stranded 
cDNA produced previously as the template (Figure 6A). Then, the aRNA was cleaned 
up and purified.  
 
The labelled RNA strand was hybridized to the bead on the beadchip containing the 
complementary gene-specific sequence (Figure 6B). Beadchips were removed from 
the overnight hybridization and then washed (Figure 6C). Analytical probes were bound 
to the hybridized beadchip, which allowed for differential detection of signals when the 
beadchips were scanned (Figure 6D). The Illumina HiScan or iScan system or bead 
array reader measured fluorescence intensity at each addressed bead location. The 
intensity of the signals corresponds to the quantity of the respective transcript in the 






Figure 6. Principle of processing the Illumina HumanHT-12 v4 Expression beadchip. A. Sample labelling 
protocol in which total RNA is converted to double-stranded cDNA to generate labelled cRNA. B. 
Hybridizing strand to beadchip. C. Washing beadchip. D. Binding probes to beadchip. E. Imaging beadchip. 
Adapted from the TargetAmp-Nano labelling kit for Illumina expression beadchip (Lit. # 269 • 5/2013-
EPILIT269 Rev. A) and the whole-genome gene expression direct hybridization assay guide (Part # 




2.6.2.2 Gene expression array quality control  
This section describes the system controls that were used for the platform. Control 
categories are built in the direct hybridization assay system. These controls test the 
main aspects of the protocol, ranging from the biological specimen, sample labelling, 
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hybridization, and signal generation. The performance of the controls was monitored by 
uploading the data on the Genomestudio application. 
 
 
Hybridization controls (high stringency), these controls test the hybridization of the 
single-stranded assay products to the immobilized beads. The controls consist of 50-
mer oligos labelled with Cy3 dye included in the hybridization reagent. They should 
generate a signal independent of both the RNA sample and the success of the sample 
preparation reactions. The expected signal for all samples was expected to be roughly 
the same value because the hybridization control is sample independent. 
Background control, this control consisted of approximately 800 probes of random 
sequences selected to have no corresponding targets in the genomes. The mean 
signal of these probes defined the system background and facilitated checking for any 
non-specific binding or cross hybridization. The signal value was expected to be lower 
than 150.  
Gene intensities, the intactness of the biological specimens was monitored by 
housekeeping gene controls. There were fourteen probes in total, two probes for each 
housekeeping gene. These genes should be expressed in any cellular sample; 
however, the average gene intensity will vary with different gene expression products, 
due to the properties of the species. 
Number of genes detected, the number of genes with a detection p-value of 0.05 and 
0.01 or less was a good indicator of the robustness of the assay. 
 
 
2.6.2.3 Statistical analysis  
 
For global gene expression between obese and non-obese donors in triplicate: 
• The data normalization was performed using the R packages ‘illuminaio’ and 
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‘limma’.  
• The quality control analysis was performed using the R package ‘limma’.  
• The hierarchical clustering analysis was performed with R using the complete 
linkage method and Euclidean distance. 
• The data were further analysed according to the Kyoto Encyclopaedia of Genes 
and Genomes (KEGG) database, the Reactome database and the Gene 
Ontology (GO) analysis. 
 
A comparison of obese and non-obese donor networks related to PNPLA7 when 
detecting signalling cascades and interaction between PNLPA7 and other genes: 
• GeneMANIA (genemania.org).  
• String V10.0 (string-db.org).	
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2.7 Confirmation of a significant difference in 
PNPLA7 between obese and non-obese donors  
 
The data generated from the gene expression arrays showed a significant difference in 
the mRNA expression level of only one gene, patatin-like phospholipase domain-
containing 7 (PNPLA7), between obese and non-obese donors. PNPLA7 gene 
expression data from the arrays were confirmed using RT-PCR. PNPLA7 protein 
expression level was determined using Western blot analysis. 
 
 
2.7.1 Testing PNPLA7 using RT-PCR	
RT-PCR was used to validate the findings from the array data that showed a 
significant difference in mRNA expression levels of PNPLA7 between obese and non-
obese groups. WJ-MSCs from obese and non-obese groups were collected, RNA was 
extracted and quantified, and cDNA was synthesized (Table 12) as explained 
previously in section (2.3.2.1). RT-PCR was performed using SYBR green master mix 
with primers designed for the targeted gene (PNPLA7) in obese and non-obese 
donors (Table 13). Sample preparation and conditions for RT-PCR were followed as 
previously described in section (2.3.2.1). The data were collected and analysed using 
the comparative threshold cycle method using TBP and GUSB as reference genes 
(Table 8). The statistical analysis methods used to describe and compare gene 
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2.7.2 Western blot analysis for PNPLA7 
A Western blot analysis was prepared to validate the protein expression levels of 
PNPLA7 in the obese and non-obese groups. 
WJ-MSCs pellets (1x106 cells) were lysed in in 400-µl of RIPA buffer (Thermo Scientific, 
UK), supplemented with cOmplete protease inhibitor cocktail (Roche, UK). The lysate 
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was homogenized by passing it ten times through a 29-G needle (Sigma-Aldrich, UK) 
and was sonicated twice every 10 seconds with a sonicator (Fisher sonic 
dismembranator model 300) at 35% of capacity. Fifteen microlitres of lysate were 
mixed with 5-µl of LDS Sample Buffer (Life Technologies, UK), boiled for 5 minutes, 
chilled on ice, spun briefly in a bench-top micro-centrifuge and loaded at 15-µl/well in a 
4-12% SDS polyacrylamide gel (Life Technologies, UK). The proteins were separated 
in MOPS SDS Running Buffer (Life Technologies, UK) at a constant current of 20-mA 
using Novex XCell SureLock® Mini-Cell system (Life Technologies) that was 
connected with a 1000/500 constant voltage power supply (Bio-Rad). The molecular 
weight of the proteins was determined using Bolt™ BenchMark™ Pre-Stained Protein 
Ladder (Life Technologies, UK). The gel was equilibrated in Transfer Buffer (Life 
Technologies, UK) for 10 minutes. The proteins were transferred from the gel to the 
0.2-µm pore size nitrocellulose membrane (Life Technologies, UK) overnight in transfer 
buffer at a constant current of 25-mA.  
The membrane was washed in TBST buffer (Thermo Fisher Scientific, UK) for 10 
minutes and blocked for 20 minutes in 5% bovine serum albumin (Sigma-Aldrich, UK) 
in TBST. The membrane was then incubated with rabbit anti-PNPLA7 antibody (Sigma-
Aldrich, UK) at a dilution of 1:1000 (20-ng/ml) in TBST on a rocking platform at room 
temperature for one hour. The membrane was washed three times every 10 minutes in 
TBST and then incubated with HRP-conjugated donkey anti-rabbit IgG (H+L) cross-
absorbed secondary antibody (Thermo Scientific, UK) diluted at 1:2500 (20-ng/ml) on a 
rocking platform at room temperature for 30 minutes. The membrane was washed 
again three times every 10 minutes in TBST. The protein was detected with an 
enhanced chemiluminescent Pierce® ECL Western Blotting Substrate (Thermo 
Scientific, UK). The images were detected and recorded using Intelligent Dark Box 
LAS-3000 (Fujifilm). 
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The membrane was washed in TBST for 10 minutes, stripped in Restore™ Western 
Blot Stripping Buffer (Thermo Scientific, UK) on a rocking platform at room temperature 
for 15 minutes and washed again for 10 minutes in TBST. The membrane was then 
incubated with a loading control HRP-conjugated mouse anti-actin antibody BA3R 
(Thermo Scientific, UK) for 1 hour and then washed three times every 10 minutes in 
TBST and exposed to Pierce® ECL Western Blotting Substrate. The images were 
detected and recorded using Intelligent Dark Box LAS-3000. Actin, used as 
housekeeping protein for the analysis. The statistical analysis methods used to 
describe and compare the protein levels between the obese and normal groups are 











3. Results  
	
The genome-wide effect of obesity on DNA methylation was evaluated in WJ-MSCs 
isolated from UCs collected immediately after delivery. The WJ-MSCs were isolated 
from mothers who exhibited healthy pregnancies; the mothers were categorized into 
obese and non-obese groups based on whether they presented with high (>30) or 
normal (19-25) BMI, respectively. The cells from UCs were isolated and cultured using 
the explant method, and their properties were evaluated. The genome-wide DNA 
methylation and gene expression profiles were assessed and compared between two 
groups. 	
	
3.1 Isolation and evaluation of WJ-MSCs    
First, this chapter describes the outcomes of method used to isolate WJ-MSCs from 
UCs. Second, it presents the assessment results of the initial observations of the 
outgrowth and proliferation rates of WJ-MSCs from fourteen donors (obese n=7 and 
non-obese n=7). Third, the biomarker expression profiles of the panel of MSC markers 
in the obese and non-obese groups are evaluated. Fourth, WJ-MSCs from both groups 
are evaluated for their differentiation potential. Lastly, the effect of obesity on immune 
response is assessed for WJ-MSCs from obese donors and compared with the results 
from the control group. 	
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To eliminate any technical errors and minimize variability among samples, all fourteen 
UCs were processed under similar conditions using sterile techniques from the day of 
collection until the end stage of the experimental procedure. Moreover, UC collection 
was conducted under tightly controlled conditions. The conditions for UC processing in 
the laboratory were standardized, and freshly prepared medium was used to culture 
samples in an incubator with a constant temperature of 37°C and provision of gases, 
including 5% O2 and 5% CO2.	
	
3.1.1 Assessment of WJ-MSCs isolated from UCs using an 
explant procedure versus enzymatic digestion  
The UCs collected from the first five donors were cut in a half and one part was 
subjected to enzymatic digestion, whereas the other was cut in smaller pieces and 
cultured as explants to isolate MSCs from WJ. The cultures obtained using the 
enzymatic method retained a high number of red blood cells from the initial day of 
processing. Very few cells were found attached to the surface of the dish in these 
cultures, and the cultures could not be expanded further (Figure 7). Cultures obtained 
using the explant method had present haematopoietic cells on the day of the procedure 
and they could be removed by changing medium. These cultures showed mostly 
adherent cells that mainly exhibited a fibroblastic morphology (Figure 7). The explant 
method for MSCs isolation was therefore easier, faster, and better for isolation of 
adherent cells that were homogenous than the enzymatic digestion method.   	
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After processing, isolating and expanding the MSCs of WJ from five cords using the 
explant and enzymatic methods, the remaining samples were processed solely using 
the explant method. Therefore, the explant method was used for the isolation and 
expansion of MSCs from WJ throughout this project. 		
 
 
Figure 7. On day 0, haematopoietic cells were present in cultures obtained from the enzymatic and 
explant methods. On day 14, more fibroblast-like cells were present in cultures obtained from WJ explants 
than in cultures obtained using the enzymatic procedure. On day 21, a network of fibroblast-like cells was 
visible in the explant cultures, whereas few attached cells were present in the culture obtained using the 
enzymatic method. 		
3.1.2  Assessment of the initial outgrowth and proliferation 
rates of explants from WJ-MSCs from obese and non-
obese donors 
The WJ portions of the UCs collected from all donors were sectioned into 10 small 
fragments on individual plates. Each fragment was approximately 1-cm2 in size. The 
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cultures containing WJ-MSCs were monitored at regular intervals to determine the start 
of outgrowth. The cells from obese and non-obese cords exhibited a predominantly 
fibroblast-like phenotype; they were spindle shaped and had a relatively high nuclear-
to-cytoplasmic ratio (Figure 8). 	
The WJ-MSCs from the control groups showed an initial outgrowth on day 7 for donors 
N1 and N3 and on day 10 for donors N4, N6, and N7. Initial outgrowth for donors N5 
and N2 was observed on days 9 and 11, respectively. In contrast, the cultures that 
were grown using explants from the obese group an initial outgrowth was evident on 
day 8 from donors O3 and O6 and on day 12 from donors O2 and O5. Donors O1 and 
O4 showed initial outgrowth on days 9 and 11, respectively. The explant culture from 
donor O7 was the slowest to establish and expand, showing the initial outgrowth on 
day 14 (Table 14, Figure 9A). 	
The mean (± standard deviation) time to the first observation of outgrowth was 9.1 
(±1.5) days in the non-obese donors and 10.5 (±2.2) days in the obese donors. 
However, the difference between the obese and non-obese groups in terms of the 
initial outgrowth of the cells was not significant (p-value 0.220, Mann-Whitney test) 
(Figure 9B and Table 15). Analysis based on the Poisson model showed that the rate 
of initial outgrowth in the non-obese group was earlier than in the obese group but still 
not significant. The 95% confidence interval of the incidence rate ratio was 1.15 (0.827 
to 1.61; p=0.395). 	
The proliferation rate of the WJ-MSC cultures from each group type was assessed 
between PD1 and PD2 using the PD formula. In the non-obese group, it took 25.2 
hours for the cells from donor N3 and 24 hours for the cells from donor N4 to double 
their populations; it took 33.1 and 32 hours for the cells from donors N2 and N7, 
respectively, to double their populations. The cells from donor N1 took 25.9 hours, and 
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the cells from donor N6 took 53.3 hours. Of the cells in the non-obese group, those 
from donor N5 displayed the longest doubling time, at 71.6 hours. In the obese group, 
the cells from donors O1, O3, O6 and O7 doubled their populations after 55.4, 28.5, 75 
and 48 hours, respectively. The cells from donors O4 and O5 each took 34.2 hours to 
double their populations, and the cells from donor O2 displayed the longest doubling 
time, at 96 hours (Table 16). 	
The median (range) PD time of the WJ-MSCs between PD1 and PD2 was 32 (24 to 
71.6) hours in the non-obese group and 48 (28.5 to 96) hours in the obese group. The 
overall median time to doubling was 34.2 (24 to 96) hours. These results suggest that 
the PD time of cells from the non-obese group was somewhat shorter than that of cells 
from the obese group; however, the difference was not significant (p-value 0.084, 
Mann-Whitney test).	
However, the Kaplan-Meier test was used to compare the cell doubling time in both 
groups in the first 34 hours (overall median PD time). The difference in the time taken 
to double within the first 34 hours between the groups was significant (p-value 0.048, 
log-rank test). Thus, the results suggest that the population doubling time of the cells 





Figure 8. Fibroblast-like cells proliferated from non-obese (n=7) and obese (n=7) WJ explants are 
morphologically indistinguishable under phase-contrast microscopy.		
	
Table 14. Number of days prior to initial outgrowth and expansion of WJ-MSCs from explant cultures 
(O=obese and N=non-obese) (n=14).	
Non-obese	 First outgrowth (days)	 Obese	 First outgrowth (days)	
N1	 7	 O1	 9	
N2	 11	 O2	 12	
N3	 7	 O3	 8	
N4	 10	 O4	 11	
N5	 9	 O5	 12	
N6	 10	 O6	 8	
N7	 10	 O7	 14			 	
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Table 15. Time of observation of initial outgrowth from explant cultures of obese and non-obese cords.	
Group	 Mean                  (standard deviation)	 Median             (minimum, maximum)	 p-value                     (Mann-Whitney test)	
Normal (n=7)	 9.14 (1.57)	 10.0 (7.0, 11.0)	
0.220	Obese (n=7)	 10.5 (2.29)	 11.0 (8.0, 14.0)	
Total (n=14)	 9.85 (2.03)	 10.0 (7.0, 14.0)		
	
Table 16. Time (hours) required for the cells to double in population between PD1 and PD2 (O=obese 
and N=non-obese) (n=14).	
Non-obese	 Proliferation rate (hours)	 Obese	 Proliferation rate (hours)	
N1	 25.9	 O1	 55.4	
N2	 33.1	 O2	 96.0	
N3	 25.2	 O3	 28.5	
N4	 24.0	 O4	 34.2	
N5	 71.6	 O5	 34.2	
N6	 53.3	 O6	 75.0	





Figure 9. A. Total mean (days) prior to the first outgrowth of MSCs from WJ explants (observed 
microscopically) from all fourteen donors. B. Mean (days) prior to the first outgrowth of MSCs from WJ 
explants in obese and non-obese donors; no significant differences were observed between the cells in the 
two groups (p-value 0.220, Mann-Whitney test). C. Cells from non-obese donors showed a significant 
faster doubling time than cells from obese donors after 34 hours (p-value 0.048, log-rank test). 		
	
3.1.3 Biomarker detection in WJ-MSCs from obese and non-
obese lines using flow cytometry  
Flow cytometry was used to determine and compare the cell surface biomarker 
expressed in the WJ-MSC populations grown in vitro from the obese and non-obese 
donor groups. Cells that were collected for biomarker identification at the PD2 stage. 
Clinical-grade BM-MSCs, served as a positive reference for MSC markers, Kasumi 
cells served as a positive control for haematopoietic cell surface markers, unstained 
MSCs were used for gating assessment, and beads were used for manual 
compensation. 	
The flow cytometer was used to gate and assess unstained cells for the phenotypic 
expression of the following markers: CD90, CD73, CD105, CD44, CD29, CD271, 
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MSCA-1, CD56, CD45 and CD34. MSC marker CD90 was expressed in 94.8%, 95.2%, 
94.5%, 97.2% and 95.2% of the gated cell populations from donors N2, N3, N4, N5 
and O6, respectively. In the cells from donors N6, N7, O1 and O2, CD90 expression 
was slightly lower (77.2%, 78.9%, 73% and 72%, respectively). CD73 expression was 
highest in the cells from donor O2, at 99.4%, and lowest in the cells from donor O3, at 
88%. CD105 expression ranged from 93.1% to 99.1%. Likewise, expression of the cell 
surface marker CD44 was observed in majority of the cells (range: 92.6% to 99.7%). 
CD29 expression levels were the highest in WJ-MSCs from all donors, but the WJ-
MSC population from donor N7 showed the lowest CD29 expression level, at 99.4%. 
The cell surface marker CD56 showed the greatest variation in expression across the 
cell lines; 40.3% of the donor O3 cell population expressed CD56, while the majority, 
80.6%, of the donor N6 cell population expressed CD56. CD56 expression levels in the 
remaining cell lines fell between these extremes (Tables 17 and 18). 	
Overall, the flow cytometric data analysis of the surface markers identified from the 
cells showed similar expression properties of the following main MSC markers in the 
non-obese and obese groups: CD90 (p-value 0.249, Mann-Whitney test), CD73 (p-
value 0.949, Mann-Whitney test) and CD105 (p-value 0.608, Mann-Whitney test). In 
addition to, CD29 (p-value 0.268, Mann-Whitney test) and CD44 (p-value 0.482, Mann-
Whitney test). One exception was CD56, the surface marker CD56 expression was 
significantly lower in the obese group than in the non-obese group (p-value 0.025, 
Mann-Whitney test) (Table 19, Figure 10). Both groups were negative for CD271 and 




Table 17. MSC marker panel showing the expression levels (percentages) of CD markers on the 
surfaces of WJ-MSCs from non-obese donors.	
CD Marker	 N1	 N2	 N3	 N4	 N5	 N6	 N7	
CD90	 85.8	 94.8	 95.2	 94.5	 97.2	 77.2	 78.9	
CD73	 98.9	 97.8	 94.8	 95.3	 99.0	 98.9	 90.5	
CD105	 95.2	 99.1	 98.6	 95.5	 99.0	 96.5	 99.1	
CD44	 96.4	 98.9	 96.6	 94.9	 99.7	 98.6	 95.1	
CD29	 99.6	 99.9	 99.8	 99.9	 99.9	 99.7	 99.4	
CD271	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	
MSCA-1	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	
CD56	 53.8	 77.5	 83.6	 80.1	 79.2	 80.6	 63.2	
CD45	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	
CD34	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00		
Table 18. MSC marker panel showing the expression levels (percentages) of CD markers on the 
surfaces of WJ-MSCs from obese donors.	
CD Marker	 O1	 O2	 O3	 O4	 O5	 O6	 O7	
CD90	 73.0	 72.0	 83.3	 89.7	 81.9	 95.2	 86.6	
CD73	 97.7	 99.4	 88.0	 95.7	 92.6	 96.6	 95.4	
CD105	 93.1	 99.0	 97.4	 98.7	 96.4	 98.9	 97.1	
CD44	 99.5	 99.4	 92.6	 97.9	 97.5	 99.0	 97.1	
CD29	 99.9	 99.8	 99.9	 99.9	 99.8	 99.8	 99.9	
CD271	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	
MSCA-1	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	
CD56	 51.6	 65.6	 40.3	 62.1	 53.9	 55.4	 75.3	
CD45	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	
CD34	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00		 	
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Table 19. Comparison of the proportion of individual surface markers identified in WJ-MSCs according 
to obesity status.                                                                                                                             
+Confidence intervals obtained using the normal approximation to the binomial distribution	
CD Marker	 Median proportion (%)	 p-value          (Mann-Whitney test)	 95% confidence interval (%)+	
Non-obese	 Obese	
CD90	 94.5	 83.3	 0.249	 -5.9 (-6.0 to -5.9)	
CD73	 95.3	 95.7	 0.949	 -0.11 (-0.13 to -0.09)	
CD105	 98.6	 97.4	 0.608	 -0.34 (-0.35 to -0.32)	
CD44	 96.6	 97.9	 0.482	 0.4 (0.38 to 0.41)	
CD29	 99.8	 99.9	 0.268	 0.11 (0.10 to 0.11)	
CD56	 79.2	 55.4	 0.025	 16.2 (-16.3 to -16.2)	
CD271	 00.0	 00.0	 0.00	 0	
MSCA-1	 00.0	 00.0	 0.00	 0	
CD34	 00.0	 0.00	 0.00	 0	
CD45	 00.0	 00.0	 0.00	 0			
	
Figure 10. Expression of positive markers (CD90, CD73, CD105, CD44 and CD29) on the surfaces of WJ-
MSCs from normal BMI (n=7) and high BMI (n=7) groups, levels did not differ significantly. CD56 was an 
exception, showing a significant difference between both groups (p-value 0.025, Mann-Whitney test). 
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3.1.4 Differentiation potential of WJ-MSCs from obese and non-
obese donors 
The WJ-MSCs isolated from obese mothers were tested to determine whether they 
exhibited differentiation potentials similar to or different from those of WJ-MSCs 
isolated from non-obese mothers. I compared differentiation propensity of WJ-MSCs 
from the obese and non-obese donors towards the adipogenic, chondrogenic and 
osteogenic lineages. The potential of the cells to commit to all three differentiation 
pathways was analysed to identify any differences between obese and non-obese 
donor cells. 
	
3.1.4.1 Differentiation of WJ-MSCs into adipocytes 	
MSCs are multipotent and, by definition, can differentiate into cells of mesodermal 
origin. Researchers have demonstrated that diet-induced obesity alters MSC 
differentiation potential. Cells from both donor groups were differentiated into 
adipocytes to determine their adipogenic propensity. 	
After the cells had been cultured for 14 days, fat droplets positively stained for 
LipidTOX indicated that the cells had undergone adipogenesis (Figure 11A). The 
undifferentiated cells and differentiated cells from all fourteen donors were then 
assessed for the level of the adipogenic-specific marker FABP4.  
The mean (± standard deviation) of the FABP4 mRNA expression level was higher in 
differentiated cells 56.5 (± 34.7) than in undifferentiated cells 0.23 (± 0.12) (Table 20). 
The differences between the differentiated and undifferentiated cells were significant 
(p-value 0.001, Wilcoxon signed rank test) and confirmed the adipogenic state of the 
cells (Figure 11A). 	
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The levels of FABP4 mRNA in differentiated cells from individual obese and non-obese 
donors were also compared. Generally, FABP4 mRNA levels varied within the samples 
from the same group as well as between samples from the obese and control groups. 
The highest FABP4 mRNA expression level in cells from the non-obese group, 57.2, 
was obtained for N6, and the highest level in cells from the obese group, 118.6, was 
obtained for subject O4; the lowest FABP4 mRNA level in the obese group, 24, was 
from O7, and the lowest value in the normal group, 11.7, was from donor N5. Overall, 
the mean (± standard deviation) FABP4 mRNA expression level was higher in the 
obese group 75.5 (± 39.5) than in the non-obese group 37.6 (± 14.8) (Table 21). 
However, the differences between the obese and non-obese groups were not 
significant (p-value 0.110, Mann-Whitney test) (Figure 11A). Analysis based on the 
Bootstrap model showed that the incidence rate ratio at the 95% confidence interval 
was -48.1 (-82.9 to 11.7).	
A second semi-quantitative analysis was performed by calculating the total surface 
area of LipidTOX-positive droplets per number of nuclei in one field to obtain the 
percentage of cellular lipid per cell. Generally, the percentage of cellular lipid per cell 
showed variations within the samples from the same group as well as between the 
obese and control groups. The highest percentage of lipid content found in either of the 
groups was 3.9% from donor N7. The lipid percentages in cells from donors N1, N2, 
O3 and O7 were close to the percentage found in donor N7 (3.6%, 3.7%, 3.4% and 
3.7%, respectively). The percentage of lipid content did not differ greatly between the 
obese donors; donor O1 showed 2.6%, and donor O4 showed 2.5%. Similar ranges of 
lipid percentages were observed in both groups; donors N3, O6, N5, N6 and O2 
showed lipid contents of 1.8%, 1.6%, 1.4%, 1.3% and 1.2%, respectively. The lowest 
percentages of lipid content were found in cells from donor O5 in the obese group and 
in cells from donor N4 in the non-obese group; these cells had 0.7% and 0.6% lipid 
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content, respectively. Overall, the mean (± standard deviation) lipid percentage of cells 
from the obese group was 2.2% (± 1.1), and the mean lipid percentage of cells from the 
non-obese group was 2.3% (± 1.3). The cells from the two groups showed no 
significant difference in cellular lipid percentage per cell (p-value 0.907, Mann-Whitney 
test) (Figure 12 and Table 22). Analysis based on the Bootstrap model showed that the 
mean lipid percentage in cells that had differentiated into adipocytes was similar in the 
obese and non-obese groups. The 95% confidence interval of the incidence rate ratio 
was 0.68 (-2.22 to 1.44).	
Although the differentiation of cells from obese and non-obese donors into adipogenic 
lineages was successful, the results did not show any significant differences between 
the samples. 		
	
Table 20. Summary of mRNA levels by differentiation status using an adipogenic-specific marker 
(FABP4).	
Group	 Mean (standard deviation)	 Median                                 (minimum, maximum)	 p-value             (Wilcoxon signed 
rank test)	Undifferentiated 
cells	 Differentiated cells	 Undifferentiated cells	 Differentiated cells	
Normal (n=7)	 0.21 (0.12)	 37.6 (14.8)	 0.17               (0.10, 0.46)	 35.7        (11.7, 57.2)	
0.001	Obese (n=7)	 0.25 (0.12)	 75.5 (39.5)	 0.20               (0.11, 0.40)	 83.8        (24.0, 118)	
Total (n=14)	 0.23 (0.12)	 56.5 (34.7)	 0.18                (0.10, 0.46)	 46.6        (11.7, 118)				 	
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Table 21. Summary of mRNA levels by obesity status using an adipogenic-specific marker (FABP4). 	
Group	 Mean                  (standard deviation)	 Median             (minimum, maximum)	 p-value             (Mann-Whitney test)	
Normal (n=7)	 37.6 (14.8)	 35.7 (11.7, 57.2)	
0.110	Obese (n=7)	 75.5 (39.5)	 83.8 (24.0, 118)	
Total (n=14)	 56.5 (34.7)	 46.6 (11.7, 118)			
Table 22. Summary of the average percentage of cellular lipid by obesity status in cells from normal and 
obese donors.	
Group	 Mean%               (standard deviation)	 Median%                  (minimum, maximum)	 p-value            (Mann-Whitney test)	
Normal (n=7)	 2.37 (1.32)	 1.86 (0.65, 3.91)	
0.749	Obese (n=7)	 2.28 (1.10)	 2.55 (0.77, 3.70)	
Total (n=14)	 2.18 (1.26)	 1.86 (0.15, 3.91)			
3.1.4.2 Differentiation of WJ-MSCs into chondrocytes 	
The WJ-MSCs obtained from obese and non-obese donors were differentiated into 
chondrocytes to determine their chondrogenic propensity.  
 After the cells were cultured for 14 days, round cells with a centrally located nucleus 
and a shiny ring in the cytoplasm around the nucleus were detected in the cultures, 
indicating that the cells had undergone chondrogenesis. This shiny ring is collagen, a 
specific protein synthesized by chondrocytes. Differentiated cells from all obese and 
non-obese donors were observed to be positively stained for Alcian blue	 (Figure 11B). 
Generally, Alcian blue staining of cultured cells is indicative of a high content of 
cartilage-specific proteoglycans in induced cultures. The staining was more intense 
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and uniform in the centres of the cultures and its intensity decreased and became 
irregular towards the outer rim of the cultures, suggesting a higher content of cartilage-
specific proteoglycans in the inner region of the cultures. 	
After the cells were cultured for 14 days, undifferentiated cells and differentiated cells 
from all fourteen donors were assessed for the levels of the chondrogenic-specific 
marker COL11A1. The mean (± standard deviation) expression level of COL11A1 
mRNA was higher in differentiated cells 10.3 (± 4.94) than in undifferentiated cells 1.92 
(± 0.74) (Table 23). The differences between the differentiated and undifferentiated 
cells were significant (p-value 0.001, Wilcoxon signed rank test), confirming the 
chondrogenic differentiation state of the cells (Figure 11B). 	
The expression of the chondrogenic-specific marker COL11A1 by differentiated cells 
from obese and non-obese donors was compared. The highest mRNA expression 
levels in the differentiated cells from non-obese and obese donors were 21.4 (N2) and 
11.6 (O2), respectively. The lowest expression levels were found in cells from donor 
N4 in the non-obese group (8.1) and in cells from donor O5 in the obese group (2.9). 
Overall, the mean (± standard deviation) COL11A1 gene expression level was higher 
in the non-obese group 12.9 (± 5.42) than in the obese group 7.77 (± 2.84) (Table 24). 
The data show that the observed differences in the mRNA expression level of 
COL11A1 in chondrogenic cells differentiated from cells obtained from obese and non-
obese donors were not significant (p-value 0.063, Mann-Whitney test) (Figure 11B). 
Analysis based on the Bootstrap model showed that 95% confidence interval of the 
incidence rate ratio was 3.13 (-1.36 to 11.7).	
Although the differentiation into chondrogenic lineages was successful, it did not reveal 
significant differences between samples from obese and non-obese donors.  	
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Table 23. Summary of mRNA levels by differentiation status using a chondrogenic-specific marker 
(COL11A1).	
Group	 Mean                                  (standard deviation)	 Median                              (minimum, maximum)	 p-value             (Wilcoxon signed 
rank test)	Undifferentiated 
cells	 Differentiated cells	 Undifferentiated cells	 Differentiated cells	
Normal (n=7)	 2.18 (0.68)	 12.9 (5.42)	 2.07              (1.33, 3.24)	 10.3        (8.16, 21.4)	
0.001	Obese (n=7)	 1.66 (0.76)	 7.77 (2.84)	 1.65              (0.57, 2.71)	 7.21        (2.96, 11.6)	
Total (n=14)	 1.92 (0.74)	 10.3 (4.94)	 1.96              (0.57, 3.24)	 8.97        (2.96, 21.4)			
Table 24. Summary of mRNA levels by obesity status using a chondrogenic-specific marker 
(COL11A1). 	
Group	 Mean                  (standard deviation)	 Median             (minimum, maximum)	 p-value                    (Mann-Whitney test)	
Normal (n=7)	 12.9 (5.42)	 10.3 (8.16, 21.4)	
0.063	Obese (n=7)	 7.77 (2.84)	 7.21 (2.96, 11.6)	





3.1.4.3 Differentiation of WJ-MSCs into osteoblast-like cells 	
The cells from all donors were differentiated into osteoblasts to determine whether the 
WJ-MSCs from obese and non-obese donors exhibit similar osteogenic propensity. 	
After the cells were cultured for 21 days, the cultures from both obese and non-obese 
donors were positively stained by Alizarin red indicating the presence of calcium 
deposits due to bone formation (Figure 11C). 	
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The undifferentiated and differentiated cells from all fourteen donors were assessed for 
the levels of the osteogenic-specific marker RUNX2. The mean (± standard deviation) 
of the mRNA expression level of RUNX2 was higher in differentiated cells 19.7 (± 11.6) 
than in undifferentiated cells 0.10 (± 0.09) (Table 25). The differences between the 
differentiated and undifferentiated cells were significant (p-value 0.001, Wilcoxon 
signed rank test), confirming that the cells had undergone osteogenesis (Figure 11C).	
Next, the levels of mRNA for the osteogenic-specific marker RUNX2 in differentiated 
cells from obese and non-obese donors were compared. The data showed that the 
mRNA expression level of RUNX2 in the non-obese group was highest in cells from 
donors N2 (25.8) and lowest in cells from donor N4 (8.63), whereas the highest and 
lowest expression levels in cells from the obese group were found in donors O7 and 
O5, at 53.0 and 9.18, respectively. Overall, the mean (± standard deviation) of the 
RUNX2 expression level was higher in the obese group 23.0 (± 15.1) than in the non-
obese group 16.5 (± 6.14) (Table 26). Non-significant differences (p-value 0.482, 
Mann-Whitney test) in the mRNA expression levels of RUNX2 were found in the 
osteogenic cells differentiated from the obese and non-obese groups (Figure 11C). 
Analysis based on the Bootstrap model showed that the 95% confidence interval of the 
incidence rate ratio was 0.54 (-15.4 to 10.4).	
Although the analysis of the differentiation of WJ-MSCs into osteogenic lineages was 




Table 25. Summary of mRNA levels by differentiation status using an osteogenic-specific marker 
(RUNX2).	
Group	 Mean                                     (standard deviation)	 Median                              (minimum, maximum)	 p-value             (Wilcoxon signed 
rank test)	Undifferentiated 
cells	 Differentiated cells	 Undifferentiated cells	 Differentiated cells	
Normal (n=7)	 0.57 (0.67)	 16.5 (6.14)	 0.22            (0.002, 0.18)	 15.8          (8.63, 25.8)	
0.001	Obese (n=7)	 0.15 (0.10)	 23.0 (15.1)	 0.11             (0.09, 0.38)	 15.3           (9.18, 53.0)	
Total (n=14)	 0.10 (0.09)	 19.7 (11.6)	 0.09           (0.002, 0.38)	 15.6          (8.63, 53.0)				
Table 26. Summary of mRNA levels by obesity status using an osteogenic-specific marker (RUNX2).	
Group	 Mean                              (standard deviation)	 Median             (minimum, maximum)	 p-value                    (Mann-Whitney test)	
Normal (n=7)	 16.5 (6.14)	 15.8 (8.63, 25.8)	
0.482	Obese (n=7)	 23.0 (15.1)	 15.3 (9.18, 53.0)	
Total (n=14)	 19.7 (11.6)	 15.6 (8.63, 53.0)			 	
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Figure 11. A. Directed adipogenic differentiation of WJ-MSCs from obese and non-obese donors 
conducted in vitro resulted in the formation of intracellular lipid droplets that were visualized with a 
fluorescent LipidTOX stain with the presence of FABP4 in adipogenic differentiated cells. B. Direct 
chondrogenic differentiation of WJ-MSCs from obese and non-obese donors conducted in vitro resulted in 
the formation of cartilage-specific proteoglycans that were visualized with Alcian blue with the presence of 
COL11A1 in chondrogenically differentiated cells. C. Direct osteogenic differentiation of WJ-MSCs from 
obese and non-obese donors conducted in vitro resulted in the presence of calcium deposits that were 
visualized with Alizarin red in the presence of RUNX2 in osteogenically differentiated cells. 	
	
Figure 12. Quantitative analysis of the average cellular lipid (percentage) in each sample group showed 
no differences between adipogenically differentiated MSCs from obese and non-obese donors (p-value 
0.749, Mann-Whitney test).  
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3.1.5 Effect of obesity on WJ-MSC immunomodulatory 
properties  
The immunomodulatory test was performed to investigate the immune response 
properties of WJ-MSCs to determine whether they were affected by an abnormal 
metabolic environment. The immunomodulatory effects of WJ-MSCs from the fourteen 
non-obese and obese donors, were compared by adding WJ-MSCs to cultures 
containing PBMCs that had been stimulated by PHA. BM-MSCs were used as a 
reference for this experiment. Co-cultures were prepared at several different 
MSC:PBMC ratios. After 3 days of co-culture, the WJ-MSCs were found to inhibit the 
proliferation of stimulated PBMCs at all tested MSC:PBMC ratios. 	
Co-culture with WJ-MSCs inhibited the proliferation of PBMCs in response to PHA. The 
inhibition by cells from the obese and non-obese groups was not significantly different 
at an MSC:PBMC co-culture ratio of 1:5, with an average inhibition of 75.5% for non-
obese and 82.7% for obese cell lines. Interestingly, when MSCs and PBMCs were co-
cultured at ratios of 1:10, 1:20 and 1:40, the data indicated significant differences 
between the obese and control groups in the degree of inhibition of PBMC proliferation 
in response to PHA (defined here as the ‘immune response’). At the 1:10 ratio, WJ-
MSCs from the obese group showed greater inhibition of the immune response 
(88.4%) than WJ-MSCs from the control group (58.7%). At the 1:20 ratio, WJ-MSCs 
from the obese cell lines also demonstrated greater inhibition of the immune response 
(79%) than WJ-MSCs from the non-obese cell lines (37.7%). At the 1:40 ratio, WJ-
MSCs isolated from donors with high BMI still showed a greater inhibition of the 
immune response (53%) than cells from donors with normal BMI (28.3%). Finally, at 
the 1:80 ratio, WJ-MSCs from obese donors inhibited PHA-induced proliferation of 
PBMCs by a non-significantly higher amount (20.4%) than their counterparts from the 
control group (7.4%) (Table 27 and Figure 13).	
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In conclusion, the WJ-MSCs derived from obese donors demonstrated significantly 
higher immune activity than the WJ-MSCs derived from non-obese donors. The 
corresponding p-values at 1:10, 1:20 and 1:40 MSC:PBMC co-culture ratios were 
0.008, 0.012, and 0.047, respectively (Mann-Whitney test). The differences in immune 
activity for the ratios 1:5 and 1:80 were, however, not significant (p-value>0.05, Mann-
Whitney test) (Table 27).  
		
Table 27. Comparison of the immune activities of WJ-MSCs derived from obese and non-obese donors at WJ-
MSC:PBMC ratios of 1:5, 1:10, 1:20, 1:40 and 1:80.		
Ratio	 Mean % (standard deviation)	 Median % (minimum, maximum)	 p-value (Mann-Whitney test)	Non-obese (n=7)	 Obese (n=7)	 Total (n=14)	 Non-obese (n=7)	 Obese (n=7)	 Total   (n=14) 
1:5	 75.5      (24.2)	 82.7  (16.0)	 79.1  (20.1)	 85.2      (36.7, 99.5)	 89.6     (58.0, 99.3)	 87.4     (36.7, 99.5)	 0.565	
1:10	 58.7      (27.0)	 88.4  (18.5)	 73.5  (27.0)	 69.9      (22.1, 91.2)	 93.9     (46.6, 97.7)	 86.4     (22.1, 97.7)	 0.008	
1:20	 37.7      (22.2)	 79.0  (21.3)	 58.3  (29.9)	 43.2     (11.4, 68.0)	 89.9     (36.5, 96.0)	 61.4     (11.4, 96.0)	 0.012	
1:40	 28.3      (20.9)	 53.0  (21.0)	 40.7  (23.9)	 20.4     (7.45, 63.4)	 61.7     (19.3, 78.5)	 39.1     (7.45, 78.5)	 0.047	





Figure 13. The immunomodulatory potential of WJ-MSCs showed higher immune activities in cell lines 
from obese donors than in cell lines from non-obese donors at the following MSC:PBMC ratios: 1:10, 1:20 
and 1:40 (n=14). A representative immunomodulatory outcome is shown for 1:5 and 1:80 MSC:PBMC 
ratios with no significant differences were observed between the immune response of cells from obese and 
non-obese donors. BM was used as a control. 		 	
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3.2 Analysis of WJ-MSC DNA methylation 
The effects of obesity on genome-wide DNA methylation of WJ-MSCs were examined 
using methylation BeadChip arrays on a dedicated Illumina microarray platform. The 
methylation data produced after scanning the arrays were analysed using Illumina’s 
GenomeStudio package and GenoSplice. The methylation assay was conducted 
specifically using WJ-MSCs from early passages that expressed common MSC 
markers, including CD90, CD73 and CD105. These WJ-MSCs were sorted from a 
triple-positive population using FACS. DNA was extracted from the sorted cells, and an 
aliquot of the eluted DNA was prepared for the bisulfite conversion reaction. A PCR 
assay designed to test bisulfite conversion efficiency, containing methylation-specific 
primers, was performed using the bisulfite-converted DNA. Successfully converted 
DNA was used for the DNA methylation assay. Illumina 450K Methylation BeadChips 
were used for genome-wide methylation. In total, 45 separate reactions were 
attempted (fourteen obese and non-obese samples that were tested in triplicate and 
three reactions that did not contain any DNA template). These 45 reactions were 
processed in one batch to minimize variations from any batch effects, allowing better 
evaluation of the potential biological relevance of DNA methylation differences among 
the samples. 
	
3.2.1 WJ-MSC sorting and gDNA extraction and quantification  
WJ-MSCs that were triple positive for CD90, CD73 and CD105 were sorted from the 
fourteen lines that had been obtained from UCs. The pre-sorting conditions for sorting 
for the triple-positively stained WJ-MSCs are shown in Figure 14.    	
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WJ-MSCs were collected after sorting the cells from all fourteen lines, including obese 
and non-obese cell lines. The recovered gDNA was eluted in 200-µl of elution buffer 
and quantified using the Qubit fluorometer. The resulting values are shown in Table 28. 
 
Figure 14. Pre-sorting of WJ-MSC populations stained with fluorescent antibodies (FITC-CD90, PE-CD73 
and APC-CD105) from obese and non-obese donors. From left to right, the 1st row shows pre-sorting of 
WJ-MSCs from non-obese donors N1, N2, N3 and N4; the 2nd row corresponds to N5, N6 and N7 cell 
populations; the 3rd row corresponds to cell populations from obese donors O1, O2, O3 and O4; and the 
4th row corresponds to cell populations from obese donors O5, O6 and O7.		
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Table 28. DNA yield after using the DNA extraction protocol. 
Measurements were determined using a Qubit instrument; 
N=non-obese (n=7), O=obese (n=7).	

















3.2.2 Assessment of bisulfite conversion efficiency of the gDNA 
samples 
Bisulfite treatment of the obese and non-obese samples was performed. For each 
reaction, 400-ng to 500-ng of gDNA was used, as recommended by Illumina. The 
ultimate purpose of this procedure was to reveal the absence or presence of methyl 
groups at cytosine residues across the genome. During the treatment process, 
unmethylated cytosine residues were converted into uracil residues, whereas cytosine 
residues that were methylated were protected from the conversion reaction. 
Subsequent downstream processes that use the elution from the bisulfite treatment, 
such as the whole-genome amplification step of the Illumina Infinium methylation 
procedure, delete all epigenetic information present on the DNA. Therefore, it was 
important to conserve the epigenetic status of the DNA in the bisulite-converted form. 
To accomplish this, the converted uracils/unconverted cytosines in the DNA samples 
were successfully whole-genome amplified. The amplified DNA was used for the 
Illumina Infinium methylation assay protocol. Infinium Human Methylation 450K 
BeadChips were selected for the assay. The data generated from scanning the arrays 
were used to infer the methylation status of the DNA. 	
The bisulfite-converted DNA was recovered in 12-µl of elution buffer. The efficiency of 
the conversion was determined by using PCR to test for false-positive methylation 
signals that may have resulted from the incomplete conversion of cytosine into uracil. 
Complete conversion of bisulfite-treated gDNA was determined by testing the amplified 
samples for the presence of specific band sizes on a pre-prepared automated 
electrophoresis gel. The primers that were designed to specifically amplify 
unmethylated copies of the MEG3 DMR produced a 120-bp band, while the primers 
designed for amplifying methylated copies of the MEG3 DMR produced a 160-bp band 
in the same reaction. Additional control reactions included unconverted DNA as a 
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template for every cell line. As expected, none of these controls produced any bands. 
Therefore, the specificity of both sets of primers for bisulfite-converted DNA was 
confirmed by the expected band sizes of the 120-bp and 160-bp PCR products. A 
negative control (H2O) that did not include any DNA template was also included in the 
PCR as a contamination indicator (Figure 15). At this stage, the samples were 
assumed to be completely converted and the 42 samples were considered ready for 
further processing using the Infinium Human Methylation 450K BeadChip kit.	
	
 
Figure 15. PCR results from the conversion reactions. Each sample from non-obese 1-7 (n=7) and obese 
1-7 (n=7) donors was bisulfite converted and tested by PCR in triplicate (1st conversion, 2nd conversion 
and 3rd conversion). Each sample was amplified separately using converted and non-converted DNA 
templates and electrophoresed on the gel. The converted (con.) version showed two bands (120-bp and 
160-bp); as expected, the native (nat.) version showed no bands. The use of H2O, which served as a 
negative control, yielded no bands.	
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3.2.3 Quality control analysis of the methylation BeadChip 
array data 
The controls provided in the Illumina methylation system assess the quality of the key 
parameters in its workflow, specifically, DNP and biotin staining, extension, target 
removal, hybridization, detected CpG sites, non-polymorphic controls, bisulfite 
conversion, specificity and negative controls. The data showed that the controls 
performed well. More importantly, the data generated from the sample-dependent 
control assays showed that the samples were of good quality and that the bisulfite 
conversion reaction was successful. The following diagrams (Figures 16-26) show the 
control dashboard that was produced by the GenomeStudio software (version 2011.1) 
and the data for each sample; each spot on the plots represents a single sample. 	
	
3.2.3.1 Sample-independent controls 
 
The staining control reaction is monitored by assessing specific beads on the array 
that are known to have biotin and DNP attached; the efficiency of the staining step is 
evaluated in the green and red channels, where both the background intensity and the 
signal intensity can be seen (Figure 16). As expected, in the red laser channel, the 
average value for DNP high staining signal intensity was greater than 3,000 (6,031), 
and the average DNP background staining intensity value was 55; the latter value was 
low, as expected. In the green channel, the DNP signal was 70 for the high-intensity 
control and 76 for the DNP background control; these low values were expected 
because red signals should not be detected in the green channel.  
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In the green channel, the biotin high-intensity control value should be greater than 
3,000, and it was 10,328. The biotin background intensity control in the green channel 
should be lower than 1,000; the observed background intensity value was 40, 
indicating that the staining reaction was efficient. In the red laser channel, the biotin 
background and biotin high staining signal intensities were less than 1,000, with values 




Figure 16. Staining control assessment using DNP and biotin in the green and red channels 
.	 	
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Extension controls assess how well each nucleotide (A, T, C and G) was 
incorporated during the extension of hairpin probes that reside on the array. These 
controls are monitored in both the green (C, G) and red (A, T) channels; a high 
intensity indicates a successful extension. In the green channel, A and T intensities 
were less than 2,000, while C and G intensities were greater than 20,000. In the red 
channel, the A and T nucleotide extension intensities were greater than 20,000 and 
those of C and G were less than 2,000, indicating that all four nucleotides were 
extended successfully, as shown in Figure 17. 
	
 
Figure 17. Extension control for each nucleotide in the green and red channels. 
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Target removal controls evaluate the efficiency of the stripping step after the 
extension reaction has occurred. The control oligonucleotides differ from the 
oligonucleotides used in the bead array for the samples, where the sample DNA 
(target) is used as a template for the extension reaction; the control oligonucleotides 
are extended using the probe sequence as a template, and this generates labelled 
targets. The target removal controls are present in the hybridization buffer. Their 
performance was monitored in the green channel and was expected to result in low 
signal intensity (<1,200) compared with that of the hybridization controls; this result 
would indicate that the targets were efficiently removed after extension (Figure 18).	
 
 
Figure 18. Target removal control assessment using the green channel only.  
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Hybridization controls examine the overall performance of the entire assay using 
synthetic targets and are independent of the amplified target (sample). These controls 
are spiked into the hybridization solution at three concentrations: high (5-pM), medium 
(1-pM), and low (0.2-pM). The signal intensities should correspond to the 
concentrations of the synthetic targets, and their signals are observed in the green 
channel. The signal intensity values were within the ranges expected from three 
different target concentrations; the signal intensities were 8,446, 16,436 and 27,350 for 
the low, medium, and high concentration levels, respectively (Figure 19). 
	
 
Figure 19. Hybridization control evaluation in the green channel.	
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3.2.3.2 Sample-dependent controls 
 
Non-polymorphic controls evaluate the overall performance of the assay from the 
amplification step to the detection step by querying a specific base in the non-
polymorphic region of the bisulfite-converted gDNA. This control enables the 
comparison of assay performance across different regions of the sample DNA. The 
non-polymorphic controls are designed to query each nucleotide (i.e., A, T, C, and G). 
The target control with the C base queries the whole-genome-amplified DNA strands 
generated from the converted strands. The signal intensities for nucleotides A and T in 
the red channel were expected to be greater than 5,000; the signal intensity values 
obtained were 9,066 for A and 11,410 for T. The signal intensities for these nucleotides 
were less than 2,000 in the green channel, as expected. However, the signal intensities 
from nucleotides C and G were 13,087 and 9,153, respectively, in the green channel, 
whereas values from the red channel for these particular nucleotides were less than 
2,000, as expected. This control confirmed that the assay was successful across both 






Figure 20. Non-polymorphic control for each nucleotide assessment using the green and red channels.	
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The detected CpG sites represent the number of CpG sites detected at p-values 
<0.01 and <0.05 in the tested samples (Figure 21).	
	
 
Figure 21. Line plot of CpG sites detected at p-values of 0.01 and 0.05 for ‘no DNA template’ samples and 
‘DNA template’ samples (n=45). 
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Bisulfite conversion I and II controls evaluate the efficiency of bisulfite conversion 
using the Infinium I and II probe designs and allele-specific single base extension. In 
the bisulfite conversion I control reaction, the converted C probes match the converted 
sequence and are extended in the case of successful conversion; in unconverted DNA 
samples, the unconverted U probe is extended instead. The performance of the 
bisulfite conversion controls C1, C2 and C3 were assessed in the green channel, and 
controls C4, C5 and C6 were evaluated in the red channel because all conversion 
control values must be greater than 5,000, the results are shown in Figure 22. The 
signal intensities from the unconverted U controls (i.e., U1, U2, U3, U4, U5 and U6) 
were evaluated in both the green and red channels and were expected to be less than 
1,000 (Figure 22). In the bisulfite conversion II control, if the A base was incorporated 
into the four (1-4) probes, the signal intensities would be over 5,000 and would be 
observed in the red channel, indicating successful bisulfite conversion. In contrast, the 
signals from the four probes (1, 2, 3 and 4) would be elevated in the green channel 
with values less than 3,000 (the observed values were 1,628, 594, 1,442 and 540, 
respectively) if the G base was incorporated across an unconverted cytosine, indicating 




















Figure 23. Bisulfite conversion II control evaluation using the green and red channels.	
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Specificity I and II controls are used to monitor the potential non-specific primer 
extension of the Infinium I and II assay probes. The Infinium specificity I control queries 
probes for the methylated and unmethylated state of each CpG locus. The G/C match 
corresponds to the methylated status of the interrogated C, while the A/T match 
corresponds to the unmethylated status of the interrogated C. The G/T mismatch 
controls test for non-specific detection of methylation signals over unmethylated 
background. Perfect match controls correspond to A/T matches that give high signals, 
and mismatch controls correspond to G/T mismatches that give weak signals. The 
performance of G/T mismatch controls was monitored in the green and red channels 
(Figure 24). The specificity II controls consist of three probes (specificity 1, specificity 2 
and specificity 3); these probes assess the potential non-specific detection of 
methylation signals over the unmethylated background; the A base must be 
incorporated across from the non-polymorphic T base. These probes were expected to 
yield high intensities (>5,000) in the red channel. The average values of probes 1, 2, 
and 3 were 10,006, 7,463 and 8,951, respectively; these outcomes were as expected. 
The three probes would give an elevated signal in the green channel in the event of 









Figure 24. Specificity control I assessment using the green and red channels. 	
	
Figure 25. Specificity control II assessment using the green and red channels.	 	
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Negative controls are random sequences that are not expected to hybridize to the 
DNA template; they are used to assess the specificity of the reaction. In particular, they 
are useful for assessing the bisulfite-converted gDNA because the chemical treatment 
reduces the sequence complexity. This type of control is also a particularly useful 
measure for analysing the background, especially for cross-hybridization and non-
specific extension. The green and red channels were used to monitor the performance 
of the negative controls (Figure 26). 	
	
 
Figure 26. Negative control performance measured using the green and red channels.	
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3.2.4 Genome-wide effect of obesity on DNA methylation 
Bisulfite-converted gDNA obtained from WJ-MSCs was tested on Illumina 450K 
methylation BeadChips to assess the impact of obesity and to detect changes resulting 
from obesity on the pattern of genome-wide DNA methylation. The experimental design 
ensured that the entire sample set would be tested in one batch. All fourteen lines were 
tested in triplicate, and three assays that did not contain any DNA were also included. 
All the samples were processed in one batch according to the Illumina Infinium 
methylation protocol. The robustness of the technique was confirmed by the fact that 
the values for all of the samples were within the quality control parameters. The data 
set generated for the methylation analyses was approximately 5-GB in size. The data 
analysis was performed using GenoSplice.	
Methylation data analysis of WJ-MSCs isolated from obese and non-obese donors 
showed that the hierarchical clusters of differentially methylated samples from each 
group clustered in clearly separate groups according to their beta values (Figure 27A). 
Moreover, the results obtained using triplicate samples of each cell line immediately 
clustered together when principal component analysis (PCA) was applied (Figure 27B). 
A comparison analysis between the averages of all obese samples with those of all 
non-obese samples identified 1% of differentially methylated CpG sites, indicating that 
changes were observed in 5,767 CpG sites. Further analysis of the sites identified as 
differentially methylated showed that 41% (2,373) of these CpG sites were significantly 
hypomethylated and 59% (3,394) were significantly hypermethylated (Figure 27C). A 
Manhattan plot displaying the significance of the associations by chromosomes 
indicates that altered methylation states were distributed across all chromosomes 
(Figure 27D). 	
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From the standpoint of functional distribution, the majority of CpG sites that were 
significantly differentially methylated were located in gene body regions; 38% (1,284) of 
these CpG sites were hypermethylated, and 31% (748) were hypomethylated. The 
intergenic sites also contained many CpG sites that were significantly differentially 
methylated; 29% (984) of these were hypermethylated, and 34% (801) were 
hypomethylated. A minority (2%) of CpG sites referenced to loci in the 1st exons were 
hypermethylated, corresponding to 71 CpG sites, and a total of 3% of CpG sites in 1st 
exons and 3’UTRs were hypomethylated, corresponding to 82 and 67 CpG sites, 
respectively (Figure 28). Based on the CpG content and the surrounding context, the 
majority of CpG sites that showed significant differential methylation were isolated 
CpGs in the genome, defined as being in open sea regions; of these, 43% (1,450) 
were hypermethylated and 47% (1,119) were hypomethylated. The minority of 
differentially methylated CpG sites occurred in the shelves; 12% (406) of these CpG 
sites were hypermethylated, and 8% (181) were hypomethylated (Figure 28). With 
respect to chromosomal location, chromosome 1 harboured the majority of the 
hypermethylated or hypomethylated CpG sites and chromosome Y contained the 
fewest (Figure 28). This outcome reflects the distribution of CpG sites across the 
chromosomes; chromosome 1 is the largest and contains the most (46,867) CpG sites, 
and chromosome Y is the smallest chromosome and contains the fewest (416) CpG 
sites.	
Subsequently, the genes associated with the significantly differentially methylated CpG 
sites were identified and analysed by comparatively analysing the data from the obese 
and non-obese donor groups; in this data, each donor was represented by the average 
of three replicates. The average difference ranged from 1% in donors O3 and O4 to 5% 
in donor O2. Donor O5 was an exception, with 32% of differentially methylated CpG 
sites. An investigation of the background of this particular obese patient revealed no 
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clear explanation for the high percentage of differentially methylated CpG sites in these 
cells (Figure 29). Among the CpG sites that exhibited differences in their methylation 
profiles, three donors (O6, O2 and O3) predominantly exhibited hypomethylation at 
56%, 80% and 81% of these sites, respectively, whereas four donors (O5, O4, O1 and 
O7) predominantly exhibited hypermethylation at 53%, 59%, 65%, and 70% of these 
sites, respectively (Figure 29).	
Next, the data from the obese donors were examined with the specific aim of 
identifying CpG sites with methylation profiles that might be influenced by an abnormal 
metabolic environment. The selection criterion chosen was that a particular CpG site 
with a significantly differentially methylated profile was detected from four or more 
obese donors. Differentially methylated CpG sites with changes equal to or greater 
than 20% and shared among four or more obese donors were detected in 67 genes. 
Six out of the seven obese donors shared 3 differentially methylated genes (NTM, 
SIM2 and STT3A), five out of the seven obese donors shared 22 differentially 
methylated genes, and four out of the seven obese donors shared 42 differentially 
methylated genes (Table 29). However, of these 67 genes, only three had more than 
one significantly differentially methylated CpG site: MAD1L1 had two sites, TRIM10 
had four sites, and ZNF714 had five sites (Table 30). Four of the seven donors had 
CpG sites in MAD1L1 and TRIM10 that were significantly differentially methylated, and 
five of the seven donors had CpG sites in ZNF714 that were significantly differentially 
methylated (Table 30). 	
The 67 genes were further filtered based on the list of polymorphic CpG sites and 
segmental duplication. Filtering based on the list of polymorphic CpG sites aimed to 
eliminate any false interpretations due to genotype polymorphisms. It was important to 
determine whether any of these genes is segmentally duplicated because these genes 
are known to have long, nearly identical DNA sequences approximately 1-kb in length 
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and these genes normally occur in multiple locations as result of duplication events and 
usually only one copy is functional, which may lead easily to misinterpretation of the 
results. Among the 67 genes filtered, 65 had probes targeting polymorphic CpGs 
(Table 31) and two genes were segmentally duplicated (DCAF6 and ZNF714).	
Further statistical analysis of the list of 67 genes was performed to determine whether 
differentially methylated CpG sites were located in polymorphic regions. If they were, 
they could be excluded. After the 67 genes were further filtered, the list was narrowed 
to 18 genes whose differentially methylated CpG sites were in non-polymorphic regions 
(Figure 30A). Most of the differentially methylated CpGs were located in the body 
(85.61%), whereas promoter areas (TSS1500, TSS200 and 5’UTR) and the 1st exon 
accounted for 12.53% of the differentially methylated sites (Figure 30B).	
The statistical power for detecting 20% methylation in this data set for 21 versus 21 
samples (7 non-obese versus 7 obese donors, each in triplicate; Figure 27) was 
approximately 99%. The same was true of the 3 versus 21 samples comparison (1 
obese versus the average of 7 non-obese donors, each in triplicate; Figure 29). The 
sample size used for the analysis was small; however, taken together, the array data 
suggest that maternal obesity might have a lasting effect on the DNA methylation 






Figure 27. A. Hierarchical clustering analysis of obese verses non-obese samples based on epigenome-
wide DNA methylation showed that each group clustered separately. B. PCA yielded separate clusters of 
obese and non-obese samples. C. The results showed that 1% of CpGs sites were differentially 
methylated in non-obese and obese donors, 41% of the CpG sites were hypomethylated and 59% of the 
CpG sites were hypermethylated. D. Changes in methylation patterns were observed to be distributed 
across all chromosomes.		 	
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Figure 28. DNA methylation status according to the genomic environment. In the context of functional 
genomic distribution, hypermethylated and hypomethylated CpG sites were similar. Similar findings were 
obtained in the context of CpG content and the surrounding environment. Differential methylation states 
were distributed across all chromosomes, with chromosomes 1, 2 and 6 harbouring the most 




Figure 29. CpG sites that were found to be differentially methylated based on the average of three 
technical replicates from obese donors and the average of all non-obese donors. Significant alteration of 
DNA methylation was observed in 1-5% of all CpG sites in 6 of 7 donors, and 32% of the CpG sites were 




Figure 30. A. List of 18 genes that are differentially methylated but are not present in polymorphic regions. 




Table 29. List of 67 genes associated with significantly differentially methylated CpG profiles 
in the specified numbers of donors 
4 donors 5 donors 6 donors 
AGPAT9 ADAMTS16 NTM 
AHRR C14orf119 SIM2 














































































Table 30. List of 75 methylation CpG sites in 67 genes for which the methylation difference was greater than or 
equal to 20% in cells from four or more obese donors. Three genes had more than one CpG site (highlighted in 
blue). The total number of CpG sites that were differentially methylated per obese donor is shown.	
Methylation Site 
Coordinate 
(hg18)	 Gene Name	 Beta value of average obese samples	 Number of donors with methylation difference of at least 0.20	O1	 O2	 O3	 O4	 O5	 O6	 O7	
chr5:5353241	 ADAMTS16	 	 X	 X	 X	 X	 X	 	 5	
chr4:84680531	 AGPAT9	 	 	 X	 	 X	 X	 X	 4	
chr5:468575	 AHRR	 	 	 	 X	 X	 X	 X	 4	
chr10:49329565	 ARHGAP22	 	 	 X	 X	 	 X	 X	 4	
chr8:1780022	 ARHGEF10	 	 	 	 X	 X	 X	 X	 4	
chr1:92190586	 BRDT	 X	 	 X	 	 X	 X	 	 4	
chr14:22637857	 C14orf119	 X	 X	 X	 	 	 X	 X	 5	
chr2:200483703	 C2orf69	 X	 X	 	 X	 	 	 X	 4	
chr8:11289019	 C8orf12	 X	 X	 X	 	 X	 X	 	 5	
chr13:110091847	 CARS2	 	 X	 	 X	 X	 X	 X	 5	
chr20:59933973	 CDH4	 X	 X	 X	 X	 	 X	 	 5	
chr14:49872721	 CDKL1	 X	 	 	 X	 X	 X	 X	 5	
chr12:103522661	 CHST11	 X	 X	 	 	 X	 	 X	 4	
chr7:73341172	 CLIP2	 	 	 X	 	 X	 X	 X	 4	
chr4:1205099	 CTBP1	 	 	 X	 X	 X	 X	 X	 5	
chr10:135193238	 CYP2E1	 X	 X	 	 	 X	 X	 	 4	
chr14:23657478	 DCAF11	 X	 X	 X	 	 	 	 X	 4	
chr1:166292176	 DCAF6	 	 X	 X	 	 X	 X	 X	 4	
chr8:142208369	 DENND3	 	 X	 	 	 X	 X	 X	 4	
chr5:169062072	 DOCK2	 X	 X	 X	 	 X	 	 	 4	
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chr6:133829849	 EYA4	 X	 	 X	 	 X	 X	 	 4	
chr12:131369514	 GALNT9	 	 	 	 X	 X	 X	 X	 4	
chr3:10303490	 GHRL	 X	 X	 	 X	 X	 	 	 4	
chr7:124182603	 GPR37	 X	 	 	 	 X	 X	 X	 4	
chr4:94785174	 GRID2	 	 X	 X	 	 X	 	 X	 4	
chr6:33145618	 HLA-DPA1	 X	 X	 	 X	 	 X	 	 4	
chr19:12737947	 HOOK2	 X	 	 X	 	 X	 	 X	 4	
chr1:18557174	 IGSF21	 	 X	 X	 	 X	 	 X	 4	
chr21:45173924	 ITGB2	 X	 	 X	 X	 	 X	 	 4	
chr2:17926797	 KCNS3	 X	 	 	 X	 X	 X	 X	 5	
chr16:2686545	 KCTD5	 	 X	 	 X	 	 X	 X	 4	
chr7:107429006	 LAMB1	 	 	 	 X	 X	 X	 X	 4	
chr19:59433522	 LILRA6	 	 X	 X	 	 X	 	 X	 4	
chr7:2049055	 MAD1L1	 X	 X	 	 	 X	 	 X	 4	
chr7:2065930	 MAD1L1	 X	 X	 	 	 X	 	 X	 4	
chr5:7930198	 MTRR	 X	 X	 	 X	 X	 X	 	 5	
chr5:16948511	 MYO10	 	 X	 X	 X	 	 X	 X	 5	
chr5:1862712	 NDUFS6	 	 X	 	 X	 X	 X	 X	 5	
chr14:74660649	 NEK9	 	 X	 	 X	 X	 	 X	 4	
chr7:34878610	 NPSR1	 X	 X	 	 X	 X	 X	 	 5	
chr11:124119166	 NRGN	 	 X	 	 X	 	 X	 X	 4	
chr11:131284679	 NTM	 X	 X	 	 X	 X	 X	 X	 6	
chr2:26555585	 OTOF	 X	 	 	 X	 X	 X	 	 4	
chr4:96979968	 PDHA2	 	 X	 X	 X	 X	 	 X	 5	
chr9:139476578	 PNPLA7	 	 X	 X	 X	 	 	 X	 4	
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chr1:117288792	 PTGFRN	 	 X	 X	 X	 	 X	 X	 5	
chr7:4821932	 RADIL	 X	 X	 X	 	 X	 X	 	 5	
chr14:55302821	 RPL13AP3	 	 X	 	 X	 X	 X	 X	 5	
chr7:4211169	 SDK1	 X	 X	 	 X	 	 X	 X	 5	
chr5:132141954	 SEPT8	 	 	 	 X	 X	 X	 X	 4	
chr2:224605669	 SERPINE2	 	 	 	 X	 X	 X	 X	 4	
chr21:37002144	 SIM2	 X	 	 X	 X	 X	 X	 X	 6	
chr20:4931091	 SLC23A2	 	 	 	 X	 X	 X	 X	 4	
chr11:124984572	 STT3A	 X	 X	 X	 X	 X	 	 X	 6	
chr1:91976255	 TGFBR3	 X	 	 X	 X	 	 	 X	 4	
chr16:20657544	 THUMPD1	 	 X	 X	 X	 X	 X	 	 5	
chr8:38967115	 TM2D2	 	 	 X	 X	 X	 	 X	 4	
chr3:195800933	 TMEM44	 X	 X	 	 X	 X	 	 X	 5	
chr2:218479852	 TNS1	 	 	 X	 X	 X	 X	 	 4	
chr8:144470710	 TOP1MT	 	 X	 	 X	 X	 X	 X	 5	
chr6:30230523	 TRIM10	 	 	 X	 X	 X	 	 X	 4	
chr6:30230502	 TRIM10	 	 	 X	 X	 X	 	 X	 4	
chr6:30230572	 TRIM10	 	 	 X	 X	 X	 	 X	 4	
chr6:30230544	 TRIM10	 	 	 X	 X	 X	 	 X	 4	
chrX:111044937	 TRPC5	 	 	 	 X	 X	 X	 X	 4	
chr6:169599375	 WDR27	 	 	 X	 X	 	 X	 X	 4	
chr6:157745134	 ZDHHC14	 	 	 	 X	 X	 X	 X	 4	
chr7:64088861	 ZNF117	 	 X	 X	 X	 X	 	 	 4	
chr1:245285114	 ZNF670	 X	 X	 	 X	 	 	 X	 4	
chr19:21056736	 ZNF714	 X	 X	 	 X	 X	 	 X	 5	
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chr19:21057204	 ZNF714	 X	 X	 	 X	 X	 	 X	 5	
chr19:21057261	 ZNF714	 X	 X	 	 X	 X	 	 X	 5	
chr19:21057104	 ZNF714	 X	 X	 	 X	 X	 	 X	 5	
chr19:21056822	 ZNF714	 X	 X	 	 X	 X	 	 X	 5	
chr7:148608580	 ZNF783	 	 	 X	 	 X	 X	 X	 4	
Total number of CpG sites per 






























3.3 Copy number variation analysis of segmentally 
duplicated genes  
Copy number analysis of the ligand-dependent coactivator of nuclear receptors DCAF6 
revealed that donors have variable copy numbers of this gene. A number of DCAF6 
copies displayed variations within the samples from the same group as well as 
between the obese and control groups. Four donors from the obese and non-obese 
groups (N2, N6, N7 and O4) had one copy of DCAF6, five donors (N1, N3, N4, N5 and 
O1) two copies and five donors from the obese group (O2, O3, O5, O6 and O7) had 
three copies of DCAF6 (Figure 31A). All donors that displayed a significant difference 
in DCAF6 methylation had three copies of the gene (asterisks), which can explain the 
differences detected in the array. Indeed, DCAF6 mRNA expression levels did not 
show any significant differences among individual donors (Figure 31B) or between the 
obese and control groups (Figure 31C).  
Analysis revealed that all fourteen donors had two copies of the ZNF714 gene, 
including the five donors in whom all five CpG sites were differentially methylated 
(asterisks) (Figure 31D). ZNF714 mRNA expression levels, however, showed no 
differences within the samples from the same group (Figure 31E) and no variation 
between the obese and non-obese groups (Figure 31F). These results suggest that the 










Figure 31. A. DCAF6 showed variation in copy number among the samples. B. DCAF6 gene expression 
was similar among fourteen samples. C. There was a non-significant difference in DCAF6 expression level 
between the obese and non-obese groups. D. ZNF714 was present in two copies in all samples. E. 
ZNF714 showed no variation in all fourteen samples. F. A non-significant difference in ZNF714 expression 
was observed in the obese and non-obese groups.		 	
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3.4 Gene expression array analysis between obese 
and non-obese donors 
A gene expression array was used to determine whether the difference in DNA 
methylation between obese and non-obese donors affected the expression of any of 
the 18 genes in all donors from both groups. The gene expression assay was 
determined, same as the DNA methylation, in CD90, CD73 and CD105 triple-positive 
population of WJ MSC sorted by FACS. RNA was extracted from all the sorted cells, 
quantified and checked for the quality. Illumina HumanHT-12 v4 Expression BeadChips 
were used for gene expression assessment. All fourteen samples from obese and non-
obese donors were run in triplicates. The reactions were processed in one batch to 
minimize variations due to batch effects and to better evaluate the potential biological 
relevance of any gene expression differences apparent in the samples from the obese 
group. Global gene expression was analysed in all samples from obese and non-obese 
donors. 			
3.4.1 WJ-MSC sorting, RNA extraction, quantification and 
qualification analysis 
WJ-MSCs that were triple positive for CD90, CD73 and CD105 were sorted from the 
fourteen lines that had been obtained from UCs. The pre-sorting conditions for sorting 
for the triple-positively stained WJ-MSCs are shown in Figure 32.    	
The mRNA was quantified using Qubit (Table 32). mRNA quality was evaluated in all 





Figure 32. WJ-MSC pre-sorting of populations of cells from obese and non-obese donors after staining 
with fluorescent antibodies (FITC-CD90, PE-CD73 and APC-CD105). From left to right, the 1st row 
corresponds to pre-sorted WJ-MSCs from non-obese donors N1, N2, N3 and N4. The 2nd row corresponds 
to N5, N6 and N7 cell populations. The 3rd row corresponds to cell populations from obese donors O1, O2, 
O3 and O4, and the 4th row corresponds to cell populations from obese donors O5, O6 and O7.		 	
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Table 32. Quantification and qualification of RNA recovered after RNA 
extraction. Measurements were obtained using a Qubit and Bioanalyzer 
instruments (N=non-obese (n=7); O=obese (n=7)).	
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Figure 33. Good-quality mRNA was demonstrated using a bioanalyzer in all non-obese (n=7) and obese 
samples (n=7).		 	
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3.4.2 Quality control analysis of the gene expression BeadChip 
array data 
The controls provided in the Illumina gene expression system assess the quality of the 
key parameters in its workflow, specifically, hybridization controls, background, gene 
intensities, and number of genes detected. The following diagrams (Figures 34-37) 
show the control dashboard that was produced with GenomeStudio software and the 














Hybridization controls (high), test the hybridization of single-stranded assay products 
to the array beads. The signals for all samples should be consistent; the hybridization 
control is independent of the samples. All signal intensity values generated from the 
samples fall consistently within the high range, indicating that the hybridization reaction 
performed well. Almost half of the samples have signal intensity values between 




Figure 34. Hybridization controls in all 42 samples.		 	
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Background probes, the mean signal intensity of these probes defines the system 
background; it consists of probes of random sequence that were selected to have no 
corresponding targets in the genomes. The signal intensities of all samples are less 
than 150, indicating good performance (Figure 35).			
	
	
Figure 35. The signal intensities of all 42 samples are less than 150.			 	
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Gene intensity metric, This metric permits comparisons of the expression of 
housekeeping genes with the expression of genes of interest; all other genes located 
on each array should be compared with the background metric. Housekeeping genes 
should produce a higher-intensity signal than the background control. These values are 
shown for all samples. In the housekeeping gene control, the signal intensities ranged 
from 6,000 to 14,000. In the all gene control, the signal intensity was much lower than 
in the housekeeping gene control, ranging from 200 to 500. These values are in 




Figure 36. Signal intensities of housekeeping genes and all genes in 42 samples.		 	
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Number of genes detected, the number of genes with a detection p-value of 0.05 and 
0.01 or less. All samples showed a high number and a similar number of detected 
transcripts, indicating good performance (Figure 37). 
	
	
Figure 37. Number of genes detected with confidence in all genes in 42 samples.		 	
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3.4.3 Effect of obesity on gene expression 
The entire sample set, including triplicates of fourteen lines, was processed in one 
batch according to the protocol described in the Illumina manual and the robustness of 
the technique was confirmed by establishing the performance of the quality control 
parameters. The data set generated for the gene expression analyses was 
approximately 1-GB in size. The data were analysed using GenoSplice. The effect of 
obesity on the expression of 16 individual genes was assessed. In addition, the effect 
of obesity on global gene expression in all samples was assessed.	
To determine whether differences in methylation of the CpG sites led to different levels 
of gene expression, data from the whole transcriptome array were analysed. This 
analysis identified 244 regulated genes that showed a fold change ≥1.5 and had 
uncorrected p-values ≤0.05 (Figure 38). Six of the seven samples from obese donors 
clustered together, whereas one donor, subject O3, clustered with the non-obese 
group (Figure 39).	
According to the KEGG database, the putative pathways involved are metabolism, 
cytochrome P450 (6.7% of genes), extracellular matrix-receptor interaction (6.0% of 
genes) and haematopoietic cell lineage (4.7% of genes). The REACTOME database 
suggested that pathways related to the mitotic cell cycle (3.9% of genes) and 
metabolism of proteins (1.8% of genes) are involved. GO analysis found that among 
the ten most significant biological processes involved, nine are linked to the cell cycle; 
this might explain our finding that the cells from non-obese donors proliferate much 
faster than the cells from obese donors. Four of the most significant cellular 
components involved are directly or indirectly linked to extracellular matrix signalling, 
which matches the predictions of the KEGG database (Figure 40).	
	190	
Among the remaining 16 genes that displayed significant differences in the methylation 
of CpG sites in the two groups, only one, PNPLA7, displayed significant differences in 
mRNA expression level in the obese and non-obese groups, suggesting a possible 

















Figure 38. List of 244 regulated genes with significantly different transcriptome level between two groups.		 	
Probe_Id Symbol FC P.Value Probe_Id Symbol FC P.Value Probe_Id Symbol FC P.Value
ILMN_2186216 GOLPH4 5.75 4.85E-05 ILMN_1750324 IGFBP5 1.64 7.15E-03 ILMN_1664464 PTGDS 2.12 1.21E-02
ILMN_1693338 CYP1B1 4.26 8.04E-10 ILMN_1656501 DUSP5 1.64 3.25E-03 ILMN_1760990 SH3GL3 2.00 3.02E-05
ILMN_1830462 XYLT1 3.88 6.22E-05 ILMN_1788107 IL11 1.64 1.28E-06 ILMN_1789639 FMOD 1.97 1.03E-02
ILMN_1726448 MMP1 3.20 2.54E-04 ILMN_1795344 GOLPH4 1.64 7.65E-08 ILMN_1781400 SLC7A2 1.94 1.11E-02
ILMN_1669046 FOXQ1 3.18 1.24E-04 ILMN_1784300 TUBA4A 1.63 1.91E-04 ILMN_1686920 CCDC58 1.93 9.93E-03
ILMN_2210519 HAPLN1 3.02 2.60E-06 ILMN_1683450 CDCA5 1.63 1.64E-02 ILMN_2384745 PSG4 1.89 3.00E-02
ILMN_1707727 ANGPTL4 2.66 3.79E-05 ILMN_1692056 HS3ST3A1 1.63 5.97E-04 ILMN_1761425 OLFML2A 1.87 4.70E-04
ILMN_1770228 KRT34 2.60 3.58E-04 ILMN_1675453 HHIP 1.63 2.01E-04 ILMN_1653824 LAMC2 1.87 3.57E-04
ILMN_2352023 RIPK5 2.57 1.99E-05 ILMN_1755657 RASIP1 1.63 5.32E-03 ILMN_1668592 STON1 1.86 2.73E-03
ILMN_1716264 ANKRD1 2.57 1.11E-04 ILMN_2221006 RAD21 1.63 3.23E-04 ILMN_2404850 RPL14 1.84 4.33E-05
ILMN_1782305 NR4A2 2.55 6.51E-08 ILMN_1742789 LPXN 1.63 7.30E-04 ILMN_2053103 SLC40A1 1.82 3.13E-03
ILMN_1730645 TMEFF2 2.43 2.63E-03 ILMN_3240520 ELTD1 1.63 7.03E-05 ILMN_2181892 BEX2 1.81 7.02E-03
ILMN_2339955 NR4A2 2.40 2.64E-10 ILMN_1689037 LIPG 1.62 1.41E-02 ILMN_2336609 SYTL2 1.79 6.72E-08
ILMN_1678812 HAPLN1 2.36 1.03E-04 ILMN_2285568 NAAA 1.62 1.34E-05 ILMN_2406501 SOD2 1.79 2.69E-03
ILMN_1666733 IL8 2.35 2.79E-03 ILMN_1653719 ITGBL1 1.62 1.38E-04 ILMN_1674285 LOC401233 1.78 4.64E-02
ILMN_2184373 IL8 2.24 2.69E-03 ILMN_1651237 CDT1 1.62 1.28E-02 ILMN_1676984 DDIT3 1.75 4.37E-06
ILMN_2113490 NTN4 2.22 5.43E-05 ILMN_1792356 DPYSL4 1.61 1.51E-02 ILMN_2390853 CTSH 1.74 2.39E-03
ILMN_1658483 IL1A 2.20 1.19E-06 ILMN_1763390 ISL1 1.61 3.00E-03 ILMN_2367883 GEM 1.69 8.73E-06
ILMN_1775042 WDR69 2.15 1.41E-05 ILMN_1678669 RRM2 1.61 3.20E-02 ILMN_1665107 ITGB1BP1 1.69 1.06E-03
ILMN_1765578 TIPARP 2.15 1.11E-13 ILMN_2163873 FNDC1 1.61 4.03E-03 ILMN_1715647 VANGL2 1.68 1.35E-02
ILMN_1799569 LOC440895 2.06 3.71E-08 ILMN_1717541 CNTNAP3 1.61 1.16E-04 ILMN_1709094 LIFR 1.68 3.94E-05
ILMN_1844593 --- 2.05 1.48E-04 ILMN_1667594 KLF10 1.61 3.98E-06 ILMN_2201596 CYTL1 1.67 6.51E-03
ILMN_2374865 ATF3 2.05 1.71E-07 ILMN_1658494 C13orf15 1.61 3.53E-06 ILMN_1693270 SUSD2 1.67 1.98E-03
ILMN_1798177 CHURC1 2.03 4.48E-04 ILMN_1717706 PLK2 1.60 6.17E-04 ILMN_1740842 SALL2 1.66 6.86E-06
ILMN_1658660 ACTC1 2.01 1.53E-02 ILMN_1663787 KLK3 1.60 7.20E-05 ILMN_1677092 GEM 1.66 2.53E-05
ILMN_1676663 TNFRSF11B 2.01 6.30E-03 ILMN_1739001 TACSTD2 1.59 1.22E-03 ILMN_1746376 SCARA3 1.65 5.44E-04
ILMN_1762255 GSTM1 2.01 3.10E-02 ILMN_2202915 FAR2 1.59 6.34E-03 ILMN_1809147 FAM118A 1.64 1.22E-03
ILMN_1682636 CXCL2 1.98 1.41E-05 ILMN_1761968 PPP1R14A 1.59 2.50E-03 ILMN_1695606 EFNB3 1.64 2.29E-05
ILMN_1720829 ZFP36 1.97 3.20E-09 ILMN_2189869 FCF1 1.59 1.64E-03 ILMN_1672743 ZNF334 1.64 7.09E-04
ILMN_1711838 SLC25A24 1.95 1.06E-03 ILMN_1747911 CDC2 1.59 2.19E-02 ILMN_1797893 PFAAP5 1.63 8.70E-12
ILMN_3271179LOC100128775 1.95 2.42E-05 ILMN_1703906 HJURP 1.58 2.47E-02 ILMN_1703955 FBXO32 1.63 3.98E-03
ILMN_2124585 GREM1 1.94 5.05E-07 ILMN_1771149 MRPL19 1.58 4.83E-04 ILMN_1662587 PNPLA7 1.62 2.37E-06
ILMN_2139970 ALDH1A3 1.94 2.51E-06 ILMN_2301083 UBE2C 1.58 4.77E-02 ILMN_1812795 RUNX1T1 1.62 3.57E-03
ILMN_2132982 IGFBP5 1.93 2.57E-03 ILMN_3240433 GSTT2B 1.58 2.16E-02 ILMN_1758128 CYGB 1.62 1.28E-07
ILMN_1723116 AMFR 1.93 2.37E-02 ILMN_1687213 C8orf13 1.57 3.28E-03 ILMN_1725338 CLDN23 1.62 2.53E-04
ILMN_3305475 LOC729708 1.91 5.11E-04 ILMN_2327994 AZIN1 1.57 4.11E-02 ILMN_2073592 CAND2 1.62 6.86E-05
ILMN_1690397 DYNC1I1 1.91 1.73E-05 ILMN_1765701 LOC399942 1.56 1.73E-03 ILMN_2384122 GPR56 1.61 2.19E-04
ILMN_2395139 SERPINB7 1.90 1.79E-02 ILMN_1673673 PBK 1.56 4.90E-02 ILMN_2153679 TBC1D3B 1.61 1.59E-04
ILMN_1807439 ALDH1A3 1.87 6.14E-05 ILMN_2409220 HMMR 1.56 4.40E-02 ILMN_1718046 ARNT2 1.60 3.92E-04
ILMN_1709800 POMZP3 1.87 8.23E-04 ILMN_2413158 PODXL 1.56 4.45E-02 ILMN_1772612 ANGPTL2 1.60 7.02E-03
ILMN_1710284 HES1 1.87 2.36E-07 ILMN_3248511 FAM167A 1.56 4.31E-03 ILMN_1797728 HMGCS1 1.59 1.25E-06
ILMN_1723035 OLR1 1.86 7.72E-03 ILMN_2412860 MCM4 1.55 2.77E-03 ILMN_1811767 INHBE 1.59 2.00E-02
ILMN_1751776 CKAP2L 1.86 8.47E-03 ILMN_2051373 NEK2 1.55 3.56E-02 ILMN_2336781 SOD2 1.59 6.45E-03
ILMN_1748840 CALB2 1.86 3.23E-03 ILMN_2144426 HIST2H2AA3 1.55 1.35E-05 ILMN_1718766 MT1F 1.59 3.75E-03
ILMN_1775501 IL1B 1.84 3.71E-03 ILMN_2173291 CYP4B1 1.55 8.16E-03 ILMN_1695271 RPP25 1.58 1.63E-03
ILMN_2063168 MALL 1.83 1.58E-03 ILMN_1676336 AADACL1 1.55 2.57E-02 ILMN_1776157 Sep-04 1.58 4.27E-03
ILMN_1747650 BMP6 1.82 2.74E-06 ILMN_1716265 PGM2L1 1.55 7.77E-08 ILMN_3233229 SNHG7 1.58 1.37E-07
ILMN_1787186 NOV 1.82 3.00E-04 ILMN_1800540 CD55 1.55 7.22E-06 ILMN_2224290 ZNF322B 1.58 1.57E-05
ILMN_2400407 CNTN1 1.82 3.55E-03 ILMN_1784454 ITGB1 1.55 1.77E-06 ILMN_1778087 ANXA8 1.57 1.25E-02
ILMN_1699421 ANXA10 1.81 1.13E-03 ILMN_1809590 GINS2 1.54 3.12E-02 ILMN_1653794 C6orf160 1.57 3.89E-02
ILMN_2174189 DKK1 1.81 1.73E-06 ILMN_2073184 S1PR5 1.54 2.47E-04 ILMN_3226181 NUDT7 1.57 7.04E-06
ILMN_1767685 SERPINB7 1.81 2.39E-02 ILMN_1680955 AURKA 1.54 2.72E-02 ILMN_1658504 CHKA 1.57 2.66E-06
ILMN_1651354 SPP1 1.80 1.35E-04 ILMN_1695414 ASF1B 1.54 3.95E-02 ILMN_1714335 RDH10 1.56 2.98E-03
ILMN_1686116 THBS1 1.80 2.85E-04 ILMN_1772821 KIAA1671 1.54 1.08E-02 ILMN_2159152 TP53TG3 1.56 2.38E-06
ILMN_1805377 ZP3 1.78 3.75E-03 ILMN_1700413 MAFF 1.53 9.33E-03 ILMN_1654966 SCARA3 1.56 2.96E-03
ILMN_1775268 HECW2 1.78 2.19E-05 ILMN_1709683 RASSF2 1.53 9.15E-04 ILMN_1772459 RPS23 1.56 1.53E-02
ILMN_1660718 GABBR2 1.77 1.39E-02 ILMN_1682599 GPRC5A 1.53 4.42E-03 ILMN_1725889 AFF2 1.56 5.29E-03
ILMN_1716382 LOC387882 1.77 7.75E-06 ILMN_2406815 LRRC17 1.53 2.08E-03 ILMN_3234837 PKDCC 1.55 2.57E-04
ILMN_1746888 PCOLCE2 1.75 6.55E-05 ILMN_1715458 PCDH10 1.53 1.00E-04 ILMN_3246060 LOC654433 1.55 8.80E-04
ILMN_1725314 GBP3 1.75 3.07E-07 ILMN_2050911 SLC22A4 1.53 2.69E-10 ILMN_1731374 CPE 1.55 4.24E-02
ILMN_1798952 KDELR3 1.75 4.36E-06 ILMN_2413650 STIL 1.52 1.03E-02 ILMN_1678422 DHX58 1.55 3.10E-07
ILMN_1714880 LIMS3 1.74 1.66E-08 ILMN_1673998 SSTR1 1.52 1.83E-04 ILMN_1716843 ELOVL2 1.55 3.50E-05
ILMN_1737205 MCM4 1.74 2.55E-04 ILMN_2069745 SSTR1 1.52 5.12E-04 ILMN_3241692 LOC100129668 1.55 2.80E-02
ILMN_1786628 LOC653355 1.74 1.60E-04 ILMN_2189870 FCF1 1.52 1.89E-02 ILMN_3243924 P2RX6 1.55 9.04E-05
ILMN_2249282 TIPRL 1.73 3.26E-05 ILMN_1695978 LINGO2 1.51 7.06E-03 ILMN_2159453 STXBP2 1.54 7.07E-03
ILMN_2376953 KCNK2 1.72 2.58E-04 ILMN_1738589 MGLL 1.51 8.83E-03 ILMN_1846922 --- 1.54 2.99E-04
ILMN_1728009 TMEM171 1.72 1.44E-03 ILMN_1751576 TEK 1.51 4.82E-07 ILMN_1809496 COPG2 1.53 1.65E-03
ILMN_1766675 CDH6 1.72 7.14E-03 ILMN_2143155 KIF11 1.51 4.14E-02 ILMN_1680874 TUBB2B 1.52 2.09E-03
ILMN_1790761 POSTN 1.71 2.18E-03 ILMN_2048591 LRRN3 1.51 1.77E-02 ILMN_1784364 STARD5 1.52 2.54E-02
ILMN_1789991 MARCH4 1.70 4.58E-04 ILMN_2167915 DSEL 1.51 6.19E-04 ILMN_3241957 LOC100133930 1.52 8.07E-06
ILMN_2196328 POSTN 1.70 7.83E-03 ILMN_3238676 ULBP2 1.51 2.98E-04 ILMN_1754538 C10orf58 1.52 7.41E-03
ILMN_2189027 LIPG 1.69 2.01E-02 ILMN_3230300 LOC729143 1.50 6.85E-06 ILMN_1764769 VWA5A 1.52 2.92E-03
ILMN_1714730 UBE2C 1.68 2.20E-02 ILMN_1737728 CDCA3 1.50 3.86E-02 ILMN_1738147 NES 1.52 3.29E-04
ILMN_3245116 GOLIM4 1.67 9.01E-09 ILMN_1717990 CALD1 1.50 3.31E-02 ILMN_1814657 TFAP4 1.52 7.62E-06
ILMN_1794522 EIF5A 1.67 1.91E-03 ILMN_1667081 CCND2 2.69 1.68E-02 ILMN_1757636 C5orf35 1.52 3.64E-03
ILMN_2349459 BIRC5 1.67 1.76E-02 ILMN_1701424 LAMC2 2.63 1.10E-04 ILMN_1716733 MYOM2 1.51 5.71E-04
ILMN_2068104 TFPI2 1.66 1.30E-04 ILMN_2196479 XRN2 2.62 5.08E-06 ILMN_2326512 CASP1 1.51 8.76E-05
ILMN_1662970 ZP3 1.66 6.11E-03 ILMN_1655867 HRASLS 2.54 3.47E-07 ILMN_1702320 JAKMIP2 1.51 1.55E-02
ILMN_1739645 ANLN 1.66 2.47E-02 ILMN_2067656 CCND2 2.41 4.89E-02 ILMN_1794612 UBA7 1.51 2.07E-08
ILMN_1695475 SEMA3C 1.65 1.27E-05 ILMN_1767556 C10orf10 2.35 3.63E-05 ILMN_1734445 LOC91461 1.51 9.60E-04
ILMN_1685079 TELO2 1.65 1.05E-02 ILMN_1745994 GAS7 2.27 6.63E-03 ILMN_1690523 LRRC20 1.50 6.79E-05




Figure 39. All obese samples clustered together within the obese group except sample O3, which 




Figure 40. Gene expression data analysis according to the KEGG database, the REACTOME database 





Figure 41. The mRNA expression levels of 16 genes showed no differences in the obese and non-obese 
groups. The single exception was the PNPLA7 gene, which showed lower expression in the obese group 
than in the non-obese group. 
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3.4.3.1 PNPLA7 is down-regulated in samples from obese donors  
The transcriptome array data were validated using PNPLA7-specific RT-PCR (Figure 
42A). There is indeed a significant difference between the two groups (p-value 0.001, 
Mann-Whitney test). The mean (± standard deviation) of the gene expression level was 
20.6 (± 2.55) in the non-obese group and 4.3 (± 2.16) in the obese group (Table 33). 
Analysis based on the Bootstrap model showed that the 95% confidence interval of the 
incidence rate ratio was 0.18 (0.15 to 0.21).	
Searches of interaction networks using GeneMANIA and String V10.0 were conducted 
to detect any possible known signalling cascades and any possible interactions 
between PNLPA7 and other genes. According to GeneMANIA, PNPLA7 has predicted 
interactions with 14 genes, including PRKAR2A and ATP7B (Figure 42B). The 
experiments revealed that PNPLA7 interacts with MAPK11, MAPK14 and PEMT 
according to String (Figure 42C). However, no significant differences were found in the 
expression levels of any of the genes pinpointed by either of the two programmes. 	
PNPLA7 is an integral component of lysosomal, mitochondrial, nuclear and 
endoplasmic reticulum membranes and is involved in metabolic and developmental 
processes. Western blot analysis did indicate that the difference between the two 
groups is maintained at the protein level (Figure 42D). Overall, the mean (± standard 
deviation) value of PNPLA7 was lower 0.36 (±0.01) in the obese group than in the non-
obese group 0.39 (± 0.01) (Table 34). The data show that significant difference (p-
value 0.006, Mann-Whitney test) at the protein level was present between the obese 
and non-obese groups. Actin, used as housekeeping protein, showed no significant 
difference between the obese and non-obese group (Figure 42D).  
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Table 33. Summary of expression of mRNA level by obesity status using PNPLA7.	
Group	 Mean                  (standard deviation)	 Median             (minimum, maximum)	 p-value              (Mann-Whitney test)	
Normal (n=7)	 20.6 (2.55)	 21.6 (16.1, 23.8)	
0.001	Obese (n=7)	 4.35 (2.16)	 3.95 (1.15, 8.18)	
Total (n=14)	 12.4 (8.73)	 12.1 (1.15, 23.8)		
	
	
Table 34. Summary of value of protein level by obesity status using PNPLA7.	
Group	 Mean                  (standard deviation)	 Median             (minimum, maximum)	 p-value              (Mann-Whitney test)	
Normal (n=7)	 0.39 (0.01)	 0.39 (0.36, 0.41)	
0.006	Obese (n=7)	 0.36 (0.01)	 0.35 (0.34, 0.38)	




Figure 42. A. PNPLA7 expression levels in all fourteen samples from obese and non-obese donors were 
assessed using RT-PCR. B. Interaction networks between PNLPA7 and other genes were identified using 
GeneMANIA. C. Interaction networks between PNLPA7 and other genes were identified using String. D. 
Western blot data demonstrate lower expression of PNPLA7 at the protein levels in the obese group 













Numerous studies have demonstrated that epigenetic modifications are affected by 
environmental factors and that these external cues can modulate the establishment 
and maintenance of these modifications, including DNA methylation. Epigenetic 
modifications cause changes in gene expression that have profound effects on 
development and health. Furthermore, epigenetic variation in foetal tissue may be the 
underlying mechanism of metabolic disease programming through interactions 
between the uterine environment and gene expression.  
Despite these observations, it is important to consider that adult obesity does not 
always give rise to a disease state, and the threshold level of body fat at which an 
individual is at an increased risk for health complications is subject to individual 
variation. There is now a recognized phenomenon, demonstrated by numerous 
epidemiological studies, known as the “obesity paradox”, whereby individuals falling in 
the overweight to mildly obese category have a reduced risk for a range of diseases 
including stroke, cancer, hypertension and heart disease (Hainer & Aldhoon-Hainerova, 
2013). The correlation between disease and weight increases only at the severely 
obese stage. However, there is growing evidence to suggest that maternal obesity 
confers suboptimal developmental potential to the foetus, although the “obesity 
paradox” could suggest that there may be a degree of individual variation in terms of 
the effects of maternal obesity on foetal development. In other words, if mildly obese 
states confer some level of protection to adults in terms of all-cause and cardiovascular 
mortality and risk increases only in severely obese individuals, a plot of the relative risk 
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of mortality against BMI would show a U-shaped or J-shaped curve (Flegal et al., 2005). 
The molecular mechanism of the “obesity paradox” phenomenon is unknown; therefore, 
it is possible that there may not be a linear relationship between increasing maternal 
BMI and unhealthy foetal development (Hainer & Aldhoon-Hainerova, 2013). 
The research discussed here focuses on maternal obesity, but studies have also 
shown that paternal obesity induces aberrant methylation patterns in sperm that could 
represent a mechanism by which obese phenotypes are transmitted to the next 
generation from the father (Donkin et al., 2016). Significant differences were found in 
the epigenome of obese men compared with that of their normal-weight counterparts, 
with epigenetic modifications found in more than 9,000 genes, including the fat mass 
and obesity-associated gene (FTO), which is linked to obesity. Further studies are 
currently investigating the transgenerational inheritance of these modifications. In this 
thesis, studies and discussions have not accounted for the potential involvement of 
paternal factors in genome-wide methylation of WJ-MSCs or other relevant tissue 
types. 
As discussed in the introduction of this thesis, studies that have investigated the effects 
of obesity on DNA methylation have been largely restricted to analysing the promoter 
regions of genes. Nevertheless, these studies present substantive evidence that 
obesity results in aberrant DNA methylation patterns that are likely to have significant 
metabolic and inflammatory consequences in the body. Recent advances in array-
based technologies have enabled researchers to assess the molecular effects of 
obesity in MSCs. With the availability of the Illumina 450K beadchip array, genome-
wide DNA methylation pattern analysis with a high coverage of promoters, 5’ UTRs, 1st 
exons, gene bodies and 3’ UTRs is now possible. 
Consequently, several recent studies have been published on obesity and genome-
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wide DNA methylation using MSCs that will provide a basis for the discussion in 
subsequent sections of this chapter. These studies highlight the level of interest in this 
subject because of the potential impact of MSCs on human health; additionally, these 
studies support the theories and results presented herein. 
The purpose of this pilot study was to investigate the effects of obesity on epigenome-
wide DNA methylation using the Human Methylation 450K BeadChip array. WJ-MSCs 
from the UCs of infants born to normal BMI and high BMI healthy pregnant mothers 
were analysed. The underlying hypothesis proposed that metabolic diseases, including 
obesity, trigger the methylation of specific genes and that these environmentally 
induced epigenetic alterations may help elucidate the stem cell niche and endogenous 
properties of MSCs. 
 
4.1 Effect of obesity on the properties of WJ-MSCs  
The results of this study demonstrate that WJ-MSCs can be isolated from obese and 
non-obese UCs under sterile conditions with minimal tissue processing using explant 
method. Various protocols allow for the isolation of WJ-MSCs (Fong et al., 2007; La 
Rocca et al., 2009), but technical limitations, such as the requirement of harsh 
enzymatic treatment, can result in cell damage and a relatively low yield. However, an 
alternative method that was first demonstrated by La Rocca et al. (2009) mitigates 
these effects. The explant method capitalizes on the specific properties of MSCs that 
enable these cells to migrate and adhere to plastic surfaces. It provides an optimal 
protocol for WJ-MSC isolation and shows improved scores in relation to the time of 
primary culture, cell number, cell morphology, immunophenotype, and differentiation 
potential over alternative methodologies for the isolation of WJ-MSCs, such as the 
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enzymatic method (Hua et al., 2013). Therefore, the protocol chosen for this study 
involved the isolation of WJ-MSCs without using enzymes, which removed the 
possibility of cell damage (De Bruyn et al., 2011). We cultured small pieces of UC 
tissue explants in an appropriate microenvironment that supports the outgrowth of cells 
from tissue (Badraiq et al., 2015; Devito et al., 2014). Moreover, the explant procedure 
is simple and non-invasive, generates a homogenous cell population and does not 
involve any enzymatic treatments, which are considered to be damaging to cells 
(Majore et al., 2011).  
The results of this study showed that the explant method for the isolation of WJ-MSCs 
from UCs in our hands was more effective and convenient than other isolation methods. 
It produced a higher number of isolated cells and required a shorter time for primary 
culture. Additionally, the cost of explant cultivation was lower and the cell cultures 
consisted of a purer cell population (Figure 7). This outcome has also been 
demonstrated by another study (Hua et al., 2013). Thus, the results indicated that the 
method of isolation may have a significant influence on the growth capacity of isolated 
cell populations. Therefore, it is crucial that a range of methods should be tested and 
optimized before committing to the method. Notably, the current existing data are 
conflicting with regard to the heterogeneity of stem cell cultures and the isolation 
procedure used. However, this study confirmed the observations of other researchers 
that cultures using the explant method are homogenous in the early passages (Majore 
et al., 2011). 
 
Explants from both groups (obese and non-obese) were cultured in standard DMEM 
supplemented with 10% FBS and had a mean initial outgrowth period of 9.1 (±1.5) 
days for non-obese and 10.5 (±2.2) days for obese patients, which are comparable to 
the results of others (Devito et al., 2014). There was no significant difference between 
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the two groups with regard to the initial outgrowth period (Figure 9B). WJ-MSCs from 
non-obese and obese explants also exhibited similar proliferation and expansion rates; 
specifically, the median PD times were 32 (24 to 71.6) hours and 48 (28.5 to 96) hours, 
respectively. These cells were tested to compare the time required for the cell number 
to double within both groups during the first 34 hours (the overall median PD time). The 
differences in the time required for doubling between the groups were statistically 
significant and the results suggest that the cell population doubling was slower in the 
obese group than in the non-obese group after 34 hours of culture (Figure 9C). To 
understand whether this is a general rule or a pure coincidence, we would need to test 
more samples. Molecular mechanisms behind this phenomenon are at this stage still 
elusive and any discussion would be speculative. Collectively, the data suggest that 
there are no growth rate differences in WJ-MSCs from obese and non-obese donors at 
their initial outgrowth stage. However, the number of cells from obese donors doubled 
at a slower rate than the cells from the non-obese group within the first 34 hours 
WJ-MSCs are identified as MSCs if they are phenotypically positive for the surface 
markers CD90, CD73 and CD105 and negative for the haematopoietic cell surface 
markers CD34 and CD45, according to the ISCT guidelines (Dominici et al., 2006). The 
cultures from normal BMI and high BMI donors exhibited similar expression patterns, 
and p-value was not significant for the MSC markers CD90, CD73, CD105, CD29 and 
CD44 (Figure 10). MSCs from obese and non-obese donors showed an absence of 
haematopoietic markers. However, the cultures from the two BMI groups showed 
different expression levels of CD56. Cells from the high BMI group exhibited a lower 
expression of CD56 than normal BMI cells (Figure 10). The CD56 expression level 
findings in this study were similar to those of previous studies in our group using the 
same cell type	 (Devito et al., 2014). Data from other studies indicated that this marker 
is primarily expressed in NK cells, muscle cells and neural cells. Moreover, this marker 
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is expressed in a small subset of CD271bright BM-MSCs (Battula et al., 2009). This 
study also showed that CD56 is expressed on the cell surface of WJ-MSCs. 
Neither of the cell lines expressed MSCA-1 when cultured in the presence of serum. 
MSCA-1 is conditionally expressed in the CD271bright BM-MSC population when 
containing only CFU-Fs (Busser et al., 2015) and has also been identified in WJ-MSCs 
that were cultured in xeno-free medium (Devito et al., 2014). Another MSC marker, 
CD271, a nerve growth factor receptor, is known to be absent in WJ-MSCs but has 
been proposed to be present in BM-MSCs (Alvarez-Viejo et al., 2015; Busser et al., 
2015; Ishige et al., 2009). In another study, WJ-MSCs were shown to have <5% 
CD271 expression levels irrespective of testing using various supporting culture 
conditions (Devito et al., 2014). However, in this study none of the cell lines from either 
group expressed CD271. This lack of expression could be due to the effect of the use 
of different FBS batches or differences between individual donors. In summary, my 
study demonstrated that WJ-MSCs from high BMI donors exhibit similar MSC surface 
marker expression pattern to MSCs from normal BMI donors. 
WJ-MSCs from both obese and non-obese donors were also tested to determine their 
differentiation capacity, in particular, their capacity to commit to the adipogenic, 
chondrogenic and osteogenic lineages. Under normal conditions, MSCs are non-
haematopoietic, multipotent cells with the capacity for multi-lineage differentiation. 
Indeed, WJ-MSCs are a potential source of stem cells for regenerative medicine 
purposes because of these properties and their capacity for self-renewal and 
immunomodulation (Ali et al., 2015). Some researchers have hypothesized that the 
properties of adult stem cells may be altered as a result of obesity (Wu et al., 2013). 
Their results support the proposed hypothesis that obesity changes the properties of 
stem cells according to the cell source. These effects are thought to be mediated by 
elevated free fatty acids (FFAs) and potentially other cytokines involved in obesity-
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associated pathways. Therefore, it is important to test the impact of maternal obesity 
specifically on the capacity of WJ-MSCs to differentiate into adipocytes. WJ-MSC 
cultures from all samples were treated concurrently in adipogenic differentiation 
medium subsequent to the differentiation procedure, and LipidTOX staining was 
applied to detect the presence of fat droplets (Figure 11A). The results showed an 
insignificant difference in the mean lipid percentage between the obese group and the 
normal BMI group (2.2% (±1.1) and 2.3% (±1.3), respectively) (Figure 12). Furthermore, 
the differentiated cells were tested for the presence of an adipogenic-specific marker 
(FABP4), and the data showed similar values for the FABP4 mRNA expression level in 
the samples from obese and non-obese donors (Figure 11A). Overall, the results 
showed that MSCs from both lean and obese mothers have the same ability to 
differentiate into adipocytes in a suitable microenvironment and under the same 
experimental conditions. 
UC-derived cell differentiation into cartilage-forming cells is likely supported with the 
structural properties of UC tissue. The human UC is very rich in hyaluronic acid, a 
native component of articular cartilage (Can & Karahuseyinoglu, 2007). In my 
experimental work, WJ-MSC samples from obese and non-obese groups were 
exposed to chondrogenic differentiation medium for 14 days. Alcian blue positive 
staining confirmed the presence of cartilage-specific proteoglycans in the induced 
cultures (Figure 11B). Furthermore, the differentiated cells were tested positive for the 
presence of the chondrogenic-specific marker (COL11A1) and the data showed similar 
levels of the mRNA COL11A1 expression in samples from obese and non-obese 
donors (Figure 11B). Overall, the results showed that MSCs from both lean and obese 
mothers had a similar ability to differentiate into chondrocytes in a suitable 
microenvironment and under the same experimental conditions. 
The potential of MSCs to differentiate into adipogenic and chondrogenic lineages has 
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been studied and discussed extensively by several groups, and the results have 
generally been consistent. However, the literature shows widely different outcomes 
with regard to the osteogenic capacity of UC-derived cells. Some investigators 
describe an osteogenic potential comparable to that of BM-MSCs (Diao et al., 2009; 
Hou et al., 2009) or even higher (Baksh et al., 2007). Other investigators have shown 
that cells collected from the human UC are poorly osteogenic and that only some of 
them are capable of undergoing osteogenic differentiation (Girdlestone et al., 2009; 
Majore et al., 2011; Suzdal'tseva et al., 2007). The WJ-MSC samples from all fourteen 
donors were treated with osteogenic differentiation medium. Following the 
differentiation treatment, Alizarin red staining was applied to detect calcium deposits 
(Figure 11C). Furthermore, the differentiated cells were tested for the presence of an 
osteogenic-specific marker (RUNX2), and the data showed similar RUNX2 mRNA 
expression levels in obese and non-obese donors (Figure 11C). Overall, the results 
showed that, in our hands, MSCs from both lean and obese mothers had the same 
ability to differentiate into osteoblasts in a suitable microenvironment and when the 
same experimental conditions were used. Although we did not compare directly 
osteogenic potential of WJ-MSC isolated in our laboratory with osteogenic potential of 
other type of MSC, low levels of RUNX2 in differentiated cells in comparison with 
studies with other cells suggested that indeed their osteogenic potential might be 
relatively low (Girdlestone et al., 2009; Majore et al., 2011; Suzdal'tseva et al., 2007). 
 
A particularly interesting observation from this study is that WJ-MSCs from obese 
donors have a considerably greater immunosuppressive potential than equivalent cells 
from non-obese donors at certain doses (Figure 13). Obesity is typically associated 
with meta-inflammation or low-grade chronic inflammation triggered by metabolic cells 
as a result of excess nutrients and energy (Egger & Dixon, 2010; Gregor & Hotamisligil, 
2011). This inflammatory response is distinct from that arising from assault, injury, or 
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infection and in association with insulin resistance, it is a combination common in 
several diseases, including hepatitis C, HIV, rheumatoid arthritis and obesity. Obese 
adipose tissue secretes inflammatory cytokines that inhibit insulin signalling, damage 
metabolic homeostasis, and contribute to the altered metabolic environment that 
imposes stress on a developing foetus. Thus, the consensus opinion is that the 
immunosuppressive capability of MSCs is not constitutive; rather, it arises as a result of 
exposure to an inflammatory uterine microenvironment (Ren et al., 2008). The 
immunomodulatory state of MSCs is dynamic and driven by various factors, one of 
which is the aforementioned inflammatory environment. MSCs derived from BM mice 
that were not exposed to inflammatory cytokines do not exhibit immunosuppression; 
rather, this property is specifically induced following exposure to a combination of pro-
inflammatory cytokines (Ren et al., 2008). These cytokines elicit their response by 
triggering the expression of various chemokines and inducible nitric oxide synthase 
(iNOS) by MSCs. Thus, the induction of immunosuppression in MSCs via the effects of 
chemokines or nitric oxide (NO) requires exposure to pro-inflammatory cytokines. The 
mechanism of immunosuppression in response to chemokines and NO is still unknown. 
It is possible that the significant up-regulation of iNOS and several leukocyte 
chemokines in response to cytokines may affect immune cells, including T-cells, B-
cells and antigen-presenting cells, and MSCs, thus allowing the high levels of NO to 
suppress immune cell function. Several inflammatory cytokines, including TNF-α and IL, 
are increased in the tissues of obese individuals (Gregor & Hotamisligil, 2011). Based 
on this study on WJ-MSCs, the inflammatory cytokines and chemokines that are likely 
to be elevated as a result of the altered metabolic state of obese donors, such as TNF-
α, may induce WJ-MSCs from obese pregnant women to secrete elevated levels of 
various immunomodulatory factors, thereby exerting a stronger inhibitory effect on the 
proliferation of PHA-stimulated PBMCs. Purified PBMCs are used in vitro to assess a 
range of lymphocyte functions, including proliferation and mitogenic stimulation (Panda 
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& Ravindran, 2013). The stimulation of PBMCs leads to an up-regulation of various cell 
surface receptors and transcription factors and PHA-stimulated PBMCs are used in this 
assay to assess immunomodulation. 
 
4.2 Effects of obesity on DNA methylation 
Several human and animal studies have documented the epigenetic modifications that 
alter gene expression as a result of stress conditions in the uterine environment during 
prenatal development (Barua & Junaid, 2015; Curley et al., 2011; Li et al., 2010; 
Sasaki et al., 2013; Vaiserman, 2015). Perinatal stress may lead to neuroendocrine 
disruptions that can impact a range of outcomes later in life, including an increased risk 
of cardio-metabolic disease. Additionally, increasing evidence indicates that epigenetic 
changes are subject to transgenerational inheritance.  
Poor intrauterine growth, which results in babies born small for gestational age (SGA), 
is known to be caused by several prenatal stressors. For example, insufficient vitamin 
B12 intake during pregnancy can lead to elevated maternal plasma homocysteine and 
is associated with SGA infants (Hogeveen et al., 2012). Low maternal plasma vitamin 
E levels can also result in SGA babies (Dreyfuss et al., 2001). The molecular 
mechanisms that give rise to SGA babies can be identified via the epigenetic analysis 
of WJ-MSCs. MSCs from SGA newborns, for example, were shown to exhibit an 
altered expression of the early growth response 1 (EGR-1)-dependent gene network, 
which is involved in the regulation of cell proliferation and oxidative stress (Sukarieh et 
al., 2014). Furthermore, intrauterine growth restriction (IUGR) is associated with an 
increased risk for metabolic diseases, such as type 2 diabetes, obesity and 
cardiovascular disease.  
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Maternal obesity gives rise to an altered metabolic environment in utero that could be a 
stressor to the developing foetus. In fact, maternal obesity is associated with the 
differential expression of multiple genes (Carty et al., 2014). When the total RNA was 
isolated from samples of whole blood and subcutaneous fat and gene expression was 
profiled using Illumina microarray technology, researchers identified differential 
expression between lean and non-lean (overweight and obese) donors. In the whole 
blood samples, six genes were differentially expressed between the two groups: 
angiopoietin-like protein (ANGPTL), cytochrome c oxidase subunit VIIa polypeptide II 
(COX7A2), eukaryotic translation initiation factor 3 subunit A (EIF3A), 6-
pyruvoyltetrahydropterin synthase (PTS), CDGSH iron sulphur domain 1 (CISD1) and 
glutaredoxin (GLRX). Furthermore, when gene expression was analysed in 
subcutaneous fat, COX7A2 expression was decreased in obese and overweight 
women compared with that in lean women. The overweight and obese groups 
exhibited similar expression patterns. Differences between the two sample types 
(whole blood and subcutaneous fat) are a result of specific environmentally induced 
expression patterns of each tissue type. COX7A2 encodes a mitochondrial protein that 
is important in steroidogenesis and oxidative stress regulation; thus, changes in its 
expression as a result of a higher BMI could explain the inflammation-induced 
pregnancy complications in obese women. 
Although the number of samples I analysed was limited in this study, as this was a 
small patient cohort, I was still able to detect significant differences between non-obese 
and obese pregnancies in terms of cell proliferation, immunomodulatory properties, 
DNA methylation and gene expression of WJ-MSCs. In addition, the possibility that the 
effects of an abnormal in utero environment are reversible and lost during in vitro 
expansion cannot be excluded. The data from my limited cohort suggest that the 
effects of maternal obesity on DNA methylation are not constitutive, although the 
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possibility that major differential methylation cannot yet be detected in second- 
passage and third-passage WJ-MSCs cannot be ruled out. Consideration must also be 
given to tissue specificity in relation to obesity-induced epigenetic changes and 
differing methods of complex data set analysis when interpreting the results of this 
study. 
The results of another study showed that specific changes in global methylation in 
placental tissues were positively correlated with maternal gestational diabetes mellitus 
(GDM), preeclampsia and obesity. This association did not hold for UC blood, and 
there was no correlation between global methylation in the placenta and the UC 
(Nomura et al., 2014). Numerous other studies have demonstrated that global 
methylation occurs least in the placenta (Ehrlich et al., 1982; Gama-Sosa et al., 1983). 
Global methylation levels in placental tissues are approximately 10% lower than those 
in UC blood (Nomura et al., 2014). The difference in global methylation between the 
placental tissues in women suffering from GDM, preeclampsia and obesity found in the 
study by Nomura et al. (2014) was relatively small (approximately 3–5%). In contrast to 
our methodology, methylation was analysed in that study using the LUMA platform. In 
terms of UC blood, there was no significant difference in the methylation of samples 
between different study groups (i.e., women with or without GDM, preeclampsia and 
obesity). Interestingly, global methylation in the placental samples was highest in the 
obese group. The results also demonstrated an association between global DNA 
methylation in the placenta and particular maternal, pregnancy and newborn 
phenotypes. For example, higher methylation in the placenta was associated with a 
decreased head circumference and body length, indicating that of the three conditions 
tested, obesity is likely to have the greatest impact on the phenotype of an infant 
(Nomura et al., 2014). These results suggest a possible mechanism for the impact of 
the uterine environment on foetal development and health. Given that IUGR is linked to 
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an increased risk for a range of later-life diseases, these results also provide further 
evidence for the Barker hypothesis, whereby the origins of adult diseases can be 
associated with foetal environmental exposure (Barker, 1998; 2004). This study also 
raises questions about the relationship between placental health, foetal growth and 
brain development and function (Nomura et al., 2014).  
The placenta controls the uterine environment by regulating the maternal-foetal 
interface, thus coordinating embryonic development. Understanding the mechanisms 
by which maternal obesity impacts obstetric outcomes and infant phenotypes, 
particularly with regard to differences in the epigenetic landscape of WJ-MSCs in 
obese individuals, is of particular interest. Data from Nomura et al. (2014) and this 
thesis suggest that methylation patterns may be tissue-specific, which is important in 
understanding the molecular mechanisms involved. Studies have shown the placenta 
to be the least methylated organ in the human body (Ehrlich et al., 1982; Gama-Sosa 
et al., 1983). Nomura et al. (2014) proposed that differences in tissue methylation could 
be explained by the fact that genes may be permanently methylated and confined in 
heterochromatic areas of the already specialized UC blood cells. Thus, they may be 
less susceptible to alterations in the uterine environment that are triggered by maternal 
metabolic changes. However, the cellular heterogeneity of the placenta is worthy of 
consideration. It is interesting to note that there are sampled and studied biopsies of 
the chorionic villi of the placenta that form the maternal-foetal interface. Further studies 
to examine whether methylation is homogenous across the placenta are required to 
understand the impact of environmental stressors, such as obesity, on specific tissue 
and cell types. Such studies would help further elucidate the mechanisms and potential 
clinical considerations associated with WJ-MSCs. The results of my study differed from 
those published by Nomura et al. (2014). My data did show significant differences in 
the methylation profiles between UC samples taken from both obese and non-obese 
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groups, irrespective of whether they were derived from specific regions of the UC (UC 
blood or WJ-MSCs). 
Several environmental factors induce meta-inflammation, particularly certain nutrient 
stimuli that are associated with modern diets, even in the absence of obesity (Egger & 
Dixon, 2010). Other factors that induce a meta-inflammatory state include inactivity, 
sleep deficit, smoking and stress. Conversely, certain nutrients exhibit anti-
inflammatory effects in the body, including nuts (Egger & Dixon, 2010) and various 
spices, including turmeric, which inhibits transcription factors associated with 
inflammation (Aggarwal & Sung, 2009). Additionally, in men, obesity-induced aberrant 
methylation patterns in sperm were abolished one week post-bariatric surgery, with 
methylation changes occurring in 1,500 genes during this short period (Donkin et al., 
2016).  
Data from other studies indicate that the correlation between maternal obesity and 
alterations in DNA methylation may be tissue-specific, which could provide an 
explanation for the discrepancy between my data and results from comparable studies. 
This study is the first to investigate an association between maternal obesity and global 
DNA methylation in WJ-MSCs. Most other studies have analysed either UC blood or 
placental samples and have usually investigated methylation changes in particular 
genes. For example, Burris et al. (2015) found that the methylation rate of aryl-
hydrocarbon receptor repressor (AHRR) was 2.1% higher in UC blood from the 
offspring of obese mothers than in that from the offspring of normal-weight mothers. In 
my cohort, four out of seven obese donors had a >20% higher methylation rate at one 
CpG site in AHRR, although there was no difference in the AHRR mRNA levels (Figure 
41). AHRR is responsible for inhibiting aryl-hydrocarbon receptor (AHR) transcription, 
which mediates drug or xenobiotic metabolism, cell growth and differentiation. Another 
factor that is associated with AHRR methylation in children is maternal smoking, 
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supporting the hypothesis that obesity is an intrauterine stressor for the developing 
foetus, similar to environmental contaminants. Therefore, studies of both individual 
genes and global methylation in UC blood, WJ-MSCs, and other tissues provide a 
growing body of evidence to support the crucial role of in utero stressors in DNA 
methylation and infant phenotype determination. In addition, DNA methylation was also 
shown to positively correlate with gestational age, birth weight and obesity (Burris et al., 
2015). The health implications of AHRR methylation are unclear, but given the potential 
implications for drug metabolism and cell growth and differentiation, the results of my 
study should be considered alongside such gene-specific research when considering 
the therapeutic application of WJ-MSCs. Similarly, Lesseur et al. (2014) found that 
obesity during pregnancy affected the DNA methylation status of the leptin (LEP) 
promoter in placental tissue. LEP is an adipokine that regulates appetite and is 
important for energy homeostasis by signalling satiety. It is produced by the placenta 
and regulates foetal growth and nutrient exchange during pregnancy. LEP expression 
is negatively associated with promoter DNA methylation. It was concluded that 
because these effects alter DNA methylation within the placental tissue, they provide a 
potential mechanism by which metabolic dysregulation arises in the offspring and 
drives obesity-related conditions in the next generation (Lesseur et al., 2014). 
Furthermore, Li et al. (2013) found that maternal obesity and diabetes in a mouse 
model were associated with extensive epigenetic changes, triggering altered 
expression of hepatic genes in male offspring. The offspring of obese mothers showed 
extensive changes in cytosine methylation related to developmental rather than 
metabolic pathways, suggesting that epigenetic changes may produce an altered 
response to a suboptimal intrauterine environment. 
Another study investigating global methylation revealed that maternal GDM is 
associated with genome-wide DNA methylation changes in both the placenta and the 
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UC blood of the exposed offspring (Finer et al., 2015), contradicting the notion of a 
tissue-specific association (Nomura et al., 2014). A study by Finer et al. (2015) 
identified genome-wide DNA methylation changes in both the placenta and cord blood 
from infants born to healthy women and women suffering from GDM using methylation 
variable position (MVP) analysis. Pathways involved in endocytosis, mitogen-activated 
protein kinase (MAPK) signalling and extracellular triggers for intracellular metabolic 
processes were found to be enriched via KEGG pathway analysis, a bioinformatics tool 
used to elucidate the function of a biological system. The study also included 
considerations of cellular heterogeneity in cord blood with methylation analysis in 
different blood cell types. The correlation between methylation and GDM held for 
lymphocytes and monocytes but not for granulocytes. Comparative data for placental 
tissue were not evaluated in this study; therefore, placental cell results were not 
corrected for heterogeneity (Finer et al., 2015). Differences in cord blood methylation 
according to cell type indicate that cellular heterogeneity in particular tissue types can 
lead to differing results in global methylation studies, which is relevant to this doctoral 
thesis. 
Another consideration is that neighbouring CpG sites exhibit correlated methylation 
states. Further analysis is required to ensure that this type of co-methylation does not 
distort the results. Finer et al. (2015) found that allowing for a 5% β-value difference 
ensured that their results were valid and not a result of chance or technical variation. In 
addition, Finer et al. (2015) recruited a cohort from the South Asian population, which 
has a greater risk of type 2 diabetes at a population level. Asians are more likely to 
develop the disease even at lower BMIs, resulting in the development of diabetes in a 
disproportionately large percentage of the population. This risk is thought to be caused 
by the propensity to have less muscle and more abdominal fat, leading to insulin 
resistance (Finer et al., 2015). This phenomenon is present at birth, with studies 
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showing that Indian newborns have higher levels of body fat and insulin than 
Caucasian babies, despite having a lower average birth weight (Yajnik et al., 2002). 
Whether this phenomenon gives rise to differing methylation states in certain tissues is 
unclear, but a strong phenotypic trend with unknown molecular mechanisms in the 
recruited cohort group that is relevant to the area of study is noteworthy. Finer et al. 
(2015) also found that differences in DNA methylation were caused by genetic variation, 
although these differences were not dependent on SNP-associated methylation. 
However, this could account for the increased global methylation in both tissue types in 
their cohort. They concluded that SNP-associated methylation may be mechanistically 
important in the interaction of genes and the environment during early development. 
Research on the differences in global DNA methylation between various ethnic or 
racial groups has been limited. Non-Caucasian head and neck cancer patients were 
reported to have increased methylation of leukocyte LINE-1 compared with Caucasians 
(Hsiung et al., 2007). Another study by Zhang et al. (2011) demonstrated lower 
methylation of the same gene in non-Hispanic blacks and Hispanics than Caucasian 
study participants and concluded that the differing frequencies of the 
methylenetetrahydrofolate reductase MTHFR-C677T polymorphism found in distinct 
racial/ethnic groups could not explain the discrepancies in global DNA methylation 
between the groups. Other unknown influences, either environmental or genetic, could 
therefore be contributing factors to the differing levels of global DNA methylation 
between races that have been observed. Further research to explore the potential 
contribution of genetic polymorphisms along with global DNA methylation may help 
explain differences between ethnic groups (Zhang et al., 2011). Regarding this thesis, 
the contribution of race/ethnicity effects to the observed differences in global DNA 
methylation cannot be determined because the impact of a small sample size cannot 
be eliminated. Future studies with a larger number of samples may help elucidate the 
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differences in global DNA methylation in obese donors according to race/ethnicity.  
Another explanation for the different results in comparable studies is the use of 
different methodologies to analyse DNA methylation. For example, methylated DNA 
immunoprecipitation covers the entire genome but has limited resolution. Reduced 
representation bisulfite sequencing and Nimblegen MethSeq allow for single CpG 
resolution, but analysis is restricted to CpG islands and promoters (Walker et al., 2015). 
It has also been shown that differences in the isolation and subculture protocols in 
different cell lines may result in differences in gene expression and pluripotency degree 
(La Rocca et al., 2009). It has been hypothesized that isolation methods may alter the 
epigenetic profile of WJ-MSCs, which in turn alter their plasticity and potential for 
therapeutic application (Phinney & Prockop, 2007). These observations further 
demonstrate the bidirectional relationship between epigenetic changes and stemness 
and the importance of considering this relationship when interpreting results between 
tissue types and in terms of cell isolation procedures.  
In this study, all fourteen UCs underwent the same treatment. Identical optimized 
conditions and sterile techniques were used for each sample from the time they were 
first collected until the very last stages of the experimental procedures. This was done 
to eliminate any technical errors and to minimize any variability among samples that 
could have impacted the outcome of the results. For the DNA methylation and gene 
expression array testing procedures, all sample reactions were processed in one batch 
to minimize variations that could result from any batch effects. This enabled the better 
evaluation of the potential biological relevance of the samples. Nevertheless, despite 
ensuring that bias attributed from technical variations was minimized, the results 
generated from some obese donors were shown to confound the data in some of the 
experiments. For these donors, I could not exclude the possibility that the changes 
seen in their results may have been caused by technical errors that were overlooked in 
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the study. Additionally, outlying results may have resulted from individual differences 
between the patients. 
	
4.3 Role of obesity in PNPLA7 
This study identified PNPLA7 (Figure 42), which is also known as neuropathy target 
esterase-related 1 (NTE-R1) or NTE-related esterase (NRE). PNPLA7 is a member of 
the PNPLAs family (Winrow et al., 2003; Zhang et al., 2016). The human genome 
expresses nine PNPLAs (PNPLA1–9) that have attracted attention, and this group 
plays crucial roles in various aspects of lipid metabolism and signalling (Kienesberger 
et al., 2009). Mutations and gene polymorphisms in humans result in disease 
phenotypes that are associated with the disruption of energy homeostasis, neuronal 
integrity, and age-related bone morphology (Andrews et al., 1988; Kienesberger et al., 
2009). PNPLA7 has an important function in triglyceride hydrolysis, energy metabolism, 
lipid droplets, and adipocyte differentiation regulation (Kienesberger et al., 2008; 
Wilson et al., 2006; Zhang et al., 2016). In obesity, excessively high levels of 
triacylglycerol in adipocytes (hypertrophy) accumulate due to an altered balance 
between lipogenic and/or lipolytic functions of the adipocytes (Ferry et al., 2003).  
PNPLA7 is an insulin-regulated and glucose-regulated lysophospholipase that plays a 
role in reducing cellular lysophosphatidic acid (LPA; 1-acyl-sn-glycerol-3-phosphate) 
under fasting conditions when lipid stores are mobilized for energy production 
(Kienesberger et al., 2008; Kienesberger et al., 2009; www.genecards.org). LPA is a 
bioactive phospholipid that regulates a broad range of responses at a cellular level 
(survival, proliferation, motility and secretion) via G-protein-coupled receptor activation  
(LPA1-receptor (R), LPA2-R, and LPA3-R). LPA is up-regulated with adipocyte 
differentiation and obesity (Chun et al., 2002; Ferry et al., 2003; Tigyi, 2001). Previous 
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studies have demonstrated that LPA is released from adipocytes in vitro and is found in 
the extracellular fluid of adipose tissue obtained through microdialysis in vivo (Ferry et 
al., 2003). 
Following findings from previous studies, it is not surprising that PNPLA7 exhibits 
reduced expression in samples from obese pregnancies. In addition, it has been 
reported that DNA methylation regulates PNPLA7 expression; it is down-regulated in 
hepatocellular carcinoma cell lines and tissue samples via the mechanism of 
transcriptional silencing by promoter hypermethylation. In cancer studies where there is 
a significant difference between tumour cells and normal cells with respect to their 
metabolic pathways, PNPLA7 is a potential biomarker for diagnosis as a gene that 
affects energy metabolism (Zhang et al., 2016).  
Taken all data together, this pilot study suggested that if significant differences in the 
PNPLA7 DNA methylation or expression could be correlated with onset of obesity in 
childhood, PNPLA7 expression might be used as a potential biomarker. Although the 
number of analysed donors is limited, this data suggest that the abnormal metabolic 
environment related to excessive body weight might bear consequences on the WJ-
MSCs and, if confirmed in future more extensive studies, might be considered as one 
of disqualifying criteria for allogeneic cellular therapy. 
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Summary 
Global DNA methylation analyses and functional studies examining proliferation rate 
and immunomodulatory potential suggest that maternal obesity during pregnancy might 
have effects on WJ-MSCs isolated from UC explants. These studies concluded that 
1. In general, cells from obese donor samples proliferate somewhat slower.  
2. The differentiation potential into adipogenic, osteogenic and chondrogenic 
lineages is similar.  
3. The WJ-MSCs from obese donors exhibited stronger inhibition of PHA-stimulated 
proliferation of PBMCs than their non-obese donor counterparts.  
4. DNA methylation data showed 18 genes with significantly different CpG 
methylation sites between obese and non-obese groups. However, two genes, 
DCAF6 and ZNF714, were found in segmentally duplicated regions. 
5.  Gene expression data showed that of the 16 genes with significantly different 
CpG methylation sites between the two groups, only PNPLA7 showed significantly 
different levels of mRNA expression between the non-obese and obese groups, a 
finding that was confirmed independently by RT-PCR and Western blotting. 
Taken together, the data of this pilot study suggested that PNPLA7 expression might 
be a potential biomarker. To understand its significance, similar studies with a larger 
sample size are warranted. Regardless, the abnormal metabolic environment 





The work from this study has elucidated research topics for subsequent projects, 
including 
• Expanding the study with a larger sample size to confer greater statistical power 
to the results and allow the study cohort to be divided into groups according to 
ethnic background. 
• Investigating the potential of PNPLA7 in other MSC cell type. 
• Investigating the potential of PNPLA7 in other tissues.  
• In vivo comparative studies using WJ-MSCs from obese and non-obese donors 
for cellular therapy; this will determine whether the differences observed 
between obese and non-obese donors from the in vitro data are also relevant in 
vivo (e.g., GVHD mouse model). 
• Investigating the potential of PNPLA7 as a predictive biomarker for communal 
diseases in children from obese pregnancies (e.g., are PNPLA7 levels at birth 
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